Clinical Chief, Medical Oncology Department Head, Thoracic ... Awards, Honors and Recognitions: Best Poster Award, Nº 695: “Epidermal growth factor receptor (EGFR) expression correlation

1

CV Dr. Enriqueta Felip M.D, PhD Clinical Chief, Medical Oncology Department Head, Thoracic and Head and Neck Oncology Units Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Associate Professor of Medicine at the Autonomous University School of Medicine, Barcelona, Spain

2

Name: Enriqueta Felip MD, PhD Place of Birth: Sitges (Barcelona), Spain Date of Birth: 12th September 1963 Address: C/ Rio del Oro 17, escalera D, 4rt. 1a 08034 Barcelona Cell Number: +34 629125392 Office Address: Medical Oncology Department

Vall d´Hebron University Hospital P. Vall d’Hebron, 119-129

08035 Barcelona, Spain Telephone Number : +34 93 2746077 Fax Number: +34 93 2746059 E-mail Address: [email protected]

[email protected]

Research unique identifier(s) (ORCID): orcid.org/0000-0002-7620-0098

Current Institutional responsabilities: Clinical Chief, Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain. Head, Thoracic and Head and Neck Oncology Units, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Associate Professor of Medicine at the Autonomous University School of Medicine (UAB), Barcelona, Spain until May 2019. From September 2019: Professor of Medicine at the University of Vic. Licensed Physician: 1987 Barcelona Medical License # 24509 Education: 1981 – 1987: School of Medicine -Universitat Autònoma de Barcelona- Barcelona, Spain.

mailto:[email protected]

mailto:[email protected]

3

Certificates: 1987 Degree in Medicine and Surgery with “A” degree. Universitat Autònoma de Barcelona, Spain. 1991 Board Certified in Medical Oncology. Spanish Board of Medical Oncology. 1994 Degree in Medicine Doctor. Universitat Autònoma de Barcelona, Spain. Postdoctoral Training: 1988 – 1991 Residency, Department of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma

de Barcelona. Positions and Appointments: 1992 – 2003 Clinical Assistant Physician Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain. 2003 – 2007 Senior Clinical Assistant Physician. Vall d’Hebron University Hospital, Barcelona, Spain. 2007 - Head, Thoracic Oncology Unit, Oncology Department Vall d’Hebron University Hospital,

Barcelona, Spain. 2007 - 2011: Clinical Chief (in functions), Medical Oncology

Department, Vall d’Hebron University Hospital, Barcelona, Spain.

2011 - Clinical Chief (competitive exam), Medical Oncology Department, Vall d’Hebron University Hospital,

Barcelona, Spain. 2017 – 2019: President CFT-SISCAT (Servei Català de la Salut).

4

Awards, Honors and Recognitions:

Best Poster Award, Nº 695: “Epidermal growth factor receptor (EGFR) expression correlation between diagnostic and post-platinum-based progression samples of non-small-cell lung cancer (NSCLC) patients”. 29th ESMO Congress, 29 October - 02 November 2005, Viena, Austria.

Dr. Robert Ginsberg Award Lectureship in Surgery 2009. International Association for the Study of Lung Cancer. 13th World Cancer Conference on Lung Cancer. San Francisco, USA. July 2009.

Premi FUNDE en la disciplina de trajectòria i recerca investigadora. Associació d’Empresàries, Directives i Professionals FUNDE. Lleida, Octubre 2009.

Premi del Col.legi Oficial de Metges de Barcelona (COMB) a l’Excel.lència Professional. Barcelona, Novembre 2012.

ESMO Women for Oncology Award. 40th ESMO European Cancer Congress, Vienna (Austria). September 2015.

“Ayuda Merck de Investigación 2016 en el Área de Investigación Clínica en Cáncer de Pulmón”. Proyecto liderado por la Dra. Enriqueta Felip: “Xenoinjertos ortotópicos derivados de pacientes como herramienta para el estudio de mecanismos de resistència adquirida en cánceres de pulmón dependientes de oncogenes”. Fundación Merck Salud, Julio 2016.

Grant for Oncology Innovation GOI Merck Serono): “New Technologies for new

treatments: Liquid biopsy meets inmunotherapy” (2016).

Dr. Enriqueta Felip as Global Highly Cited Researchers list 2019 (Source: Clarivate Analytics). https://clarivate.com/hcr.

Dr. Enriqueta Felip as Global Highly Cited Researchers list 2018 (Source: Clarivate Analytics). https://clarivate.com/hcr.

https://clarivate.com/hcr

https://clarivate.com/hcr

5

Other Scientific recognitions:

6

2017: Member of Foundation Council of the European Thoracic Oncology Platform

(ETOP).

2017 – 2020: Elected Member of the Board of Directors “International Association

for the Study of Lung Cancer” (IASLC)”.

2018 – May 2019: President of “Comissió Farmacoterapeútica per al SISCAT

(CFT-SISCAT) CAT SALUT.

President of “Comissió Oncològica de l’Hospital Universitari Vall d’Hebrón”.

Coordinator of “Lung Cancer Programme” European School of Oncology (ESO), September 2013.

Member of the following Scientific Societies: Grupo Español de Cáncer de Pulmón (GECP), Sociedad Española de Oncología Médica (SEOM), Asociación Española de Investigación sobre el càncer (ASEICA), European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC).

Co-Chair del 4th European Lung Cancer Conference (ELCC), Ginebra Març 2014.

Co-Chair International Association for the Study of Lung Cancer (IASLC -20th World Conference on Lung Cancer WCLC19, 7-10 Setembre 2019.

Founder and President of of ICAPEM: “Asociación para la investigación del Cáncer de Pulmón en Mujeres” (2011 – 2015). Nowadays she is active member of the Steering Committee.

2009 - 2015: Mentor of Resident physicians (Oncology Service), Vall d’Hebron University Hospital Hospital Vall d’Hebron desde 2009 fins l’any 2015. Certified bt the Generalitat de Catalunya on 21/05/2014.

Coordinator: 1st and 2nd ESMO Consensus Conference in Lung Cancer in 2001 and in 2014.

Between 2013 – 2015: Member “Consell Assessor de Medicació Hospitalària de

Dispensació Ambulatòria (CAMHDA).

Between 2008 and 2015: Author “Non-small-cell lung cancer (NSCLC) and “Small cell lung cancer guidelines (SCLC)”: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Entre els anys 2008-2015.

2015 IESE Master: “Programa de Alta Dirección de Instituciones Sanitarias”.

AQU (Agència per a la Qualitat del Sistema Universitari de Catalunya) Certificate: 31/10/2018: Application to Associate Professor (CERTIFICATION APROVED).

Ongoing Research Projects / Grants:

7

1. Use of next-generation sequencing technologies for the identification of new therapeutic targets and prognostic markers in lung carcinoma poorly characterized AECC Scientific Foundation 1.200.000,00€ Coordinator: CIMA VHIO PI: EFelip 245.000€ 2014 – 2019

2. Wnt/Beta-Catenin inhibitors as promising therapy for NSCLC treatment

Instituto de Salud Carlos III 122.815,00€ 2014 – 2017 Co-PI: EFelip

3. New technologies for new treatments: liquid biopsy meets immunotheraphy

GOI - Merck 384.000,00€ 2015 – 2018 Co-PI: EFelip

4. Wnt/beta-catenin pathway activation in advanced non-small cell lung cancer:

implications in resistance to inmunotherapy and novel terapeutic strategies Instituto de Salud Carlos III 135.520,00€ 2018 – 2020 Co-PI: EFelip

5. Non-invasive prognostic markers for Resected Early-STage NSCLC: role of

circulatING and exosomal miRNAs and free circulating DNA (RESTING) ERA-NET Transcan 2017 (ISCIII-AECC) 612.809,00€ Coordinator: IRST-IRCCS VHIO PI: EFelip 157.329,00€ 2018– 2020

6. An Epidemiological Studyof ALK gene rearrangement: prevelance and

clinical outcomes in patients with non-small cell lung cancer in Europe Agencia Financiadora: European Thoracic Oncology Platform – ETOP 2011 – 2019 IP: Enriqueta Felip Centro de Gestión: VHIO

7. Xenoinjertos ortotópicos derivados de pacientes como herramienta para el

estudio de mecanismos de resistencia adquirida en cánceres de pulmón dependientes de oncogenes FUNDACIÓN MERCK SALUD Importe: 25.000€ 2016 – 2017 IP: Enriqueta Felip

8. Ajut per donar suport a les activitats dels grups de recerca (SGR)

8

AGAUR 32.500€ 2018-2019 IP: Enriqueta Felip

Editorial Boards:

Cancer & Chemotherapy Reviews. Editor-in-Chief. Eduardo Díaz-Rubio. From May 2006.

Journal of Clinical Oncology. Associated Editor. Spanish Edition.

Annals of Oncology. Associated Editor. Scientiffic Revisor:

Cancer.

European Journal of Cancer.

Journal Thoracic Oncology.

Clinical and Translational Oncology.

Lung Cancer.

Annals of Oncology.

Cancer & Chemotherapy Reviews.

Clinical Cancer Research.

Journal of Clinical Oncology.

Lancet Oncology.

Scientific and Medical Societies:

ESMO (European Society for Medical Oncology) www.esmo.org

- “Full member” from December 1995. - 35th ESMO Congress, Milano (Italy), 2010. Member of the Scientific

Committee. - Between 2005 - 2013: Faculty Coordinator in Chest Tumors. - December 2018 – 31st August 2020: Member of the ESMO Nomination

Committee. - “4th ELCC (European Lung Cancer Congress).

ESO (European School of Oncology) www.eso.org - September 2013: Coordinator of “Lung Cancer Programme”.

ETOP (European Thoracic Oncology Platform) www.etop.org - Member of Foundation Council, 2017.

http://www.esmo.org/

http://www.eso.org/

http://www.etop.org/

9

EMTCO (European Multidiciplinary Conference in Thoracic Oncology - Lugano (Switzerland). Member of the Scientific Committee in 2009 and 2011

ASCO (American Scoiety of Clinical Oncology) www.asco.org

- “Active member” from November 1996.

IASLC (International Association for the Study of Lung Cancer) www.iaslc.org - “Active member” International from January 2001. - Member of the Board of Directors (Elected for period 2018 - 2021). - “11th WCLC (World Conference on Lung Cancer), Barcelona (Spain) 2005.

Scientific Secretary & Member of the Organizing Committee. - “12th WCLC (World Conference on Lung Cancer), Seoul (Korea), 2007.

Member of the International Scientific Committe. - “13rd WCLC (World Conference on Lung Cancer), San Francisco (USA) 2009.

Member of the International Scientific Committee. - “14th WCLC (World Conference on Lung Cancer), Amsterdam (The

Netherlands), 2011. Member of the International Scientific Committe. - Chair and Member of the Organizing Committee in “20th WCLC (World

Conference on Lung Cancer), Barcelona (Spain) September 2019.

SEOM (Sociedad Española de Oncología Médica) www.seom.org

- Vice-President for the years 2019-2021. Elected amomg all SEOM partners on October 2019. - Active member from June 1994. - 2005 SEOM Congress: Member of the Organizing Committee. - 2013 SEOM Congress: Member of the Scientific Committee.

GECP (Grupo Español Cáncer de Pulmón) www.gecp.org - Active member. - Member, Executive Committee, “Spanish Lung Cancer Group” (SLCG). - Member of the Scientific Committe in the years: 2002, 2004 and 2006.

“Active member” International Lung Cancer Partnership (ILCP) from June 2006.

Full member BIMA (Barcelona Internacional Medical Academy) since 2012.

Member, “Consell Assessor de la Medicació Hospitalària de Dispensació Ambulatòria (CatSalut), from January 2013.

Direction of Doctoral Thesis:

http://www.asco.org/

http://www.iaslc.org/

http://www.seom.org/

http://www.gecp.org/

10

Cedrés Pérez, Susana M. Estudio de marcadores moleculares en pacientes con tumores torácicos. Date: 26/11/2014. Cum Laude (Dr. Felip as Director).

Martínez Rodríguez, P. Cáncer de pulmón de cèl·lula no pequeña ALK positivo. Prevalencia y características. La inmunohisioquímica como método diagnostico. Date: 24/04/2015. Cum Laude (Dr. Felip as Co-Director).

Publication List:

1. M. Navarro, E. Felip, L. García, J. Bellmunt, L. Jolis, S. Morales, D. Rubio. Addison's disease secondary to prostatic carcinoma. A case report. Tumori, 1990; 76: 611-613.

2. E. Felip, A. Rovirosa, A. Salud, F. Capdevila, J. Bellmunt, J. Giralt. Orbital metastases from transitional-cell cancer of the urinary bladder. Urologia Internationalis, 1991; 46: 82-84.

3. A. Rovirosa, A. Salud, E. Felip, F. Capdevila, J. Giralt, J. Bellmunt. Cavitary pulmonary metastases in transitional cell carcinoma of the bladder. Urologia Internationalis, 1992; 48: 102-104.

4. J.M. del Campo, E. Felip, D. Rubio, R. Vidal, B. Bermejo, R. Colomer, V. Zanon. Long-Term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol, 1994; 53: 27-32.

5. R. Vergés, E. Felip, I. Alastuey, F. Capdevila, X. Maldonado, R. Bodi, J. Giralt, L. Salvador. Combined chemotherapy, radiotherapy and surgery in inflammatory breast carcinoma. Acta Oncologica, 1995; 34: 123-124.

6. E. Felip, J.M. del Campo, D. Rubio, M.T. Vidal, R. Colomer, B. Bermejo. Overexpression of c-erbB-2 in epithelial ovarian cancer: prognostic value and relationship with response to chemotherapy. Cancer, 1995; 75: 2147-2152.

7. J.M. del Campo, E. Felip. J. Giralt, G. Raspall, S. Bescos, S. Casado, J. Maldonado. Preoperative silmutaneous chemo-radiotherapy in locally advanced cancer of the oral cavity and oropharynx. Am J Clin Oncol, 1997; 20: 97-100.

8. E. Felip, J.M. del Campo, R. Bodi, R. Vera, S. Casado, D. Rubio. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage IIIB non-small cell lung cancer patients. Am J Clin Oncol, 1997; 20: 404-406.

9. R. Rosell, E. Felip, B. Massuti, JL González-Larriba, D. Benito, MP López-Cabrerizo, O. Salamanca, C. Camps, J. Puerto-Pica. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer. Seminars in Oncoly 1997; 24 (Suppl 12): S56-S60.

10. X. Maldonado, J. Alonso, J. Giralt, MG Cucurella, JM del Campo, A. Rovira, E.

Felip, J. Capellades, E. Grivé, D. Rubio, J. Gili. 31Phosphorus magnetic resonance spectroscopy in the assessment of head and neck tumors. Int J Radiat Oncol Biol Phys, 1998; 40: 309-312.

11. E. Felip, B. Massuti, C. Camps, D. Benito, D. Isla, JL González-Larriba, MP López-Cabrerizo, O. Salamanca, J. Puerto-Pica, A. Moyano, J. Baselga, R. Rosell. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small-cell lung cancer: Comparison of two phase II trials. Clinical Cancer Research, 1998; 4: 2723-2728.

12. M. Monzó, R. Rosell, E. Felip, J. Astudillo, J.J. Sánchez, J. Maestre, C. Martin, A. Font, A. Barnadas, A. Abad. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. J Clin Oncol, 1999; 17: 2100-2104.

11

13. J. Ferrer, MA. Villarino, G. Encabo, E. Felip, B. Bermejo, S. Vilà, R. Orriols. Diagnostic utility of CYFRA 21-1, CEA, CA125, NSE, and SCC level determination in serum and pleural fluid of patients with pleural effusions. Cancer, 1999; 86: 1488-1495.

14. R.Rosell, E. Felip. Role of multimodality treatment for lung cancer. Seminars in Surgical Oncology, 2000; 18: 143-151.

15. E. Felip, R. Rosell, V. Alberola, J. Gomez-Codina, J. Maestre, J. Astudillo, C. Camps, J.L. Gonzalez-Larriba, I. Moreno, A. Paredes, A. Artal, R. García-Gómez, P. Garrido, F. Cardenal, I. Barneto, J.J. Sánchez. Preoperative high-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non-small-cell lung cancer: Results of a Randomized Multicenter Trial. Clinical Lung Cancer, 2000; 4: 287-293.

16. E. Felip, R. Rosell. Is the evidence in favour of neoadjuvant chemotherapy in stage IIIA(N2) non-small cell lung cancer solid enough? Monaldi Archives for Chest Disease, 2000; 5: 305-310.

17. E. Felip. Neoadjuvant chemotherapy in non-small cell lung cancer: A standard approach? Tumori, 2000; 86 (5 Suppl 1): S51-S55.

18. D. Isla, R. Rosell, JJ Sánchez, A. Carrato, E. Felip, C. Camps, A. Artal, JL González-Larriba, P. Azagra, V. Alberola, C. Martin, B. Massuti. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol, 2001; 19:1071-1077

19. R. Rosell, J.M. Sánchez, M. Tarón, A. O’Brate, J.I. Gutierrez, M. Monzó, E. Felip, J.J. Sánchez, V. Alberola. Novel approaches in the treatment of non-small-cell lung cancer. Oncology, 2001; 15 (3 Suppl): 1-9.

20. E. Felip, R. Rosell. New strategies in the treatment of resectable non-small cell lung cancer. Expert Rev Anticancer Ther, 2001; 1: 222-228.

21. R. Rosell, E. Felip. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Seminars in Oncoly, 2001; 4 (Suppl 14): 37-44.

22. R. Rosell, E. Felip, J. Maestre, J. M. Sanchez, J.J. Sanchez, J.L. Manzano, J. Astudillo, M. Taron, M. Monzó. The role of chemotherapy in early non-small cell lung cancer management. Lung Cancer, 2001; 34: S63-S74.

23. E. Felip. Coordinating author for the ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol, 2001; 12: 1049-1050.

24. E. Felip. Coordinating author for the ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol, 2001; 12: 1051-1052.

25. E. Felip, R. Rosell. Neoadjuvant chemotherapy in non-small cell lung cancer. Current Medicinal Chemistry, 2002; 9: 893-898.

26. E. Felip. New anti-tubulin agents. Tumori, 2002; 1 (Suppl 4): 17-18.

27. E. Felip, R. Rosell, M. Domine, L. Santomé, P. Garrido, A. Font, A. Catarro, J. Terrasa, C. Vadell, J.M. Mañe, J.Baselga. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Ann Oncol, 2003; 14: 1549-1554.

28. F. Cardenal, M. Domine, B. Massutí, A. Carrato, E. Felip, P. Garrido, O. Juan, A. Artal, I. Barneto, G. López-Vivanco, M. Balcells, R. Rosell. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer, 2003; 39: 201-207.

29. R. Rosell, M. Taron, V. Alberola, B. Massuti, E. Felip. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer, 2003; 41 Suppl 1:S97-102.

30. V. Alberola, C. Camps, M. Provencio, D. Isla, R. Rosell, C. Vadell, I. Bover, A. Ruiz-Casado, P. Azagra, U. Jiménez, J.L. González-Larriba, P. Diz, F. Cardenal, A. Artal, A. Carrato, S. Morales, J.J.Sánchez, R.de las Peñas, E. Felip and G. López-

http://www.ncbi.nlm.nih.gov/pubmed/12867068

http://www.ncbi.nlm.nih.gov/pubmed/12867068

12

Vivanco. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a spanish lung cancer group phase III randomized trial. J Clin Oncol, 2003; 21: 3207-3213.

31. E. Felip. Revision of chemotherapy in early stages. Current Oncology Reports, 2004; 6 (Suppl I): S34.

32. R. Rosell, M. Taron, A. Ariza, A. Barnadas, J.L. Mate, N. Reguart, M. Margelí, E. Felip, P. Mendez, and R. García-Campelo. Molecular Predictors of Response to Chemotherapy in Lung Cancer. Seminars in Oncology, 2004; 31, 1, (Suppl. I) 20-27.

33. R. Rosell, E. Felip, M. Taron, J. Majo, P. Mendez, M. Sanchez-Ronco, C. Queralt, J. J. Sanchez, and J. Maestre. Gene expression as a predictive marker of outcome in stage IIIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clinical Cancer Research, 2004; 10 (Suppl.15) 4215s-4219s.

34. R. Rosell , J.M. Sanchez , M. Taron, T. Moran, B. Ciuraqui, M. Canela, E. Felip, B. Massuti, C. Camps. Pemetrexed in previously treated non-small-cell lung cancer. Oncology. 2004;18 (8 Suppl 5):63-71.

35. M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M.S. Ronco, C. Queralt, J. Majo, J.M. Sanchez, J.J. Sanchez, J. Maestre. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004; 20:2443-9.

36. R. Rosell, E. Felip, R. Garcia-Campelo, C. Balana. The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer, 2004; 46: 135-148.

37. E. Felip, M. Taron, R. Rosell, P. Mendez, C. Queralt, M. Sanchez Ronco, J.J. Sanchez, J.M. Sanchez, J. Maestre, J. Majo. Clinical Significance of Hypoxia-Inducible Factor-1 Messenger RNA expression in locally advanced non-small-cell-lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery. Clinical Lung Cancer, 2005; 5: 299-303.

38. C. Camps, E. Felip, J.M. Sanchez, B. Massuti, A. Artal, L. Paz-Ares, A. Carrato, V. Alberola, A. Blasco, J. Baselga, L. Astier, M. Voi and R. Rosell. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol, 2005; 16: 597-601.

39. J. Tabernero, F. Rojo, I. Marimón, M. Voi, J. Albanell, M. Guix, F. Vázquez, J. Carulla, M. Cooper, J. Andreu, A. Van Vreckem, J. Bellmunt, V. Manne, J. A. Manning, C. Garrido, E. Felip, J. M. del Campo, M. García, S. Valverde and J. Baselga. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hou infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol, 2005; 23: 2521-2533.

40. E. Felip, N. Pavlidis, R.A. Stahel; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol 2005; Suppl 1:30-1.

41. E. Felip, N. Pavlidis, R.A. Stahel; ESMO Guidelines Task Force. ESMO Minimum Clinical .Recommendations for diagnosis, treatment .and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2005; Suppl 1:28-9.

42. G. Giaccone, C. Debruyne, E. Felip, PB. Chapman, SC. Grant, M. Millward, L. Thiberville, G. D'addario, C. Coens, LS. Rome, P. Zatloukal, O. Masso, C. Legrand. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol, 2005;23:6854-64.

43. R. Rosell, E. Felip, N. Reguart, T. Moran. Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. Future Oncol, 2005;1: 319-22.

13

44. R. Rosell, M. Cuello, F. Cecere, M. Santarpia, N. Reguart, E. Felip, M. Taron. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 2006, 18: 135-43.

45. E. Felip, A. Font, R. Rosell, C. Saura. Small-cell lung cancer treatment: Present status and expectations. Business Briefing: European Pharmacotherapy 2006, 2-5.

46. C. Camps, B. Massuti, A. Jimenez, I. Maestu, RG. Gomez, D. Isla, JL. Gonzalez, D. Almenar, A. Blasco, R. Rosell, A. Carrato, N. Vinolas, N. Batista, CG. Giron, A. Galan, M. Lopez, R. Blanco, M. Provencio, P. Diz, E. Felip; Spanish Lung Cancer Group. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006, 17: 467-72.

47. A. Prat, E. Felip. Adjuvant chemotherapy in non-small cell lung cancer. Cancer & Chemotherapy Reviews, 2006; 1: 5-12.

48. R. Rosell, M. Cuello, F. Cecere, M. Santarpia, N. Reguart, E. Felip, M. Taron. Usefulness of predictive tests for cancer treatment. Bull Cancer 2006; 93:101-8.

49. E. Felip, R. Rosell. Clinical experience with erlotinib in non-small-cell lung cancer. Drugs Today (Barc). 2006, 42: 147-56.

50. E. Felip, E. Vilar. The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. Ann Oncol, 2006; 17 Suppl 10:108-112.

51. Morales R, Cedres S, Felip, E.Targeted agents in non-small cell lung cancer: Establishing new standards of treatment. 2007. Cancer and Chemotherapy Reviews. 2: 162-167.

52. E. Felip, R. Rosell. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn. 2007; 7:261-8.

53. ESMO Guidelines Working Group, E. Felip. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2007; 18 Suppl 2:II32-3.

54. C. Alemán, L. Sanchez, J. Alegre, E. Ruiz, A. Vázquez, T. Soriano, J. Sarrapio, J. Teixidor, J. Andreu, E. Felip, L. Armadans, T. Fernández De Sevilla. Differentiating between malignant and idiopathic pleural effusions: the value of diagnostic procedures. QJM. 2007; 100:351-9.

55. M.Cobo, D. Isla, B. Massuti, A. Montes, J.M. Sanchez, M. Provencio, N. Viñolas, L. Paz-Ares, G. Lopez-Vivanco, M.A. Muñoz, E. Felip, V. Alberola, C. Camps, M. Domine, J.J. SanchezJ, M. Sanchez-Ronco, K. Danenberg, M. Taron, D. Gandara, R. Rosell. Customizing cisplatin based on quantitative excision repair cross-complementing 1mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol, 2007; 25:2747-54.

56. E. Felip, S. Cedrés, S. Peralta, A. Prat. Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). Ann Oncol, 2007;18 Suppl 9:143-6.

57. R. Rosell, E. Felip, L. Paz-Ares. How could pharmacogenomics help improve patient survival? Lung Cancer, 2007; 57 Suppl 2:S35-41.

58. E. Felip, M. Santarpia, R. Rosell. Emerging drugs for non-small-cell lung cancer. Expert Opin Emerg Drugs, 2007; 12:449-60.

59. E. Felip, R. Rosell. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag. 2008, 4:579-85.

60. A. Bottomley, C. Debruyne, E. Felip, M. Millward, L. Thiberville, G. D'Addario, L. Rome, P. Zatloukal, C. Coens, G. Giaccone. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer, 2008; 44:2178-84.

61. E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, G. Sala, S. Cedres, S. Peralta, H. Maacke, D. Foernzler, M. Parera, J. Möcks, C. Saura, U. Gatzemeier, J. Baselga. Aphase II pharmacodynamic study of erlotinib in patients with advanced

14

non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res, 2008; 14:3867-74.

62. A.T. Chan, E. Felip; ESMO Guidelines Working Group. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008; 19 Suppl 2:ii81-2.

63. X. Pivot, E. Felip; ESMO Guidelines Working Group. Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008; 19 Suppl 2:ii79-80.

64. R.A. Stahel, W. Weder, E. Felip; ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008; 19 Suppl 2:ii43-4.

65. M. Sørensen, E. Felip; ESMO Guidelines Working Group. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008; 19 Suppl 2:ii41-2.

66. G. D'Addario, E. Felip; ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008; 19 Suppl 2:ii39-40.

67. E. Briasoulis, N. Pavlidis, E. Felip; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol, 2008; 19 Suppl 2:ii106-7.

68. S. Cedrés, A. Prat, P. Martínez, E. Pallisa, G. Sala, J. Andreu, J.M. Del Campo, I. Quispe, J. Baselga, E. Felip. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer, 2009; 66:257-61.

69. E. Felip, P. Garrido, J.M. Trigo, M. López-Brea, L. Paz-Ares, M. Provencio, D. Isla. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin Transl Oncol, 2009; 11:284-9.

70. L. Licitra, E. Felip; ESMO Guidelines Working Group. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009; 20 Suppl 4:121-2.

71. A.T. Chan, E. Felip; ESMO Guidelines Working Group. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009; 20 Suppl 4:123-5.

72. E. Briasoulis, N. Pavlidis, E. Felip; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009; 20 Suppl 4:154-5.

73. R.A. Stahel, W. Weder, E. Felip; ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009; 20 Suppl 4:73-5.

74. M. Sørensen, E. Felip; ESMO Guidelines Working Group. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009; 20 Suppl 4:71-2.

75. G. D'Addario, E. Felip; ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009; 20 Suppl 4:68-70.

76. E. Muñoz, S. Cedrés, E. Felip. Rare tumours of the chest. Eur J Cancer, 2009; 45 Suppl 1:400-1.

77. Rosell R , Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M, Felip E; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958-67.

15

78. E.H. Tan, R. Ramlau, A. Pluzanska, H.P.Kuo, M. Reck, J. Milanowski, J.S. Au, E. Felip, P.C. Yang, D. Damyanov, S. Orlov, M. Akimov, P. Delmar, L. Essioux, C. Hillenbach, B. Klughammer, P. McLoughlin, J. Baselga. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol, 2010; 21:217-22

79. L. Crinò, W. Weder, J. van Meerbeeck, and E. Felip On behalf of the ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010; 21Suppl 5: 103-115.

80. G. D'Addario, M. Früh, M. Reck, P. Baumann, W. Klepetko, and E. Felip On behalf of the ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010; 21Suppl 5: 116-119.

81. M. Sørensen, M. Pijls-Johannesma, and E. Felip On behalf of the ESMO Guidelines Working Group. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010; 21Suppl 5: 120-125.

82. R. A. Stahel, W. Weder, Y. Lievens, and E. Felip On behalf of the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010; 21Suppl 5: 126-128.

83. V. Grégoire, J.-L. Lefebvre, L. Licitra, and E. Felip On behalf of the EHNS–ESMO–ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010; 21Suppl 5: 184-186.

84. T. C. Chan, V. Grégoire, J.-L. Lefebvre, L. Licitra, and E. Felip On behalf of the EHNS–ESMO–ESTRO Guidelines Working Group. Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010; 21Suppl 5: 187-189.

85. N. Altorki, M. E. Lane, T. Bauer, P. C. Lee, M. J. Guarino, H. Pass, E. Felip, N. Peylan-Ramu, A. Gurpide, F. W. Grannis, J. D. Mitchell, S. Tachdjian, R. S. Swann, A. Huff, D. F. Roychowdhury, A. Reeves, L. H. Ottesen, D. F. Yankelevitz. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non–small-cell lung cancer. J Clin Oncol, 2010; 28: 3131-7.

86. E. Felip, R. Rosell, J. A Maestre, J. M Rodríguez-Paniagua, T. Moran, J. Astudillo, G. Alonso, J. M Borro, J.L González-Larriba, A. Torres, C. Camps, R. Guijarro, D. Isla, R. Aguiló, V. Aberola, J. Padilla, A. Sánchez-Palencia, J. J. Sánchez, E. Hermosilla, B. Massuti. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol, 2010; 28: 3138-45.

87. Felip E, Cedres S, Checa E, Martinez P. How to integrate current knowledge in selecting patients for first line in NSCLC? Annals of Oncology 2010; 21: S230-S233.

88. Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E. Sunitib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer 2010; 70: S180-S187.

89. Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Baron FJ, Cobo M, Maestu I, Moreno I, Mesia C, Izquierdo A, Felip E, Lopez-Brea M, Márquez A, Sanchez Ronco M, Taron M, Santarpia MC, Rosell R. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011; 71 (2): 191-198.

16

90. Dienstmann R, Martinez P, Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget. 2011 March (3):165-77.

91. Felip E, Gridelli C, Baas P, Rosell R, Stahel R; Panel Members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 2011 Jul;22 (7):1507-19.

92. Cedrés S, Núñez I, Longo M, Martínez P, Checa E, Torrejón D, Felip E. Serum tumor markers CEA, CYFRA21-1 and CA-125 are associated with worse prognosis in advanced non-small-cell Lung cancer (NSCLC). Clin Lung Cancer, 2011; 12(3): 172-9.

93. Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer. 2011;74 (1):1-6.

94. Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther, 2011; 11 (9):1223-31.

95. Carbone DP, Felip E. Adjuvant therapy in non-small cell lung cancer: Future treatment prospects and paradigms. Clin Lung Cancer, 2011; 12 (5): 261-71.

96. Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, De Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer, 2011; 74 (3): 544-8.

97. Stahel R, Thatcher N, Früh M, Le Péchoux, Potsmus PE, Sorensen JB, Felip E. Panel members 2011: 1st ESMO Consensus Conference in Lung Cancer: Lugano 2010: Small Cell Lung Cancer. Ann Oncol, 2011; 22 (9): 1973-1980.

98. Dienstmann R, De Dosso S, Felip E, Tabernero J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol. Oncol. 2011; 6(1):15-26.

99. Gridelli C, Felip E. Targeted therapies development in the treatment of advanced nonsmall cell lung cancer. J. Biomed Biotechnology. 2011: 415-641.

100. Gómez JJ, De Castro J, Concha Á, Felip E, Isla D, López-Ríos F, Paz-Ares L; Ramírez J, Sanz J, Garrido P. Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. 2012. Revista Española De Patología, 2012; 45: 14-28.

101. Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, Jiang GL, Reck M, Schneider Cp. Safety and Efficacy of First-ine bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung Trial (MO19390). J Thorac Oncol 2012; 7 (1): 203-211.

102. Martinez P, Felip E. Brain metastases: The need for a more tailored approach in non-small cell lung cancer patients. Clinical & Translational Oncology 2012; 14 (1): 1-2.

103. Rosell R, Carcereny E, Gerbvais R, Vergnenegre A, massuti B, Felip E, Palmero R, Garcia Gómez R, Pallarés C, Sánchez JM, porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, De Castro J, Milella M, reguart N, Altavilla G, Jiménez U, Provencio M, Moreno MA, Terrassa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, López-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sánchez Ronco N, Drozdowskyj A, Queralt C, De Aguirre I, Ramírez JL, Sánchez JJ, Molina MA, taron M, Paz-Ares L. On behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the

17

Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label randomized phase 3 trial. Lancet Oncology 2012; 13 (3): 239 -246.

104. Cedres S, Montero MA, Martinez P, Rodriguez-Freixinós V, Torrejón D, Gabaldón A, Salcedo M, Ramón y Cajal S, Felip E. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012. Jul;77(1):192-8.

105. Cedrés S, Mulet-Margalef N, Montero MA, Martínez P, Martínez A, Felip E. Rectal metastases from squamous cell carcinoma: A case report and review of the literature. Case report Med. 2012, April. Case Rep Med. 2012:947524.

106. Garrido P, De Castro J, Concha A, Felip E, Isla D, López Ríos, Paz Ares L, Ramírez J, Sanz J, Gómez JJ. Guidelines for biomarker testing in advanced non-small cell lung cancer. A National Consensus of the Spanish Society of medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clinical Translational Oncology 2012;14 (5): 338-49.

107. Felip E, Martinez Martí A. DNA repair protein expression in resected NSCLC: A different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma? Annals of Oncology 2012. June Sep;23(9):2211-4.

108. Cedrés S, Torrejón D, Martínez A, Martínez P, Navarro A, Zamora E, Mulet-Margalef N, Felip E. Neutrophil to lymphocyte ratio (NLR) as an indicator of por prognosis in stage IV non-small cell lung cancer. Clin. Transl. Oncol. 2012 Nov;14(11):864-9.

109. Felip E, Martinez P. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers? Ann Oncol 2012; 10: 189-192.

110. Chan AT, Grégoire V, Lefevre JL, Licitra L, Hui EP, Leung SF, Felip E (EHNS-ESMO-ESTRO Guidelines Working Group). Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice. Ann Oncol 2012; 23, 7:vii 83-5.

111. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. ESMO Guidelines Working Group. Metastatic Non Small Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis treatment and Follow up. Ann Oncol; 2012; 23: Vii 56-64.

112. Felip E, Ranson Malcom, Cedrés S, Dean E, Brewster M, Martinez P, McNally V, ross G, Galdermans D. A phase Ib, Dose finding Study of Erlotinib in Combination With a Fixed Dose of pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer. 2012; 13 (6):432- 441.

113. Martinez P, Hernández-Losa J, Montero MA, Cedrés S, Castellví J, Martínez Martí A, Tallada N, Murtra-Garrell N, Navarro Mendivil A, Rodríguez Freixinós V, Canela M, Ramón y Cajal S, Felip E. Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic methods for ALK Positive Non-Small Cell Lung Cancer Patients. PLos One 8 (1):e52261.

114. Felip E, Martínez Martí A, Martínez P, Cedrés S, Navarro A, Adjuvant treatment of resected non small cell lung cancer: State of the Art and new Potential Developments. Curr Opin Oncol 2013; 25 (2): 115-20.

115. Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, ARmand JP, Sheperd FA, Harbison CT, Baerman D, Park JS, Vakkalagadda B, Kurland JF, pathak AK, Herbst RS. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer 2013; 49 (8): S1815-1824.

116. Cedrés S, Fariñas L, Stejpanovic N, martinez P, Martinez A, Zamora E, Montero MA, Felip E. Bone metastases with nerve root compression as a late complication in patients with epitelial mesothelioma. J Thorac Dis 2013; 5 (2):E35-7.

117. Garrido AC, Felip E. HER2 driven non-small cell lung cancer (NSCLC): Potential therapeutic approaches. Transl Lung Cancer Research 2013; 2: 122-7.

https://www.ncbi.nlm.nih.gov/pubmed/22567021

18

118. Mazières J, Peteres S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Manuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors a HER2 mutation: Epidemiologic characteristics and thaerapeutics perspectives. J Clin Oncol 2013; 31 (16):1997-2003.

119. Gamarra F, Boffetta P, De Ruysscher D, Felip E, Gaga M, Grigoriu B, Huber RM, Janes SM, Marquette CH, Massard G, Noel JL, Sculier JP, Meert AP. Thoracic OncologyHERMES syllabus: Setting the basis for thoracic oncology training in Europe. Eur Respir J 2013; 42 (3): 568-71.

120. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, Peters S: ESMO Guidelines Working Group. Early and locally advanced non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Annals of Oncology 2013; (6): 89-98.

121. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E. Small cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Annals of Oncology. 201; (24): 99-105.

122. Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernández Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. Clinical response to a Lapatinib-based Therapy for a Li- Fraumeni Syndrome Patient with a Novel HER2V659 E Mutation. Cancer Discov. 2013; (11):1238-44.

123. Dientsmann R, Rodon J, Prat A, Pérez-Garcia J, Adamo B, Felip E, Cortés J, Lafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: Opportunities for a targeted therapies in solid tumors. Ann Oncol 2014 Mar;25(3):552-63.

124. Remon J, Molina-Montes E, Majem M, Lianes P, Isla D, Garrido P, Felip E, Viñolas N, de castro J, Artal A, Sánchez MJ. Lung Cancer in women: An overview with special focus on Spanish women. Clin Transl Oncol. 2014 Jun;16(6):517-28.

125. Camps C, Felip E, Garcia Campelo R, Trigo JM, Garrido P. SEOM Clinical Guidelines for the treatment of non-small cell lung cancer (NSCLC). Clin. Transl. Oncol 2013 Clin Transl Oncol. 2015 Dec;17(12):1020-9.

126. Stahel R, Peters S, Baas P, Brambilla E, Capuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer 2013; 82 (3): 375-82.

127. Cedrés S, Montero MA, Zamora E, Martínez A, Martínez P, Fariñas L, Navarro A, Torrejón D, Gabaldón A, Ramón y Cajal S, Felip E. Expression of Wilm’s tumour gene (WT1) is associated with survival malignant pleural mesothelioma. Clinical Transl. Oncol. 2013 Clin Transl Oncol. 2014 Sep;16(9):776-82.

128. Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol 2013;8(12):1529-37.

129. Prat A, Adamo B , Fan C , Peg V , Vidal M , Galván P , Vivancos A , Nuciforo P , Palmer HG , Dawood S , Rodón J , Cajal SR , Del Campo JM , Felip E , Tabernero J , Cortés J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 18;3 Sci Rep. 2013 Dec 18;3:3544.

130. Martinez P, Martinez-Marti A , Navarro A , Cedrés S , Felip E . Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate? Lung Cancer. 2014 Jan Lung Cancer. 2014 May;84(2):97-100.

131. Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel R, Peters S, Felip E; Panel Members. 2nd ESMO Consensus Conference on Lung Cancer: early stage nonsmall cell lung

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lung+Cancer+in+women%3A+An+overview+with+special+focus+on+Spanish+women.


https://www.ncbi.nlm.nih.gov/pubmed/?term=Expression+of+Wilm%E2%80%99s+tumour+gene+(WT1)+is+associated+with+survival+malignant+pleural+mesothelioma



19

cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014 Aug;25(8):1462-74.

132. Jänne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P, Felip E. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol 2014;9(3):316-23.

133. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R.The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clin Cancer Res 2014; 20(7):2001-10.

134. Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S. 2nd ESMO Consensus Conference on Lung Cancer: Non-Small-Cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014 Ann Oncol. 2014 Aug;25(8):1475-84.

135. Martinez P, Martinez-Marti A, Navarro A, Cedres S,Felip E. Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate? Lung Cancer 2014; 84 (2): 97-100.

136. Shaw A, Kim D, Mehra R, Tan D, Felip E, Chow L, Camidge D, Vansteenkiste J, Sharma S, De Pas T, Riely G, Solomon B, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, goldwasse M, Boral A, Engelman J. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 27; 370 (13):1189-97.

137. Kerr K, Bubendorf L, Edelman M, Marchetti A, Mok T, Novello S, O’Byrne K, Stahel R, Peters S, Felip E. 2nd ESMO Consensus Conference on Lung Cancer: Pathology and Molecular Biomarkers for Non-small-cell lung cancer. Ann Oncol. Apr. Ann Oncol. 2014;25(9):1681-90.

138. Costa C, Molina MA, Drozdowskyj A, Gimenez-Capitan A,Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T et al. The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research 2014; 20(7): 2001-2010.

139. Peghin M, Ruiz Camps I, Garcia-Vidal C, Cervera C, Andreu J, Martin M, Gavaldà J, Gudiol C, Moreno A, Felip E, Pahissa A. Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. J Infect 2014; (4): 387-95.

140. Novello S, Besse B, Felip E, Barlesi F, Mazières J, Zalcman G, Von Pawel J, Reck M, Capuzzo F, Ferry D, Carcereny E, Santoro A, Garcia-Ribas I, Scagliotti G, Soria JC. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Ann Oncol. 2014, Ann Oncol. 2014 Nov;25(11):2156-62.

141. Martínez P, Sales Fidalgo PA, Felip E. Ganitumab for the treatment of small-cell lung cancer. Expert Opin Investig Drugs. 2014; 23 (10):1423-32.

142. Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: Randomized non comparative phase IIIb NEXT trial. Target Oncol. Target Oncol. 2015 Jun;10(2):255-65.

143. Cherny NI; ESMO Guidelines Working Group (Dr. Felip is member of the ESMO GWC). ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol 2014; 25 (3): 143-52.


https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Martinez,%20P

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Martinez-Marti,%20A

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Navarro,%20A

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Cedres,%20S

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Felip,%20E&ut=11249111&pos=%7b2%7d&excludeEventConfig=ExcludeIfFromFullRecPage

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kerr+K%2C+Bubendorf+L%2C+Edelman+M%2C+Marchetti+A%2C+Mok+T%2C+Novello+S%2C+O%E2%80%99Byrne+K%2C+Stahel+R%2C+Peters+S%2C+Felip+E.+2nd+ESMO+Consensus+Conference+on+Lung+Cancer%3A+Pathology+and+Molecular+Biomarkers+for+Non-small-cell+lung+cancer.+Ann+Oncol.+Apr.

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Costa,%20C

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Molina,%20MA

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Drozdowskyj,%20A

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Gimenez-Capitan,%20A

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Bertran-Alamillo,%20J

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Bertran-Alamillo,%20J

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Karachaliou,%20N

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Gervais,%20R

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Massuti,%20B&ut=13200853&pos=%7b2%7d&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Wei,%20J

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Moran,%20T&ut=13423612&pos=%7b2%7d&excludeEventConfig=ExcludeIfFromFullRecPage

https://www.ncbi.nlm.nih.gov/pubmed/?term=A+phase+II+randomized+study+evaluating+the+addition+of+iniparib+to+gemcitabine+plus+cisplatin+as+first-line+therapy+for+metastatic+non-small-cell+lung+cancer

https://www.ncbi.nlm.nih.gov/pubmed/?term=Weekly+and+every+2+weeks+cetuximab+maintenance+therapy+after+platinum-based+chemotherapy+plus+cetuximab+as+first-line+treatment+for+non-small+cell+lung+cancer%3A+Randomized+non+comparative+phase+IIIb+NEXT+trial.

20

144. Schrijvers D, Cherny NI; ESMO Guidelines Working Group (Dr. Felip is member of the ESMO GWC). ESMO Clinical Practice Guidelines on palliative care: Advanced Care Planning. Ann Oncol; 25 (3): 138-42.

145. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A; ESMO Guidelines Working Group. (Dr. Felip is member of the ESMO GWC). Renal Cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 201; 25 (3): 49-56.

146. Felip E, Concha A, de castro J, Gómez-Romáqn J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015 Feb; 17 (2): 103-12.

147. Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: A phase I /II randomized trial. Exp Hematol Oncol 2014; 7; 3 (1):26.

148. Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O’Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators. Lungscape: Resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol 2014; 9 (11): 1675-84.

149. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Capuzzo F, Paolini J, Usari T, Lyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371 (23): 2167-77.

150. Spigel DR, Barlesi F, Felip E, Kim J, Olivo M, Nokihara H, Yang JC, Satouchi M, Katakami N, Iannotti N. Efficacy and Safety of Eribulin Compared with Treatment of Physician’s Choice (TPC) in Patients with Advanced Non-Small-Cell Lung cancer (NSCLC): Results form a Phase 3 Study: Locally Advanced Non-small Cell Lung cancer. Int J Radiat Oncol Biol Phys 2014; 90(5):1266.

151. Capuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer 2015; 87 (2): 89-95.

152. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nucifor P, Palmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortés J. ERRATUM: Genomic analyses across Six cáncer types identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep. 2015; 11; 5: 8179.

153. Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Martí A, Martínez P; Felip E. Analysis of Expression of programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM).PLoS One. 2015 Mar 16;10(3):e0121071.

154. Gridelli C, Balducci L, Ciardiello F, Di Maio M, Felip E, Langer C, Lilenbaum RC, Perrone F, Senan S, de Marinis F. Treatment of Elderly Patients With Non-Small Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2015; 7: S1525-7304.

155. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372 (21):2018-28.

156. Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S; Panel Members. 2nd ESMO Consensus



21

Conference in Lung Cancer: Locally –advanced stage III non-small-cell lung cancer (NSCLC). Ann Oncol; Ann Oncol. 2015 Aug;26(8):1573-88.

157. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372 (18):1689-99.

158. Thress KS, Paweletz CO, Felip E, Cho BC, Stetson, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560-2.

159. Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsch Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D. A Randomized Phase Study of Ganetespib, A Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer (GALAXY-1). Ann Oncol. 2015 Aug;26(8):1741-8.

160. Vansteenkiste JF, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC. Safety and Efficacy of Buparlisib (BKM 120) in patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer (NSCLC): results From the Phase II BASALT-1 Study. J Thorac Oncol 2015 Sep;10(9):1319-1327.

161. Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Targeted Oncology 2015;10 (2), 255-265.

162. Karachaliou N, Mayo de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sanchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E. Spanish Lung Cancer Group. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. Jama Oncology 2015; 1 (2), 149-157.

163. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, goss GD, LUX-Lung Investigators. Afatinib versus erlotinib as second line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907.

164. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, lena H, Poddubdkaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nosquamous Non-Small-Cell-Lung Cancer. N Engl J Med 2015; 373 (17):1629-39.

165. De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, raventos C, tang J, Guerini-Rocco E, Martínez Sáez E, lois S, Marín O, de la Cruz X, Piscuoglio S, towers R, Vivancos A, Peg V, Ramon y cajal S, Carles J, Rodon J, González-cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumors than plasma. Nat Commun. 2015 Nov 10;6:8839.

166. Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Massuti B,

https://www.ncbi.nlm.nih.gov/pubmed/?term=Eberhardt+WE%3B+De+Ruysscher+D%3B+Weder+W%3B+Le+P%C3%A9choux+C%3B+De+Leyn%3B+Hoffmann+H%3B+Westeel+V%3B+Stahel+R%3B+Felip+E%3B+Peters+S%3B+Panel+Members.+2nd+ESMO+Consensus+Conference+in+Lung+Cancer%3A+Locally+%E2%80%93advanced+stage+III+non-small-cell+lung+cancer+(NSCLC).

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Heigener,%20DF

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Pereira,%20JR&ut=1766823&pos=%7b2%7d&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Felip,%20E&ut=11249111&pos=%7b2%7d&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Mazal,%20J

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Manzyuk,%20L

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Tan,%20EH&ut=1607116&pos=%7b2%7d&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Merimsky,%20O

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Sarholz,%20B

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Esser,%20R

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Gatzemeier,%20U&ut=11760904&pos=%7b2%7d&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Karachaliou%2C+Niki&cacheurlFromRightClick=no

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Mayo-de+las+Casas%2C+Clara

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Queralt%2C+Cristina

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=de+Aguirre%2C+Itziar

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Melloni%2C+Boris

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Cardenal%2C+Felipe

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Cardenal%2C+Felipe

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Garcia-Gomez%2C+Ramon

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Massuti%2C+Bartomeu

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Sanchez%2C+Jose+Miguel

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Porta%2C+Ruth&cacheurlFromRightClick=no

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Ponce-Aix%2C+Santiago

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Moran%2C+Teresa

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Moran%2C+Teresa

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Carcereny%2C+Enric

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Felip%2C+Enriqueta

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cerebrospinal+fluid-derived+circulating+tumour+DNA+better+represents+the+gen%C3%B2mic+alterations+of+brain+tumors+than+plasma

22

Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep. 2015 Dec 7;5:17499.

167. Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, de Marinis F, feng JF, Grossi F, kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016; 27 (3):417-23.

168. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50.

169. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesns A, Kazarnowicz A, beck JT, Westeel V, Felip E, debieuvre D, Madroszyk A, Adam J, lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM. TG4010 immunotherpy and first-line chemotherapy for Advanced non-small-cell lung cancer (TIME): results from the phase 2b part of randomised, double-blind, palcebo controlled, phase 2b/3 trial. Lancet Oncol 2016; 17 (2): 212-23.

170. Vergnenegre A, Massuti B, de marinis F, Carcereny E, Felip E, Do P, Sanchez JM, Paz-Ares L, Chouaid C, Rosell R; Spanish Lung Cancer Group, Italian Association of Thoracic Oncology and French Lung Cancer Group. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. J Thorac Oncol. 2016 Jun;11(6):801-7.

171. Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, cantarini M, Vishwanathan K, Janne PA, Ranson M, Dickinson PA. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol 2016; 77 (4): 767-76.

172. Gridelli C, Besse B, Brahmer JR, Crinò L, Felip E, Leese P, Cantarini M, Vishwanathan K, Janne PA, Ranson M, Dickinson PA. The evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an Internal Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2016 May;17(3):161-8.

173. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung càncer (ASCEND-1): Updated results from the multicentre, opne label, phase 1 trial. Lancet Oncol. 2016 Apr;17(4):452-463.

174. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial Efficacy of Crizotinib Versus Chemotherapy in patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: results From Profile 1014. J Clin Oncol. 2016 Aug 20;34(24):2858-65.

175. Chatterjee M, Turner DC, Felip E, Lena H, Capuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T,

https://www.ncbi.nlm.nih.gov/pubmed/?term=BIM+and+mTOR+expression+levels+predict+outcome+to+erlotinib+in+EGFR-mutant+non-small-cell+lung+c%C3%A0ncer.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Economic+Analysis+of+First-Line+Treatment+with+Erlotinib+in+an+EGFR-Mutated+Population+with+Advanced+NSCLC

https://www.ncbi.nlm.nih.gov/pubmed/?term=Intracranial+Efficacy+of+Crizotinib+Versus+Chemotherapy+in+patients+With+Advanced+ALK-Positive+Non-Small-Cell+Lung+Cancer%3A+results+From+Profile+1014

https://www.ncbi.nlm.nih.gov/pubmed/?term=Intracranial+Efficacy+of+Crizotinib+Versus+Chemotherapy+in+patients+With+Advanced+ALK-Positive+Non-Small-Cell+Lung+Cancer%3A+results+From+Profile+1014

23

Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Flotten O. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small cell lung cancer. Ann Oncol 2016 Jul;27(7):1291-8.

176. Cedres S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martínez Martí A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E. Analysis of expression pf PTEN/PI3K pathway and programmed cell death ligand (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer. 2016 Jun;96:1-6.

177. Gridelli C, Besse B, Brahmer JR, Crinò L, Felip E, de Marinis. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A new Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of The Italian Association of Thoracic Oncology. Clin Lung Cancer. 2016; 17(3):161-8.

178. Reck M, Luft A, Szcesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pierters A, Kong Sanchez T, Fairchild J, Spigel D. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016 Nov 1;34(31):3740-3748.

179. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT. Multicenter Phase II Study of Whole-Body and Intracranial ACtivity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: results From ASCEND-2. J Clin Oncol 2016;34(24):2866-73.

180. Smit EF, Wu YL, Gervais R, Zhou C, Felip E, Feng J, Guclu SZ, Hoiczyk M, Dorokohova E, Freudensprung U, Grange S, Perez-Moreno PD, Mitchell L, Reck M. A Randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with Advanced non-small-cell lung cancer (CurrentS). Lung Cancer. 2016 Sep;99:94-101.

181. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Felip E, Purkalne G. ESMO / ASCO recommendations for a Global Curriculum (GC) in Medical oncology-edition 2016. Ann Oncol 2016; 27(8):1378-81.

182. Herbst RS, Baas P, Pérez Garcia JL, Felip E, Kim DW, Han JY, Molina J, kim JH, ARvis CD, AHn MJ, Majem M, Fidler MJ, Surmont V, De Castro J, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. Pembrolizumab vs. Docetaxel for Previosuly Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assesment. J Thorac Oncol 2016; 11 (10S):S174-S175.

183. Borghaei H, Brahmer J, Horn L, Ready N, Steins M, Felip E, Paz-Ares L, Barlesi F, Antonia S, Fayette J, Rizvi N, Crino L, Reck M, Erich Eberhardt WE, Hellmann M, Desai K, Li A, Healey D, Spigel D, Mathias C. Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis. J Thorac Oncol 2016; 11 (10S):S237-S238.

184. Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl N, Aggarwal C, horn L, patnaik A, Middleton GW, Gubens M, Hellmann M, Soria JC, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. Long-term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. J Thorac Oncol 2016; 11 (10S): S241-S242.

185. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Nocello S, Papotti M, Pérol M, Smit EF Syrigos K, van Meerbeeck JP, van Zandwijk N, Chich-Hsin Yan J, Zhou C, Vokes E. The potential of combined immunotherpay and antiangiogenesis for the

https://www.ncbi.nlm.nih.gov/pubmed/?term=Analysis+of+expression+pf+PTEN%2FPI3K+pathway+and+programmed+cell+death+ligand+(PD-L1)+in+malignant+pleural+mesothelioma+(MPM

https://www.ncbi.nlm.nih.gov/pubmed/?term=A+Randomized%2C+double-blind%2C+phase+III+study+comparing+two+doses+of+erlotinib+for+second-line+treatment+of+current+smokers+with+Advanced+non-small-cell+lung+cancer

24

synergistic treatment of Advanced NSCLC. J Thorac Oncol 2017 Feb;12(2):194-207.

186. Isla D, Majem M, Viñolas N, Artal A, Blasco A, Felip E, Garrido P, Remón J, Baquedano M, Borrás JM, Die Trill M, Garcia-Campelo R, Juan O, León C, Lianes P, López Ríos F, Molins L, Planchuelo MA, Cobo M, Paz-Ares L, Trigo JM, de castro J. A consensus statement on the gender perspective in lung cancer. Clin Transl Oncol. 2017 May;19(5):527-535.

187. Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Carcereny E, Chow LQ, Koczywas M, Garasino MC, Christoph D, Toh CK, Johnson ML, Chaft J, Kurata T, Qiu J, Kowanetz M, COleman S, Mocci S, Sandler A, Gettinger SN, Peters S. Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results. J Thorac Oncol 2016; 11 (11 S): S251-S252.

188. Gamarra F, Noël JL, Brunelli A, Dingemans AC, Felip E, Gaga M, Grigoriou BD, Hardavella G, Huber RM, janes S, Massard G, Putora PM, Sculier JP, Schnabel PA, Ramella S, Van Raemdonck D, Meert AP. Thoracic Oncology HERMES: European currículum recommendations for training in thoracic oncology. Breathe (Sheff) 2016; 12(3): 249-255.

189. Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, cassier P, Liu B, Kowanetz M, O’Hear C, Fassò M, Sandler A, Gettinger SN. Long Term Safety and Clinical ACtivity of Atezolizumab Monotherapy in Metastatic NSCLC: Final results from Phase Ia Study. J Thorac Oncol 2016; 11 (11S): S309-310.

190. Isla D, Felip E, Viñolas N, Provencio M, Majem M, Artal A, Bover I, Lianes P, DE Las Peñas R, Catot S, DE Castro J, Blasco A, Terrasa J, González-Larriba JL, Juan O, Dómine M, Bernabe R, Garrido P. Lung Cancer in Women with a Family History of Cancer: The Spanisg Female-specific Database WORLD07. Anticancer Res. 2016; 36 (12):6647-6653.

191. Gridelli C, Ascierto PA, Barberis MC, Felip E, Garon EB, O’brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F. Immunotherapy of non-small cell lung cancer: report from an International experts panel Meeting of the Italian association of thoracic oncology. Expert Opin Biol Ther 2016; 16 (12): 1479-1489.

192. Pereira C, Giménez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gómez-Lçopez G, Graña O, Rubio-Camarillo M, Martínez-Martí AL, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano DG, Sozzi G, Felip E, Montuenga L, Roz L, Villanueva A, Sánchez Céspedes. Genomic Profiling of patient Derived Xenografts for lung Cancer identifies B2M inactivation impairing Immunorecognition. Clin Cancer Res. 2017 Jun 15;23(12):3203-3213.

193. Rivera F, Andres R, Felip E, Garcia Campelo R, Lianes P, Llombart A, Piera JM, Puente J, Rodriguez CA, Vera R, Virizuela JA, Martin M, Garrido P. Medical Oncology future plan of the Spanish Society of Medical Oncology: Challenges and future needs of the Spanish Oncologists. Clin Transl Oncol 2017 Apr;19(4):508-518.

194. Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA. Pembrolizumab as first-line therapy for patients with PD-L1-positive Advanced non-small cell Lung cancer: A phase 1 Trial. Ann Oncol. 2017 Apr 1;28(4):874-881.

195. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. Apr 20;35(12):1288-1296.

https://www.ncbi.nlm.nih.gov/pubmed/?term=A+consensus+statement+on+the+gender+perspective+in+lung+cancer

https://www.ncbi.nlm.nih.gov/pubmed/?term=A+consensus+statement+on+the+gender+perspective+in+lung+cancer

25

196. Guillaument-Adkins A, Rodríguez-Esteban G, mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martínez-martí A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H. Single-cell transcriptome conservation in cryopreserved cells and tissues. Genome Biol 2017 Mar 1;18(1):45.

197. Remon J, Pardo N, Martínez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM, Felip E. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. Lung Cancer 2017; 106:70-75.

198. Viñolas N, Garrido P, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E. Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. Cancer Invest 2017; 28;35 (5): 358-365.

199. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017; 5 (5): 435-444.

200. Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev 2017; 55: 181-189.

201. Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, Victoria I, Viñolas N, Vivancos A, Arance A, Felip E. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma and Melanoma. Cancer Res. 2017; 77(13):3540-3550.

202. Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A. Evaluation of the VeriStrat serum protein test in patients with adavanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer 2017; 109:101-108.

203. Meulendijks D, Jacob W, voest EE, Mau-Sorensen M, Martinez Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-LorenteG, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN. Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clin Cancer Res 2017; 23 (18): 5406-5415.

204. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinb versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and Crizotinib (ASCEND-5): A randomized, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18 (7): 874-886.

205. Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Cristoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, Van den Heuvel M, Rothenstein J, Reck M, Paz Ares L, Sepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With




26

Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017;35 (24): 27781-2789.

206. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, Van den Heuvel MM, Ciuleanu TE, Badin F, ready N, Hiltermann TJN, nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villacruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376(25):2415-2426.

207. Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-worls setting: the WORLD07 database. Clin Transl Oncol. 2017 Dec;19(12):1537-1542.

208. Felip E, Hirsch V, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, palmer M, Ehrnrooth E, Gadgeel SM. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clin Lung Cancer 2018 Jan;19(1):74-83.e11.

209. Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017 Sep 4;8(1):410.

210. Katami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N, Satouchi M, Barlesi F. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer. Ann Oncol 2017;28(9):2241-2247.

211. Martinez-Martí A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Dual MET and ERB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell Lung cancer (NSCLC). Ann Oncol 2017; 28 (10): 2451-2457.

212. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, geese WJ, Li A, Blackwood-Chirchir A, Heale D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previosuly Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Checkmate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-3933.

213. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib on non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicenter, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 2017 Dec;18(12):1590-1599.

214. Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W,

https://www.ncbi.nlm.nih.gov/pubmed/?term=Convergent+Akt+activation+drives+acquired+EGFR+inhibitor+resistance+in+lung+cancer.

27

Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium. Prevalence and clinical association of gene mutations through Multiplex Mutation testing in patients with NSCLC: Resulat sfrom the ETOP Lungscape Project. Ann Oncol 2018 Jan 1;29(1):200-208.

215. Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; ETOP Lungscape Consortium. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from ETOP Lungscape Project. J Thorac Oncol 2018 Mar;13(3):413-425.

216. Goss G, Shepherd F, Ahn MJ, Bazhenova L, Crino L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne P, Yang J. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two Phase II trials. Ann Oncol 2018 Mar 1;29(3):687-693.

217. Navarro A, Felip E. Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope? Transl Lung Cancer Res 2017; (Suppl 1): S78-S83.

218. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zeron-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Association of the Lung Immune Prognostic Index Witj Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncology 2018; 4(3): 351-357.

219. Gridelli C, Baas P, Barlesi F, Ciardiello F, Crino L, Felip E, Gadgeel S, Papadimitrakopoulou V, paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, De Marinis F. Second-Line treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2018 Jul;19(4):301-314.

220. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crino L. Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3 year update and outcomes in patients with liver metastases. Ann Oncol. 2018 Apr 1;29(4):959-965.

221. Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol 2018; 29 (suppl_1): i20-i27.

222. Cedres S, Felip E, Cruz C, Martínez de Castro A, Pardo N, Navarro A, Martínez Martí A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V, Vivancos A. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. J Natl Cancer Inst 2018 Aug 1;110(8):914-917.

223. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378(22): 2078-2092.

28

224. Moran T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, Garcia Y, Blanco R, Snachez S, Villacorta CR, Queralt C, Velarde JM, Rosell R. Monitoring EGFR-T790M mutation in serum / plasma for prediction of response to third-generation EGFR inhibitors in patients with Lung Cancer. Oncotarget, 2018; 9(43): 27074-27086.

225. Goss GD, Felip E, Cobo M, lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous cell carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncology 2018 Sep 1;4(9):1189-1197

226. Navarro A, Martínez-Martí A, Felip E. HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them? J Thorac Oncol 2018; 13(7): 874-876.

227. Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulo V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F. Second –Line Treatment Options in Non-Small-Cell Lung Cancer: report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2018; 19(4):301-314.

228. Solomon BJ, Kim DW, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J Usari T, Tang YY, Wilner KD, Blackhall F, Mok TS. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2018 Aug 1;36(22):2251-2258.

229. Wu Yi-Long, Zhang Li, Kim Dong-Wan, Liu Xiaoqing, Lee Dae Ho, Yang James Chih-Hsin, Ahn Myung-Ju, Vansteenkiste Johan F, Su Wu-Chou, Felip E, Chia Vincent, Glaser Sabine, Pultar Philippe, Zhao Sylvia, Peng Bin, Akimov Mikhail, Tan Daniel S W. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung J Clin Oncol. 2018 Nov 1;36(31):3101-3109.

230. Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear, C, Fasso M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer 2018; 101: 201-209.

231. Camidge D Ross, Kim Hye Ryun, Ahn Myung-Ju, Yang James Chih-Hsin, Han Ji-Youn, Lee Jong-Seok, Hochmair Maximilian J, Li Jacky Yu-Chung, Chang Gee-Chen, Lee Ki Hyeong, Gridelli Cesare, Delmonte Angelo, Garcia Campelo Rosario, Kim Dong-Wan, Bearz Alessandra, Griesinger Frank, Morabito Alessandro, Felip E, Califano Raffaele, Ghosh Sharmistha, Spira Alexander, Gettinger Scott N, Tiseo, Marcello, Gupta Neeraj, Haney Jeff, Kerstein David, Popat Sanjay. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 2018; 379:2027-2039.

232. Blumenthal Gideon M, Bunn Paul A Jr, Chaft Jamie E, McCoach Caroline E, Perez Edith A, Scagliotti Giorgio V, Carbone David P, Aerts Hugo J W L, Aisner Dara L, Bergh Jonas, Berry Donald A, Jarkowski Anthony, Botwood Nicholas, Cross Darren A E, Diehn Max, Drezner Nicole L, Doebele Robert C, Blakely Collin M, Eberhardt Wilfried E E, Felip E, Gianni Luca, Keller Steven P, Leavey Patrick J, Malik Shakun, Pignatti Francesco, Prowell Tatiana M, Redman Mary W, Rizvi Naiyer A, Rosell Rafael, Rusch Valerie, de Ruysscher Dirk, Schwartz Lawrence H, Sridhara Rajeshwari, Stahel Rolf A, Swisher Stephen, Taube Janis Marie M, Travis William D, Keegan Patricia, Wiens Jacinta R, Wistuba Ignacio I, Wynes Murry W, Hirsch

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Solomon,%20BJ&ut=31771&pos=1&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Kim,%20DW&ut=18087&pos=2&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Nakagawa,%20K&ut=14407&pos=4&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Mekhail,%20T&ut=198899&pos=5&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Felip,%20E&ut=21074&pos=6&excludeEventConfig=ExcludeIfFromFullRecPage&cacheurlFromRightClick=no

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Cappuzzo,%20F&ut=52609&pos=7&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Paolini,%20J&ut=1440108&pos=8&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Usari,%20T&ut=1644726&pos=9&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Tang,%20YY&ut=2045225&pos=10&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Wilner,%20KD&ut=124341&pos=11&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Blackhall,%20F&ut=39310&pos=12&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Mok,%20TS&ut=15268&pos=13&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Wu%2C+Yi-Long

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Zhang%2C+Li

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Kim%2C+Dong-Wan

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Liu%2C+Xiaoqing

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Lee%2C+Dae+Ho

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Yang%2C+James+Chih-Hsin


https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Ahn%2C+Myung-Ju

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Vansteenkiste%2C+Johan+F

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Su%2C+Wu-Chou

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Chia%2C+Vincent

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Chia%2C+Vincent

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Glaser%2C+Sabine

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Pultar%2C+Philippe

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Zhao%2C+Sylvia

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Peng%2C+Bin

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Akimov%2C+Mikhail&cacheurlFromRightClick=no

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Tan%2C+Daniel+S+W

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Tan%2C+Daniel+S+W

https://www.ncbi.nlm.nih.gov/pubmed/?term=Phase+Ib%2FII+Study+of+Capmatinib+(INC280)+Plus+Gefitinib+After+Failure+of+Epidermal+Growth+Factor+Receptor+(EGFR)+Inhibitor+Therapy+in+Patients+With+EGFR-Mutated%2C+MET+Factor-Dysregulated+Non-Small-Cell+Lung+Cancer

https://www.ncbi.nlm.nih.gov/pubmed/?term=Phase+Ib%2FII+Study+of+Capmatinib+(INC280)+Plus+Gefitinib+After+Failure+of+Epidermal+Growth+Factor+Receptor+(EGFR)+Inhibitor+Therapy+in+Patients+With+EGFR-Mutated%2C+MET+Factor-Dysregulated+Non-Small-Cell+Lung+Cancer

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Horn,%20L&ut=92894&pos=1&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Gettinger,%20SN&ut=98886&pos=2&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Gordon,%20MS&ut=27165035&pos=3&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Herbst,%20RS&ut=6265&pos=4&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Gandhi,%20L&ut=171006&pos=5&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Felip,%20E&ut=21074&pos=6&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Sequist,%20LV&ut=40094&pos=7&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Spigel,%20DR&ut=23176&pos=8&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Antonia,%20SJ&ut=57645&pos=9&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Balmanoukian,%20A&ut=794392&pos=10&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Cassier,%20PA&ut=52543&pos=11&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Liu,%20B&ut=229821&pos=12&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Kowanetz,%20M&ut=447729&pos=13&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=O'Hear,%20C&ut=1961856&pos=14&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=O'Hear,%20C&ut=1961856&pos=14&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Fasso,%20M&ut=1772170&pos=15&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Grossman,%20W&ut=27558334&pos=16&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Sandler,%20A&ut=30462&pos=17&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Soria,%20JC&ut=2479&pos=18&excludeEventConfig=ExcludeIfFromFullRecPage

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Camidge%2C+D+Ross

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Kim%2C+Hye+Ryun

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Ahn%2C+Myung-Ju


https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Han%2C+Ji-Youn

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Han%2C+Ji-Youn

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Lee%2C+Jong-Seok

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Hochmair%2C+Maximilian+J

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Li%2C+Jacky+Yu-Chung

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Chang%2C+Gee-Chen

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Chang%2C+Gee-Chen

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Lee%2C+Ki+Hyeong

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Gridelli%2C+Cesare

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Delmonte%2C+Angelo

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Garcia+Campelo%2C+Rosario

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Kim%2C+Dong-Wan

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Bearz%2C+Alessandra

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Griesinger%2C+Frank

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Morabito%2C+Alessandro

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Califano%2C+Raffaele

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Ghosh%2C+Sharmistha

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Spira%2C+Alexander

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Gettinger%2C+Scott+N

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Tiseo%2C+Marcello

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Tiseo%2C+Marcello

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Gupta%2C+Neeraj

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Haney%2C+Jeff

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Kerstein%2C+David

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Popat%2C+Sanjay

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Popat%2C+Sanjay

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Blumenthal%2C+Gideon+M

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Bunn%2C+Paul+A+Jr

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Chaft%2C+Jamie+E

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=McCoach%2C+Caroline+E

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Perez%2C+Edith+A

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Perez%2C+Edith+A

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Scagliotti%2C+Giorgio+V

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Carbone%2C+David+P

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Aerts%2C+Hugo+J+W+L

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Aisner%2C+Dara+L

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Bergh%2C+Jonas

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Berry%2C+Donald+A

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Jarkowski%2C+Anthony&cacheurlFromRightClick=no

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Botwood%2C+Nicholas

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Cross%2C+Darren+A+E

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Cross%2C+Darren+A+E

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Diehn%2C+Max

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Drezner%2C+Nicole+L

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Doebele%2C+Robert+C

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Blakely%2C+Collin+M

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Eberhardt%2C+Wilfried+E+E

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Eberhardt%2C+Wilfried+E+E

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Gianni%2C+Luca

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Keller%2C+Steven+P

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Leavey%2C+Patrick+J

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Malik%2C+Shakun

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Malik%2C+Shakun

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Pignatti%2C+Francesco

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Prowell%2C+Tatiana+M

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Redman%2C+Mary+W

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Rizvi%2C+Naiyer+A

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Rosell%2C+Rafael

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Rusch%2C+Valerie

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=de+Ruysscher%2C+Dirk

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Schwartz%2C+Lawrence+H

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Sridhara%2C+Rajeshwari

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Sridhara%2C+Rajeshwari

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Stahel%2C+Rolf+A

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Swisher%2C+Stephen

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Taube%2C+Janis+Marie+M

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Travis%2C+William+D

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Travis%2C+William+D

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Keegan%2C+Patricia

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Wiens%2C+Jacinta+R

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Wistuba%2C+Ignacio+I

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Wynes%2C+Murry+W

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Hirsch%2C+Fred+R

29

Fred R, Kris M. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec;13(12):1818-1831.

233. Garrido Pilar, Vinolas Nuria, Isla Dolores, Provencio Mariano, Majem Margarita, Artal Angel, Carcereny Enric, Garcia Campelo Rosario, Lianes Pilar, De La Penas Ramon, Felip E. Lung cancer in Spanish women: The WORLD07 project. European Journal of Cancer Care. 2019 Jan;28(1):e12941.

234. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A1, Rodríguez-Cid J1, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 22;379(21):2040-2051.

235. Martinez-Marti A, Navarro A, Felip E. COX-2 inhibitors in NSCLC: never-ending story or misplaced? Transl Lung Cancer Res. 2018; 7(Suppl 3):S191-S194.

236. Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun. 2018 Nov 7;9(1):4655.

237. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654-1667.

238. Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax. 2018 Nov 24. pii: thoraxjnl-2018-212194.

239. Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol. 2018. Dec 10. doi: 10.1093/annonc/mdy512. [Epub ahead of print].

240. Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino M. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 Jan 8.doi: 10.1093/annonc/mdy553. [Epub ahead of print].

241. Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019;108:120-128.

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Hirsch%2C+Fred+R

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Kris%2C+Mark+G


https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Garrido%2C+Pilar

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Vinolas%2C+Nuria

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Isla%2C+Dolores

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Provencio%2C+Mariano

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Majem%2C+Margarita

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Artal%2C+Angel

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Carcereny%2C+Enric

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Garcia+Campelo%2C+Rosario

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=Lianes%2C+Pilar

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=De+La+Penas%2C+Ramon

https://apps-webofknowledge-com.ezproxy.bibliotecasalut.gencat.cat/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=C5MJOB73NRTFSIpcCdS&field=AU&value=De+La+Penas%2C+Ramon

https://www.ncbi.nlm.nih.gov/pubmed/?term=Paz-Ares%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Luft%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Vicente%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Tafreshi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%BCm%C3%BC%C5%9F%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Mazi%C3%A8res%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Hermes%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87ay%20%C5%9Eenler%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87ay%20%C5%9Eenler%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cs%C5%91szi%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=F%C3%BCl%C3%B6p%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rodr%C3%ADguez-Cid%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Wilson%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sugawara%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kato%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20KH%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20KH%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cheng%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Novello%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Halmos%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20X%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lubiniecki%20GM%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Piperdi%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kowalski%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kowalski%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=30280635

https://www.ncbi.nlm.nih.gov/pubmed/?term=KEYNOTE-407%20Investigators%5BCorporate%20Author%5D


https://www.ncbi.nlm.nih.gov/pubmed/?term=Martinez-Marti%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30393598

https://www.ncbi.nlm.nih.gov/pubmed/?term=Navarro%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30393598

https://www.ncbi.nlm.nih.gov/pubmed/?term=Felip%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30393598


https://www.ncbi.nlm.nih.gov/pubmed/?term=Fassunke%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%BCller%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Keul%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Michels%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Dammert%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Schmitt%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Plenker%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Plenker%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lategahn%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Heydt%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Br%C3%A4gelmann%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Tumbrink%20HL%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Alber%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Klein%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Heimsoeth%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Heimsoeth%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Dahmen%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Fischer%20RN%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Scheffler%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ihle%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Priesner%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Scheel%20AH%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Wagener%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Wagener%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kron%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Frank%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Garbert%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Persigehl%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=P%C3%BCsken%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Haneder%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Schaaf%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Schaaf%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rodermann%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Engel-Riedel%20W%5BAuthor%5D&cauthor=true&cauthor_uid=30405134


https://www.ncbi.nlm.nih.gov/pubmed/?term=Smit%20EF%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Merkelbach-Bruse%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30405134


https://www.ncbi.nlm.nih.gov/pubmed/?term=Reinhardt%20HC%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kast%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Wolf%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rauh%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=B%C3%BCttner%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30405134

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sos%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=30405134


https://www.ncbi.nlm.nih.gov/pubmed/?term=Solomon%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Besse%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Bauer%20TM%5BAuthor%5D&cauthor=true&cauthor_uid=30413378


https://www.ncbi.nlm.nih.gov/pubmed/?term=Soo%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Camidge%20DR%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Chiari%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Bearz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Bearz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gadgeel%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Riely%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Tan%20EH%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Seto%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=James%20LP%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Clancy%20JS%5BAuthor%5D&cauthor=true&cauthor_uid=30413378


https://www.ncbi.nlm.nih.gov/pubmed/?term=Abbattista%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Martini%20JF%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Peltz%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Thurm%20H%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ou%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=30413378

https://www.ncbi.nlm.nih.gov/pubmed/?term=Shaw%20AT%5BAuthor%5D&cauthor=true&cauthor_uid=30413378


https://www.ncbi.nlm.nih.gov/pubmed/?term=Mart%C3%ADnez-Terroba%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Behrens%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Agorreta%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Mons%C3%B3%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Millares%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30472670


https://www.ncbi.nlm.nih.gov/pubmed/?term=Rosell%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30472670


https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramirez%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Remirez%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Torre%20W%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gil-Bazo%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Idoate%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=de-Torres%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Pio%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30472670


https://www.ncbi.nlm.nih.gov/pubmed/?term=Wistuba%20II%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Pajares%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=30472670

https://www.ncbi.nlm.nih.gov/pubmed/?term=Montuenga%20LM%5BAuthor%5D&cauthor=true&cauthor_uid=30472670


https://www.ncbi.nlm.nih.gov/pubmed/?term=Zugazagoitia%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramos%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Trigo%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Palka%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%B3mez-Rueda%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Jantus-Lewintre%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Jantus-Lewintre%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Camps%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Isla%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Iranzo%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ponce-Aix%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Garc%C3%ADa-Campelo%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Provencio%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30535340


https://www.ncbi.nlm.nih.gov/pubmed/?term=Franco%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Bernab%C3%A9%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Juan-Vidal%20O%5BAuthor%5D&cauthor=true&cauthor_uid=30535340


https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Castro%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sanchez-Torres%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sanchez-Torres%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Faul%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lanman%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=30535340

https://www.ncbi.nlm.nih.gov/pubmed/?term=Garrido%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30535340




https://www.ncbi.nlm.nih.gov/pubmed/?term=Peters%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Dafni%20U%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Boyer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=De%20Ruysscher%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Faivre-Finn%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30624547




https://www.ncbi.nlm.nih.gov/pubmed/?term=Girard%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Guckenberger%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Haanen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Le%20Pechoux%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Mornex%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozsahin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozsahin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30624547


https://www.ncbi.nlm.nih.gov/pubmed/?term=Planchard%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Raben%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramalingam%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Reck%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Smit%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Stahel%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Stahel%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Stenzinger%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Swanton%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Vallone%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30624547

https://www.ncbi.nlm.nih.gov/pubmed/?term=Garassino%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30624547


https://www.ncbi.nlm.nih.gov/pubmed/?term=Levy%20BP%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Giaccone%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30654297



https://www.ncbi.nlm.nih.gov/pubmed/?term=Garassino%20MC%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Domine%20Gomez%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Domine%20Gomez%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30654297



https://www.ncbi.nlm.nih.gov/pubmed/?term=Ponce-Aix%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Menezes%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=MacBeth%20KJ%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Risue%C3%B1o%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Risue%C3%B1o%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Slepetis%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20X%5BAuthor%5D&cauthor=true&cauthor_uid=30654297

https://www.ncbi.nlm.nih.gov/pubmed/?term=Fandi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30654297




30

242. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G Jr, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial. Ann Oncol. 2019 Jan 18. Ann Oncol. 2019 Jan 18. doi: 10.1093/annonc/mdy545.

243. Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol 2019 May 14 (5) 793-801.

244. Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother. 2019 Mar;68(3):341-352. doi: 10.1007/s00262-019-02310-2.

245. Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clin Lung Cancer. 2019 May;20(3):e407-e412. doi: 10.1016/j.cllc.2018.12.022. Epub 2019 Jan 4.

246. Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019 Jun;14(6):1086-1094. doi: 10.1016/j.jtho.2019.02.017. Epub 2019 Feb 27.

247. Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12.

248. Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019 Mar 19. pii: theoncologist.2018-0380. doi: 10.1634/theoncologist.2018-0380. [Epub ahead of print].

249. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.

250. Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Herbst%20RS%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Baas%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Perez-Gracia%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=30657853


https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20DW%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Han%20JY%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Molina%20JR%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=30657853


https://www.ncbi.nlm.nih.gov/pubmed/?term=Dubos%20Arvis%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ahn%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Majem%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Fidler%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Surmont%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Castro%20G%20Jr%5BAuthor%5D&cauthor=true&cauthor_uid=30657853


https://www.ncbi.nlm.nih.gov/pubmed/?term=Garrido%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Shentu%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Emancipator%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Samkari%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30657853

https://www.ncbi.nlm.nih.gov/pubmed/?term=Jensen%20EH%5BAuthor%5D&cauthor=true&cauthor_uid=30657853



https://www.ncbi.nlm.nih.gov/pubmed/?term=Garon%20EB%5BAuthor%5D&cauthor=true&cauthor_uid=30657853


https://www.ncbi.nlm.nih.gov/pubmed/?term=Use+of+archival+versus+newly+collected+tumor+samples+for+assessing+PD-L1+expression+and+overall+survival%3A+An+updated+analysis+of+KEYNOTE-01

https://www.ncbi.nlm.nih.gov/pubmed/?term=Barlesi%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30711649


https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20DW%5BAuthor%5D&cauthor=true&cauthor_uid=30711649


https://www.ncbi.nlm.nih.gov/pubmed/?term=Han%20JY%5BAuthor%5D&cauthor=true&cauthor_uid=30711649





https://www.ncbi.nlm.nih.gov/pubmed/?term=Gubens%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=30711649


https://www.ncbi.nlm.nih.gov/pubmed/?term=Surmont%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30711649

https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=30711649

https://www.ncbi.nlm.nih.gov/pubmed/?term=Deitz%20AC%5BAuthor%5D&cauthor=true&cauthor_uid=30711649




https://www.ncbi.nlm.nih.gov/pubmed/?term=Nadal%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30725206

https://www.ncbi.nlm.nih.gov/pubmed/?term=Massuti%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30725206

https://www.ncbi.nlm.nih.gov/pubmed/?term=D%C3%B3mine%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30725206

https://www.ncbi.nlm.nih.gov/pubmed/?term=Garc%C3%ADa-Campelo%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30725206

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cobo%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30725206



https://www.ncbi.nlm.nih.gov/pubmed/?term=Levy%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30808583


https://www.ncbi.nlm.nih.gov/pubmed/?term=Bennouna%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30808583


https://www.ncbi.nlm.nih.gov/pubmed/?term=Abreu%20DR%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Isla%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Barlesi%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Molinier%20O%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Molinier%20O%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Madelaine%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Audigier-Valette%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20SW%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20HR%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozguroglu%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Erman%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Erman%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Badin%20FB%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Mekhail%20TM%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Scheff%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Chisamore%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sadrolhefazi%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30808583

https://www.ncbi.nlm.nih.gov/pubmed/?term=Riess%20JW%5BAuthor%5D&cauthor=true&cauthor_uid=30808583


https://www.ncbi.nlm.nih.gov/pubmed/?term=Dziadziuszko%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30825613


https://www.ncbi.nlm.nih.gov/pubmed/?term=Dafni%20U%5BAuthor%5D&cauthor=true&cauthor_uid=30825613


https://www.ncbi.nlm.nih.gov/pubmed/?term=Was%C4%85g%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Biernat%20W%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Finn%20SP%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kammler%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kammler%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Tsourti%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rabaglio%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ruepp%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Roschitzki-Voser%20H%5BAuthor%5D&cauthor=true&cauthor_uid=30825613

https://www.ncbi.nlm.nih.gov/pubmed/?term=Stahel%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=30825613






https://www.ncbi.nlm.nih.gov/pubmed/?term=Leighl%20NB%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Hellmann%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Hui%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Carcereny%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30876831



https://www.ncbi.nlm.nih.gov/pubmed/?term=Eder%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=30876831


https://www.ncbi.nlm.nih.gov/pubmed/?term=Balmanoukian%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Aggarwal%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Horn%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Patnaik%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gubens%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30876831

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramalingam%20SS%5BAuthor%5D&cauthor=true&cauthor_uid=30876831



https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30876831








https://www.ncbi.nlm.nih.gov/pubmed/?term=Peltz%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30890623

https://www.ncbi.nlm.nih.gov/pubmed/?term=Chioda%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=30890623







https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=30892989

https://www.ncbi.nlm.nih.gov/pubmed/?term=Soo%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=30892989

https://www.ncbi.nlm.nih.gov/pubmed/?term=Riely%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=30892989




https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30892989

https://www.ncbi.nlm.nih.gov/pubmed/?term=Abbattista%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30892989


https://www.ncbi.nlm.nih.gov/pubmed/?term=Satouchi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30892989

https://www.ncbi.nlm.nih.gov/pubmed/?term=Camidge%20DR%5BAuthor%5D&cauthor=true&cauthor_uid=30892989

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kao%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30892989



https://www.ncbi.nlm.nih.gov/pubmed/?term=Gadgeel%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=30892989


https://www.ncbi.nlm.nih.gov/pubmed/?term=Martini%20JF%5BAuthor%5D&cauthor=true&cauthor_uid=30892989


https://www.ncbi.nlm.nih.gov/pubmed/?term=Putora%20PM%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Glatzer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Belderbos%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30935574


https://www.ncbi.nlm.nih.gov/pubmed/?term=Blackhall%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Califano%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cappuzzo%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30935574


https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Marinis%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Dziadziuszko%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30935574



https://www.ncbi.nlm.nih.gov/pubmed/?term=Fr%C3%BCh%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30935574




https://www.ncbi.nlm.nih.gov/pubmed/?term=McDonald%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Nestle%20U%5BAuthor%5D&cauthor=true&cauthor_uid=30935574


https://www.ncbi.nlm.nih.gov/pubmed/?term=O%27Brien%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Paz%20Ares%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Peeters%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30935574


https://www.ncbi.nlm.nih.gov/pubmed/?term=P%C3%B6ttgen%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramella%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30935574


https://www.ncbi.nlm.nih.gov/pubmed/?term=Slotman%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Troost%20EGC%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Van%20Houtte%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30935574

https://www.ncbi.nlm.nih.gov/pubmed/?term=Westeel%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30935574


https://www.ncbi.nlm.nih.gov/pubmed/?term=Widder%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30935574




31

251. Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist. 2019 Apr 11. pii: theoncologist.2018-0695. doi: 10.1634/theoncologist.2018-0695. [Epub ahead of print]

252. Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276-X. doi: 10.1016/j.jtho.2019.03.020. [Epub ahead of print]

253. Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen S, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol. 2019 Jun;135:74-77. doi: 10.1016/j.radonc.2019.02.010. Epub 2019 Mar 15.

254. Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R. Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget. 2019 Apr 2;10(26):2576. doi: 10.18632/oncotarget.26855. eCollection 2019 Apr 2.

255. Garcia-Vidal E, Badia R, Pujantell M, Castellví M, Felip E, Clotet B, Riveira-Muñoz E, Ballana E, Esté JA. Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. Antiviral Res. 2019 May 8;168:18-27. doi: 10.1016/j.antiviral.2019.05.003. [Epub ahead of print].

256. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M1, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019 Jun 2:JCO1900934. doi: 10.1200/JCO.19.00934. [Epub ahead of print]

257. Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Am J Respir Crit Care Med. 2019 Jun 5. doi: 10.1164/rccm.201807-1292OC. [Epub ahead of print]

258.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sequist%20LV%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gray%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Harb%20WA%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lopez-Chavez%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Doebele%20RC%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Modiano%20MR%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Modiano%20MR%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Jackman%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Baggstrom%20MQ%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Atmaca%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30975923





https://www.ncbi.nlm.nih.gov/pubmed/?term=Adiwijaya%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kuesters%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kamoun%20WS%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Andreas%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Pipas%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Santillana%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cho%20BC%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cho%20BC%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Park%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30975923

https://www.ncbi.nlm.nih.gov/pubmed/?term=Shepherd%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=30975923


https://www.ncbi.nlm.nih.gov/pubmed/?term=Michels%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Massut%C3%AD%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Schildhaus%20HU%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Franklin%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sebastian%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30978502


https://www.ncbi.nlm.nih.gov/pubmed/?term=Groh%C3%A9%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Groh%C3%A9%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rodriguez-Abreu%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Abdulla%20DSY%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Bischoff%20H%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Brandts%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30978502


https://www.ncbi.nlm.nih.gov/pubmed/?term=Corral%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Corral%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Dingemans%20AC%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Pereira%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Fassunke%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Fischer%20RN%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gardizi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Heukamp%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Insa%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Insa%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kron%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Menon%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Persigehl%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30978502


https://www.ncbi.nlm.nih.gov/pubmed/?term=Riedel%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rothschild%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=30978502



https://www.ncbi.nlm.nih.gov/pubmed/?term=Scheffler%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Schmalz%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30978502


https://www.ncbi.nlm.nih.gov/pubmed/?term=Limburg%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30978502


https://www.ncbi.nlm.nih.gov/pubmed/?term=Karachaliou%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Karachaliou%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30978502


https://www.ncbi.nlm.nih.gov/pubmed/?term=Hellmich%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=Nogova%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30978502

https://www.ncbi.nlm.nih.gov/pubmed/?term=B%C3%BCttner%20R%5BAuthor%5D&cauthor=true&cauthor_uid=30978502





https://www.ncbi.nlm.nih.gov/pubmed/?term=Putora%20PM%5BAuthor%5D&cauthor=true&cauthor_uid=31015173

https://www.ncbi.nlm.nih.gov/pubmed/?term=Glatzer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31015173



https://www.ncbi.nlm.nih.gov/pubmed/?term=Belderbos%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31015173



https://www.ncbi.nlm.nih.gov/pubmed/?term=Blackhall%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31015173

https://www.ncbi.nlm.nih.gov/pubmed/?term=Califano%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31015173


https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Marinis%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31015173

https://www.ncbi.nlm.nih.gov/pubmed/?term=Dziadiuszko%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31015173






https://www.ncbi.nlm.nih.gov/pubmed/?term=McDonald%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31015173

https://www.ncbi.nlm.nih.gov/pubmed/?term=Nestle%20U%5BAuthor%5D&cauthor=true&cauthor_uid=31015173


https://www.ncbi.nlm.nih.gov/pubmed/?term=Brien%20MO%5BAuthor%5D&cauthor=true&cauthor_uid=31015173




https://www.ncbi.nlm.nih.gov/pubmed/?term=P%C3%B6ttgen%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31015173

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramella%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31015173


https://www.ncbi.nlm.nih.gov/pubmed/?term=Troost%20EGC%5BAuthor%5D&cauthor=true&cauthor_uid=31015173




https://www.ncbi.nlm.nih.gov/pubmed/?term=Widder%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31015173


https://www.ncbi.nlm.nih.gov/pubmed/?term=Slotman%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=31015173


https://www.ncbi.nlm.nih.gov/pubmed/?term=Mor%C3%A1n%20T%5BAuthor%5D&cauthor=true&cauthor_uid=31069018


https://www.ncbi.nlm.nih.gov/pubmed/?term=Bosch-Barrera%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Aguirre%20I%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramirez%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Mesia%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31069018



https://www.ncbi.nlm.nih.gov/pubmed/?term=Roa%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sais%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Garc%C3%ADa%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Blanco%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sanchez%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Villacorta%20CR%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Queralt%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Queralt%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31069018

https://www.ncbi.nlm.nih.gov/pubmed/?term=Velarde%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=31069018



https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Vidal%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31077767

https://www.ncbi.nlm.nih.gov/pubmed/?term=Badia%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31077767

https://www.ncbi.nlm.nih.gov/pubmed/?term=Pujantell%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31077767

https://www.ncbi.nlm.nih.gov/pubmed/?term=Castellv%C3%AD%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31077767


https://www.ncbi.nlm.nih.gov/pubmed/?term=Clotet%20B%5BAuthor%5D&cauthor=true&cauthor_uid=31077767

https://www.ncbi.nlm.nih.gov/pubmed/?term=Riveira-Mu%C3%B1oz%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31077767

https://www.ncbi.nlm.nih.gov/pubmed/?term=Riveira-Mu%C3%B1oz%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31077767

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ballana%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31077767

https://www.ncbi.nlm.nih.gov/pubmed/?term=Est%C3%A9%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=31077767



https://www.ncbi.nlm.nih.gov/pubmed/?term=Hellmann%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rizvi%20NA%5BAuthor%5D&cauthor=true&cauthor_uid=31154919


https://www.ncbi.nlm.nih.gov/pubmed/?term=Leighl%20NB%5BAuthor%5D&cauthor=true&cauthor_uid=31154919




https://www.ncbi.nlm.nih.gov/pubmed/?term=Balmanoukian%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Aggarwal%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Horn%20L%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Patnaik%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gubens%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31154919




https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldman%20JW%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Scalzo%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Jensen%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kush%20DA%5BAuthor%5D&cauthor=true&cauthor_uid=31154919

https://www.ncbi.nlm.nih.gov/pubmed/?term=Hui%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31154919



https://www.ncbi.nlm.nih.gov/pubmed/?term=Garmendia%20I%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Pajares%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Hermida-Prado%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ajona%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=B%C3%A9rtolo%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sainz%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lav%C3%ADn%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lav%C3%ADn%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rem%C3%ADrez%20AB%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Valencia%20K%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Moreno%20H%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Ferrer%20I%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Behrens%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cuadrado%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31166114



https://www.ncbi.nlm.nih.gov/pubmed/?term=Bustelo%20XR%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gil-Bazo%20I%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Alameda%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lecanda%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Calvo%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31166114


https://www.ncbi.nlm.nih.gov/pubmed/?term=S%C3%A1nchez-C%C3%A9spedes%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=S%C3%A1nchez-C%C3%A9spedes%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Wistuba%20II%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Granda-Diaz%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rodrigo%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Garc%C3%ADa-Pedrero%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=31166114



https://www.ncbi.nlm.nih.gov/pubmed/?term=Montuenga%20LM%5BAuthor%5D&cauthor=true&cauthor_uid=31166114

https://www.ncbi.nlm.nih.gov/pubmed/?term=Agorreta%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31166114


32

Dr. Felip’s Accumulated Impact Factor (1990- January 2019): 2.373,99

Median Impact Factor: 11,25

H Index: 58

Total citations: 15.542

Median citations: 73,65

Abstracts:

1. Combined modality therapy in inflammatory breast carcinoma. L. Jolis, R. Bodi, M.

Navarro, E. Felip, J. Bellmunt, L.A. Solé, D. Rubio. ECCO 5. Londres. Anglaterra. Setembre 1989.

2. Bone marrow involvement in small cell lung cancer. M. Navarro, L. Jolis, E. Felip, J. Bellmunt, S. Morales, D. Rubio. ECCO 5. Londres. Anglaterra. Setembre 1989.

3. Ciprofloxacin as empiric treatment of neutropenic febrile episodes in patients with solid tumours. J.A. Capdevila, E. Felip, A. Pahissa, D. Rubio, B. Almirante, J. Gavaldá, F. Fernández, J.M. Matínez Vázquez. V European Congress of Clinical Microbiology and Infectious Diseases. Noruega. Setembre 1991.

4. Brain tumor after cranial irradiation for childhood acute lymphoblastic leukemia. J. Ortega, R. Vergés, E. Felip, T. Olivé, J. Sánchez de Toledo, J. Giralt. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

5. Improved survival in medulloblastoma treated by SIOP II protocol. J. Giralt, J. Sánchez de Toledo, R. Vergés, I. Alastuey, E. Felip, J. Prats. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

6. Ceftazidime plus amikazin versus ciprofloxacin in the treatment of fever in neutropenic solid tumours patients. E. Felip, J. Capdevila, F. Capdevila, J.M. del Campo, D. Rubio. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

7. Second look in advanced ovarian cancer. J.M. del Campo, E. Felip, F. Capdevila, I. Alastuey, D. Rubio. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

8. Carboplatin-cyclophosphamide in the treatment of advanced ovarian epithelial carcinoma. J.M. del Campo, E. Felip, F. Capdevila, A. Salud, D. Rubio. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

9. Solid tumours in multiple myeloma patients. A. Salud, J.M. Porcel, C. Araguás, E. Felip, F. Capdevila, J. Bueno. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

10. Predictive value of CA 12.5, CA19.9 and CA 15.3 to define chemotherapy response in advanced ovarian cancer patients. E. Felip, J.M. del Campo, R. Vergés, I. Alastuey, D. Rubio. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

11. Phase II study of pirarubicin in pretreated patients with head and neck tumours. J.M. del Campo, E. Felip, R. Vergés, F. Capdevila, I. Alastuey, D. Rubio. Sixth

33

European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

12. Endobronchial metastasis. A. Salud, A. Rovirosa, E. Felip, F. Capdevila, I. Alastuey, J.M. del Campo. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

13. Antinuclear antibodies in neoplastic patients. A. Salud, R. Solans, C. Pérez, V. Fonollosa, E. Felip, F. Capdevila, D. Rubio. Sixth European Conference on Clinical Oncology and Cancer Nursing. ECCO 6. Florència. Itàlia. Octubre 1991.

14. Simultaneous chemotherapy and radiotherapy for advanced head and neck cancer. J.M. del Campo, E. Felip, J. Giralt, G. Raspall, X. Maldonado, S. Bescos, D. Rubio. Seven European Conference of Clinical Oncology. ECCO 7. Jerusalem. Israel. Novembre 1993.

15. 31 P NMR spectroscopy study on the evolution of locally advanced tumors of the oral cavity and oropharynx to combined chemo-radiotherapy. X. Maldonado, J. Alonso, J.M. del Campo, J. Giralt, M. Cucurella, E. Felip, J. Capellades, D. Rubio, J. Gili. XXI Annual Meeting of the European Society for Therapeutic Radiology and Oncology ESTRO. Granada. Setembre 1994.

16. Overexpression of c-erbB-2 in epithelial ovarian cancer: prognostic value. E. Felip, J.M. del Campo, D. Rubio, R. Colomer, M.T. Vidal. XIX Congress of the European Society for Medical Oncology. ESMO. Lisboa. Portugal. Novembre 1994.

17. Serum levels of c-erbB-2 protein in patients with ovarian cancer. E. Felip, J.M. del Campo, D. Rubio, R. Colomer, R. Vera, G. Encabo. XXXVII Annual Meeting of the American Society of Clinical Oncology (ASCO). Los Angeles. USA. Maig 1995.

18. Cisplatin and vinorelbine in the treatment of stage IIIB non-small cell lung cancer patients. E. Felip, JM. del Campo, R. Vera, R. Bodi, S. Casado, D. Rubio. Sixth international congress on anti-cancer treatment. Paris. França. Febrer 1996.

19. Simultaneous chemo-radiotherapy in stage III-IV cancer of the oral cavity and oropharynx: Results of two phase studies. J.Giralt, X. Maldonado, J.M. del Campo, E. Felip, D. Malet, N. Carballo, G. Raspall. XV Annual Meeting of the European Society of Therapeutic Radiation Oncology (ESTRO). Viena. Àustria. Setembre 1996.

20. Application of phosphorus-31 magnetic resonance spectroscopy to study advanced head and neck carcinomas. X. Maldonado, J.Alonso, J. Giralt, J.M. del Campo, M. Cucurella, E. Felip, J. Capellades, A. Rovira. XV Annual Meeting of the European Society of Therapeutic Radiation Oncology (ESTRO). Viena. Àustria. Setembre 1996.

21. GM-CSF mouthwashes for severe oral mucositis in locally advanced head and neck tumors to combined chemo-radiotherapy. X.Maldonado, J.Giralt, N.Carballo, J.M. del Campo, E. Felip, S.Bescos, R.Bodi, J.Gonzalez. XV Annual Meeting of the European Society of Therapeutic Radiation Oncology (ESTRO). Viena. Àustria. Setembre 1996.

22. Una prova randomizada de quimioterapia préoperatoria (cisplatina a 50 mg/m2 ou 100 mg/m2) para o estágio IIIA (N2) NSCLC. J.A. Maestre, M. Canela, R. Fenili, R. Rosell, E. Felip. XXVIII Congresso Brasileiro de Pneumologia e Tisologia. Belo Horizonte. Brasil. Setembre 1996.

23. Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m2 or 100 mg/m2) for stage IIIA (N2) non-small cell lung cancer. E. Felip, M. Canela, V. Alberola, JL González Larriba, J. Maestre, R. Rosell. 4th Central European Lung Cancer Conference, Gdansk. Polònia. Setembre 1996.

24. A randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m2 or 100 mg/m2) for stage IIIA (N2) NSCLC. M. Canela, E. Felip, J. Teixidor, R. Fenili, J. Astudillo, R. Rosell, J. Pujol, JA Maestre. IV European Conference on General Thoracic Surgery. Còrdova. Octubre 1996.

34

25. Preoperative simultaneous chemo-radiotherapy in locally advanced cancer of the oral cavity and oropharynx. S. Casado, JM del Campo, E. Felip, J. Giralt, X. Maldonado, S. Bescos, G. Raspall. 21st Congress of the European Society for Medical Oncology (ESMO). Viena. Àustria. Novembre 1996.

26. Gemcitabine and cisplatin in non-small cell lung cancer (NSCLC): results from a phase II study. M. Gonzalez-Barón, A. Ordoñez, M. Gracia, C. García Girón, M. Constela, FR García Arroyo, J. Lizón, B. Sanchez, J. Aguíar, JL García Puche, A Gómez, A. Duque, M Barrios, E. Felip, J. Dorta. 33 Annual Meeting of the American Society of Clinical Oncology (ASCO). Denver. USA. Maig 1997.

27. A sequence-dependent paclitaxel-etoposide phase II trial in patients with non-small cell lung cancer (NSCLC). B. Massuti, E. Felip, JL González-Larriba, D. Benito, MP López-Cabrerizo, O. Salamanca, C. Camps, J. Puerto-Pica, R. Rosell. 8th World Conference on Lung Cancer. Dublín. Irlanda. Agost 1997.

28. Spanish Lung Cancer Group randomized trial of preoperative chemotherapy

(cisplatin either 50 mg/m2 or 100 mg/m2) in stage IIIAN2 non-small cell lung cancer (NSCLC). E. Felip, I. Moreno, M. Canela, V. Alberola, J. Gómez-Codina, JL Gónzalez-Larriba, A. Antón, MP López-Cabrerizo, J. Maestre, R. Rosell. 8th World Conference on Lung Cancer. Dublín. Irlanda. Agost 1997.

29. Spanish Lung Cancer Group randomized trial of preoperative chemotherapy (cisplatin either 100 mg/m2 or 50 mg/m2) in stage IIIA(N2) non-small-cell lung cancer (NSCLC). E. Felip, R. Rosell, I. Moreno, V. Alberola, G. Gomez-Codina, J.J. Sanchez, A. Paredes, C. Camps, R. Garcia Gomez, A. Artal, P. Garrido, F. Cardenal, I. Barneto. American Society of Clinical Oncology (ASCO) 34 annual meeting. Los Angeles. USA. Maig 1998.

30. A novel anti-apoptosis gene: Survivin as a prognostic marker in non-small-cell lung cancer. E. Felip, M. Monzó, J.J. Sánchez, J. Astudillo, J. Maestre, C. Martín, A. Font, A. Barnadas, A. Abad, R. Rosell. Chemotherapy of Non-Small Cell Lung Cancer: Ten Years Later. Perugia International Cancer Conference VI. Perugia. Itàlia. Octubre 1998.

31. Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 100 mg/m2 or 50 mg/m2) in stage IIIA(N2) non-small-cell lung cancer (NSCLC). E. Felip, R. Rosell, I. Moreno, V. Alberola, J.L. Gonzalez-Larriba, J. Gómez-Codina, JJ Sánchez, A. Paredes, C. Camps, R. García-Gómez, A. Artal, P. Garrido, F. Cardenal, I. Barneto. First World Conference on Clinical Cooperative Research for Lung Cancer. Brussel·les. Bèlgica. Març 1999.

32. The development of a multicenter cooperative group: the Spanish lung cancer group (SLCG) experience. B. Massuti, V. Alberola, A. Antón, I. Barneto, C. Camps, F. Cardenal, A. Carrato, E. Felip, P. Garrido, J. Gómez-Codina, J. González-Larriba, P. Lianes, R. Rosell. First World Conference on Clinical Cooperative Research for Lung Cancer. Brussel·les. Bèlgica. Març 1999.

33. Originality and independence within cooperative groups: The Spanish Lung Cancer Group experience. R. Rosell, V. Alberola, B. Massuti, A. Antón, A. Carrato, J. Gómez-Codina, C. Camps, JL González-Larriba, I. Barneto, A. Artal, P. Garrido, P. Lianes, F. Cardenal, E. Felip. First World Conference on Clinical Cooperative Research for Lung Cancer. Brussel·les. Bèlgica. Març 1999.

34. A phase II study of bi-weekly gemcitabine/paclitaxel in advanced non-small cell lung cancer (NSCLC). C. Martin, D. Isla, JL González-Larriba, E. Felip, C. Camps, A. Antón, A. Carrato, P. Azagra, V. Alberola, B. Massuti, JJ. Sanchez, M. Monzó, R. Rosell. 35 Annual Meeting of the American Society of Clinical Oncology (ASCO). Atlanta. USA. Maig 1999.

35. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. R. Rosell, M. Monzó, E. Felip, J. Astudillo, JJ. Sanchez, I. Rosas, C. Martin, A. Font, A. Barnadas, A. Abad. 35 Annual Meeting of the American Society of Clinical Oncology (ASCO). Atlanta. USA. Maig 1999.

35

36. Phase II multi-institutional study of irinotecan (CPT-11) and cisplatin (CDDP) on a three-week schedule in patients with advanced non-small cell lung cancer (NSCLC). F. Cardenal, M. Domine, B. Masutti, E. Felip, A. Carrato, P. Garrido, V. Alberola, A. Anton, I. Barneto, R. Rosell. Ten European Conference on Clinical Oncology and Cancer Nursing (ECCO-10). Viena. Àustria. Setembre 1999.

37. Multi-institutional phase II study of an intensive single dose of irinotecan (CPT-11) and cisplatin (CDDP) every three weeks in patients with advanced non-small-cell lung cancer (NSCLC). F. Cardenal, M. Domine, B. Masutti, A. Carrato, E. Felip, P. Garrido, O. Juan, A. Artal, I. Barneto, R. Rosell. 36 Annual Meeting of the American Society of Clinical Oncology (ASCO). New Orleans. USA. Maig 2000.

38. Assessment of tubulin mutations in a phase II study of biweekly gemcitabine/paclitaxel (T) in advanced non-small-cell lung cancer. R. Rosell, A. O'Brate, J. Sanchez, D. Isla, E. Felip, C. Camps, JL Gonzalez-Larriba, A. Anton, A. Carrato, P. Azagra. 9th World Conference on Lung Cancer. Tòkyo, Japó. Setembre 2000.

39. Preliminary results of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC): A phase II study. E. Felip, A. Font, R. Rosell, P. Garrido, A. Carrato, S. Terrasa, J. Mane, L. Santome, J. Baselga. 9th World Conference on Lung Cancer. Tòkyo, Japó. Setembre 2000.

40. Phase II study of an intensive single dose of irinotecan (CPT-11) and cisplatin (CDDP) every three weeks in patients with advanced non-small cell lung cancer. M. Domine, F. Cardenal, B. Massuti, A. Carrato, E. Felip, P. Garrido, O. Juan, A. Artal, I. Barneto, G. Lopez-Vivancos, R, Rosell. 9th World Conference on Lung Cancer. Tòkyo, Japó. Setembre 2000.

41. Preliminary results of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC): A phase II study. E. Felip, A. Font, R. Rosell, P. Garrido, A. Carrato, S. Terrasa, J. Mane, L. Santome, J. Baselga. 25th Congress of the European Society for Medical Oncology. Hamburg. Alemanya. Octubre 2000.

42. Final results of a Spanish Lung Cancer Group (SLCG) phase II study of paclitaxel (PAC) plus gemcitabine (GEM) in locally advanced and metastatic non-small-cell lung cancer. D. Isla, JL Gonzalez-Larriba, E. Felip, C. Camps, A. Artal, A. Carrato, P. Azagra, V. Alberola, B. Massuti, R. Rosell. 25th Congress of the European Society for Medical Oncology (ESMO). Hamburg. Alemanya. Octubre 2000.

43. NATCH trial comparing neoadjuvant versus adjuvant taxol/carboplatin versus surgery alone in stage I-II, T3N1 non-small cell lung cancer (NSCLC) patients. E. Felip. 7th IASLC Lung Cancer Biology Workshop: Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer. Barcelona, Spain. Maig 2001.

44. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive small-cell lung cancer (SCLC): A Spanish Lung Cancer Group phase II study. E. Felip, A. Font, R. Rosell, P. Garrido, M. Domine, L. Santome, A. Carrato, I. Marimón, S. Terrasa, C. Vadell, M. Mañé, J. Baselga. 37 Annual Meeting of the American Society of Clinical Oncology (ASCO). San Francisco. USA. Maig 2001.

45. Phase II study of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC). L. Santomé, E. Felip, R. Rosell, M. Domine, A. Font, P. Garrido, A. Carrato, J. Terrasa, J. Mañe, J. Baselga. The European Cancer Conference (ECCO 11). Lisboa. Portugal. Octubre 2001.

46. BMS-184476 as second-line treatment in non-small-cell lung cancer patients: results of a multicenter phase II trial. E. Felip, C. Camps, J.M. Sanchez, A. Aloe, B. Massuti, A. Artal, L.Astier, A. Carrato, L. Paz-Ares, C. Garrido, M. Taron, C. Queralt, V. Alberola, R. Rosell. 38 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando. USA. Maig 2002.

36

47. Prognostic factors (PF) in recurrent endometrial carcinoma (REC): A review of a single-centre experience. J.M. Del Campo, R. Verges, A. Gil, S. Gonzalez, A. García, J. Martinez-Palones, L. Santome, E. Felip, J.Giralt, J.Baselga. 39 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago.USA. Maig 2003.

48. Xeroderma pigmentosum complementation group D(XPD) associated with survival in a randomized neoadjuvant/adjuvant paclitaxel/carboplatin trial in early non-small-cell lung cancer (NSCLC). E. Felip, I De Aguirre, J.A. Maestre, A. Torres, M. Rodriguez-Paniagua, J.J. Sanchez, D. Betticher, C.Sederholm, F. Griesinger, R. Rosell. 39 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. Maig 2003.

49. Analysis of xeroderma pigmentosum complementation group D (XPD) in the NATCH trial: a neoadjuvant/adjuvant paclitaxel/carvoplatin trial in early non-small –cell lung cancer (NSCLC). E. Felip, B. Massuti, I. De Aguirre, G. Alonso, J. Maestre, A. Torres, M. Rodriguez-Paniagua, J.M. Borro, J.J. Sanchez, R. Rosell. 10 World Conference on Lung Cancer. Vancuver.Canada. Agost 2003.

50. Chemotherapy following surgery in early stage non-small cell lung cancer. Multimodality therapy in stage IIIAN2 disease.New agents under development. Pharmacogenomics: individualised therapy.Expert opinion. E. Felip, R. Rosell. 10 World Conference on Lung Cancer. Vancuver.Canada. Agost 2003.

51. Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer 8LD-SCLC) patients, following response to chemotherapy and thoracic irrradiation (EORTC 08971, the SILVA study). G. Giaccone, C. Debruyne, E. Felip, M. Millward, G. D’Addario, L. Thiberville, L.Rome, P. Zatloukal, C. Legrand. 40 Annual Meeting of the American Society of Clinical Oncology (ASCO). New Orleans. USA. Maig 2004.

52. BRCA1 and HIF-1α mRNA expression and chemoresistance in non-small-cell lung cancer (NSCLC). M. Taron, R. Rosell, J. Souglakos, P. Mendez, E. Felip, A. Barnadas, M. Sanchez, C. Queralt, JJ Sánchez. 40 Annual Meeting of the American Society of Clinical Oncology (ASCO). New Orleans. USA. Maig 2004.

53. ERCC1, RRM1 and XPD mRNA expression as a predicitve marker of outcome in non-small-cell lung cancer (NSCLC) patients after platinum/gemcitabine induction chemotherapy followed by surgery. E. Felip, R. Rosell, M. Tarón, L. Santomé, P. Mendez, M. Sanchez, JJ. Sánchez, C. Queralt, J. Baselga, J. Majó. 40 Annual Meeting of the American Society of Clinical Oncology (ASCO). New Orleans. USA. Maig 2004.

54. Clinical experience of erlotinib in non-small cell lung cancer. E. Felip. 5 European Conference Perspectives in Lung Cancer. Berlin. Germany. Novembre 2004.

55. Epidermal growth factor receptor (EGFR) expression correlation between diagnostic and post-platinum-based progression samples of non-small-cell lung cancer (NSCLC) patients. E. Felip. 29 ESMO Congress. Vienna. Austria. Novembre 2004.

56. ERCC1 mRNA-based randomized phase II trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). R. Rosell, M. Cobo, D. Isla, B. Massuti, A. Montes, L. Paz-Ares, M. Munoz, N. Vinolas. G.L. Vivanco, E. Felip. 41 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando. USA. Jun 2005.

57. Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results. E. Felip, F. Rojo, A. Heller,D. Foernzler, C. Valverde, B. Klughammer, J. Ramos H. Maacke, U. Brennscheidt, J. Baselga . 41 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando. USA. Jun 2005.

58. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC)

37

patients. M. Cobo, D. Isla, J. Sánchez, B. Massuti, A. Montes, L. Paz-Ares, M. Muñoz, N. Viñolas, G. López-Vivanco. E. Felip. 11th World Conference on Lung Cancer. Barcelona, Spain. Jul 2005.

59. Phase I/II trial of patupilone once every 3 weeks in patients with non-small cell lung cancer. K. Osterlind, J. Sánchez, P. Zatloukal, J. Hamm, C. Belani, E. Kim, E. Felip, I. Sklenar, M. Berton, A. Johri. 11th World Conference on Lung Cancer. Barcelona, Spain. Jul 2005.

60. Radiosurgery (RS) for brain metastases (BM) in patients with lung cancer. Synchronous vs. Metachronous presentation did not influence on survival. S. Villa, V. Navarro, A. Lucas, M. Gil, M. Arnaiz, M. Brell, J. Jové, X. Maldonado, N. Viñolas, E. Felip. 11th World Conference on Lung Cancer. Barcelona, Spain. Jul 2005.

61. Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, H. Maacke, J. Möcks, U. Brennscheidt, U. Gatzemeier, J. Baselga. 11th World Conference on Lung Cancer. Barcelona, Spain. Jul 2005.

62. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): A phase I/II trial. JM. Sánchez, A. Mellemgaard, M. Perry, P. Zatloukal, J. Hamm, CP. Belani, E. Kim, E. Felip. 42 Annual Meeting of the American Society of Clinical Oncology (ASCO). Atlanta. USA. Jun 2006.

63. Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platium based chemotherapy: FISH results. E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, H. Maacke, J. Möcks, U. Brennscheidt, U. Gatzemeier, J. Baselga. 42 Annual Meeting of the American Society of Clinical Oncology (ASCO). Atlanta. USA. Jun 2006.

64. Women (w) with advanced non-small cell lung cancer (NSCLC) participating in first-line spanish lung cancer group (SLCG) trials. Analysis of characterisitics and treatment outcomes compared to men (M). D. Isla, E. Felip, P.Garrido, N. Viñolas, P. Lianes, R. García-Campelo, JJ. Sánchez, V. Alberola, C. Camps, R. Rosell. 31 st ESMO Congress. Istanbul, Turkey. Oct 2006.

65. Phase II pharmacodynamic trial of erlotinib in previously treated patients with advanced non-small cell lung cancer: Study results. E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, H. Maacke, J. Möcks, U. Brennscheidt, U. Gatzemeier, J. Baselga. 31 st ESMO Congress. Istanbul, Turkey. Oct 2006.

66. Comparison of epidermal growth factor receptor (EGFR) and downstream markers expression in samples from non-small cell lung cancer (NSCLC) patients, at diagnosis and after progression following platinum-based chemotherapy. S. Cedrés, E. Felip, A. Prat, J. Majo, E. Pallisa, J. De Gracia, E. Vilar, M. Parera, J. Baselga. 31 st ESMO Congress. Istanbul, Turkey. Oct 2006.

67. The NATCH trial: Observations on the neoadjuvant arm. E. Felip, R. Rosell, B. Massuti, G. Alonso, J. L. González-Larriba, C. Camps, D. Isla, C. Mas, J. J. Sanchez, J. A. Maestre. 43 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. May 2007.

68. A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC). M. Reck, N. Frickhofen, U. Gatzemeier, H. Fuhr, S. Lanzalone, M. J. Lechuga, E. Wang, R. Chao, E. Felip. 43 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. May 2007.

69. Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials. D. Isla, E. Felip, P. Garrido, N. Viñolas, R. García-Campelo, P. Lianes, I. Bover, J. Terrasa, J. J. Sánchez, R. Rosell. 43 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. May 2007.

70. Analysis of possible relationships between tumor biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC): data from the

38

prospective MERIT study. M. Reck, J. Milanowski, S.K. Au, P.C. Yang, M. Akimov, C. Duymelinck, T. Gutjahr, P. McLoughlin, C. Hillenbach, E. Felip. 14 meeting of the European Cancer Conference (ECCO). Barcelona. Spain. Sep 2007.

71. Preliminary findings of a phase I dose-escalation study of sumitinib in combination with gemcitabina plus cisplatin in advanced non-small cell lung cancer (NSCLC). M. Reck, N. Frickhofen, U. Gatzeimer, H.G. Fuhr, S. Lanzalona, E. Wang, R. Chao, E. Felip. 14 meeting of the European Cancer Conference (ECCO). Barcelona. Spain. Sep 2007.

72. The NATCH trial: chemotherapy toxicity and response on the neoadjuvant arm. E. Felip, R. Rosell, B. Massuti, G. Alonso, J.L. Gonzalez-Larriba, C. Camps, D. Isla, C. Mas, J.J. Sanchez, J.A. Maestre. 12th World Conference on Lung Cancer (IASLC), Seoul, Korea. Sep 2007.

73. Preliminary data from a prospective case registry of European women with lung cancer: a WALCE (Women Against Lung Cancer in Europe) Project. S. Novello, A. Ceribelli, C. Casadio, O. Martelli, M.R. Migliorino, M. Longo, S. Binato, E. Cappelletto, R. Buosi, E. Felip. 12th World Conference on Lung Cancer (IASLC), Seoul, Korea. Sep 2007.

74. Gender differences in non-small cell lung cancer (NSCLC) patients (p): A retrospective study based in Spanish Lung Cancer Group (SLCG) trials. N. Viñolas, D. Isla, E. Felip, P.Garrido, R. Garcia-Campelo, P. Lianes, I. Bover, J. Terrasa, C. Vadell, R. Rosell. 12th World Conference on Lung Cancer (IASLC), Seoul, Korea. Sep 2007.

75. Erlotinib as first-line treatment for untreated patients with advanced or metastatic non-small cell lung cancer (NSCLC). Mesía, A. García-Velasco, E. Felip, C. García-Girón, D. Almenar, A. Rueda, A. Artal, M. Gay, P. Regueiro, B. Massutí. 12th World Conference on Lung Cancer (IASLC), Seoul, Korea. Sep 2007.

76. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer (NSCLC): preliminary results from a phase I dose escalation study. Reck, N. Frickhofen, U. Gatzemeier, H.G. Fuhr, S. Lanzalone, M.J. Lechuga, E. Wang, R. Chao, E. Felip. 12th World Conference on Lung Cancer (IASLC), Seoul, Korea. Sep 2007.

77. Risk factors for non-smoking women. E. Felip. 12th World Conference on Lung Cancer (IASLC), Seoul, Korea. Sep 2007.

78. A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients. E. Felip, M. Ranson, S. Cedres, E. Dean, E. De Droogh, M. Brewster, V. A. McNally, G. Ross, D. Galdermans; 44 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. May 2008.

79. A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS). B. Besse, E. F. Smit, E. Felip, S. Siena, F. Blackhall, F. Barlesi, G. Giaccone. 44 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. May 2008.

80. Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non- small cell lung cancer (NSCLC). S. Cedrés Pérez, A. Prat, E. Felip, S. Peralta, J. Perez, J. del Campo, G. Sala, J. Andreu, E. Pallisa, J. Baselga. 44 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. May 2008.

81. Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. R. Bahleda, E. Felip, R. S. Herbst, N. H. Hanna, S. A. Laurie, F. A. Shepherd, J. P. Armand, C. J. Sweeney, E. Calvo-Aller, J. C. Soria. 44 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. May 2008.

http://journals.lww.com/jto/Fulltext/2007/08001/The_NATCH_trial__chemotherapy_toxicity_and.232.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Preliminary_data_from_a_prospective_case_registry.743.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Preliminary_data_from_a_prospective_case_registry.743.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Gender_differences_in_non_small_cell_lung_cancer.656.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Gender_differences_in_non_small_cell_lung_cancer.656.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Erlotinib_as_first_line_treatment_for_untreated.1126.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Erlotinib_as_first_line_treatment_for_untreated.1126.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Sunitinib_in_combination_with_gemcitabine_plus.1146.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Sunitinib_in_combination_with_gemcitabine_plus.1146.aspx

http://journals.lww.com/jto/Fulltext/2007/08001/Risk_factors_for_non_smoking_women__M16_02.59.aspx

39

82. Phase II study of Pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): A proof-of-concept study. N. Altorki, J. Heymach, M. Guarino, P. Lee, E. Felip, T. Bauer, S. Swann, D. Roychowdhury, L.H. Ottesen, D. Yankelevitz. 33rd ESMO Congress, Stockholm, Sweden. Setembre 2008.

83. First-line erlotinib in stage IIIb/IV non-small-cell lung cancer (NSCLC) with dose escalation to toxicity in current and former smokers (C/Fs): A phase II study. B. Besse, E. Smit, E. Felip, S. Siena, F. Blackhall, F. Barlesi, G. Giaccone. 33rd ESMO Congress, Stockholm, Sweden. Sep 2008.

84. A Phase I, dose-escalation study to determine the maximum tolerated dose of Erlotinib when combined with Pertuzumab in previously treated Non-Small-Cell Lung Cancer patients. E. Felip, M. Ranson, S. Cedres, E. Dean, E. De Droogh, M. Brewster, V. McNally, G. Ross, D. Galdermans. 33rd ESMO Congress, Stockholm, Sweden. Sep 2008.

85. Computed Tomography (CT) predicts accurately the pathologic tumor size in stage I non-small cell lung cancer. S.M. Cedres, I. Quispe, C. Serrano, P. Martinez, I Braña, V. Rodriquez, M. Deu, E. Felip. European Multidisciplinary Conference in Thoracic Oncology (EMCTO), Lugano, Switzerland. May 2009.

86. Surgery (S) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage non-small cell lung cancer (NSCLC): Results of the NATCH multicenter, randomized phase III trial. E. Felip, B. Massuti, G. Alonso, J. L. González-Larriba, C. Camps, D. Isla, E. Costas, J. J. Sánchez, F. Griesinger, R. Rosell; 45 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando. USA. Jun 2009.

87. Lung cancer in women: The Spanish female-specific database WORLD 07. N. Viñolas, M. Magem, P. Garrido, A. Artal, J. De Castro, R. G. Campelo, D. Isla, E. Felip, M. Amador, R. Rosell. 45 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando. USA. Jun 2009.

88. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. R. Bahleda, J. Soria, C. Harbison, J. Park, E. Felip, N. Hanna, S. A. Laurie, J. Armand, F. A. Shepherd, R. Herbst. 45 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando. USA. Jun 2009.

89. A phase III randomized trial of surgery (S) alone, or preopeartive (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cáncer (NSCLC): NATCH follow-up data. E. Felip, B. Massuti, G. Alonso, J.L. González-Larriba, C. Camps, D. Isla, J.A. Maestre, J.M.R. Paniagua, T. Overbeck, E. Costas, J.J. Sánchez, R. Rosell. Presidential address and selected proffered papers. 13th World Cancer Conference on Lung Cancer. San Francisco. USA. Jul 2009.

90. Lung cancer in women: The Spanish female-specific database WORLD 07. P. Garrido, N. Viñolas, M. Magem, A. Artal, J. De Castro, R. G. Campelo, D. Isla, E. Felip, M. Amador, R. Rosell. 13th World Cancer Conference on Lung Cancer. San Francisco. USA. Jul 2009.

91. Assessing the value of preoperative chemotherapy in early-stage non-small cell lung cancer: mature data and prognostic factors analysis of a phase III randomized trial of surgery alone vs preoperative paclitaxel/carboplatin (PC) vs postoperative PC. Final NATCH data. B. Massuti, J.M. Sánchez, G. Alonso, J.A. Maestre, J.L. González-Larriba, C. Camps, J.M.Rodriguez-Paniagua, E. Felip, J.J. Sánchez, R. Rosell. 34th ESMO–15th ECCO Congress, Berlin, Germany. Sep 2009.

92. Serum carcinoembryonic antigen (CEA) levels are associated with worse prognosis in advanced non-small cell lung cancer (NSCLC). S. Cedrés, I. Nuñez, M. Longo, P.N. Martínez, E. Rodríguez Checa, M. Cazorla, E. Felip. 2nd European Lung Cancer Conference. Ginebra, Switzerland. Apr-May 2010.

93. Small cell lung cancer in women: The Spanish female-specific database WORLD07. N. Vinolas, D. Isla, E. Felip, P. Garrido, M. Majem, J. Terrasa, A. Artal,

40

M. Garcia-Campelo, M. L. Amador, R. Rosell. 46 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. June 2010

94. Serum carcinoembryonic antigen (CEA) levels and prognosis in early and advanced non-small cell lung cancer (NSCLC). S. Cedres Perez, I. Nuñez, M. Longo, P. Martínez, E. Rodríguez Checa, M. Cazorla, E. Felip. 46 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. June 2010.

95. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. R. B. Cohen, P. A. Janne, J. A. Engelman, P. Martínez, Y. Nishida, S. Gendreau, B. Wu, E. Felip. 46 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. June 2010.

96. Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). E. Felip, M. Ranson, S. Cedres, M. Brewster, V. Mcnally, M. Venturi, A. Passioukov, G. Ross, D. Galdermans. 46 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago. USA. June 2010

97. Serum carcinoembryonic antigen (CEA) levels are associated with worse prognosis in advanced non-small cell lung cancer (NSCLC). S.Cedres, I. Nunez, M. Longo M, E. Felip, et al. Journal Of Thoracic Oncology Volume: 5 Issue: 5 Supplement: 1 Pages: S88-S88. May 2010.

98. Neoadjuvant versus adjuvant chemotherapy . E. Felip, P. Martínez Journal Of Thoracic Oncology Volume: 5 Issue: 5 Supplement: 1 Pages: S21-S21. May 2010.

99. Pleurodesis (P) outcome in a series of metastatic cancer patients (PTS) with symtomatic malignant pleural effusion (MPE). V. Rodriguez-Freixinos, G. Sanchez-Olle, G. Argiles, E. Felip, et al. 35th European-Society-for-Medical-Oncology (ESMO) Milan, Italy Oct 2010. European Soc Med Oncol. Annals Of Oncology Volume: 21 Supplement: 8 Pages: 398-398 Oct 2010.

100. Small cell lung cancer in women: the spanish female-specific database World07. M. Majem, N. Vinolas, D. Isla, E. Felip, et al. 35th European-Society-for-Medical-Oncology (ESMO) Milan, Italy OCT 2010. European Soc Med Oncol Annals Of Oncology Volume: 21 Supplement: 8 Pages: 349-349 Oct 2010.

101. Serum tumor markers CEA, CYFRA and CA125 are associated with worse prognosis in advanced non- small cell lung cancer (NSCLC). S. Cedre, I. Nunez, M. Longo, E. Felip, et al. 35th European-Society-for-Medical-Oncology (ESMO) Milan, Italy OCT 2010. Annals Of Oncology Volume: 21 Supplement: 8 Pages: 131-131 Oct 2010

102. A Double-Blind, Randomized, Parallel, Two-Arm Phase H Trial of BMS-690514 versus Erlotinib in Previous Chemotherapy-Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Safety Review. E. Sbar, B. Besse, E. Felip, et al. Journal Of Thoracic Oncology Volume: 5 Issue: 12 Supplement: 7 Pages: S538-S539 Dec 2010.

103. Serum Carcinoembryonic Antigen (CEA) levels Are Associated with Worse Prognosis in Advanced Non-Small Cell Lung cancer (NSCLC). Cedres S, Nunez I, Longo M, Martinez PN, Checa ER, Cazorla M, Felip E. J Thorac Oncol 2010; 5: S88-S88.

104. Neoadjuvant versus Adjuvant Chemotherapy. Felip E, Martinez P. J Thorac Oncol 2010; 5: S21-S21.

105. Pleurodesis (P) Outcome in a series of metastatic cancer patients (PTS) with syntomatic malignant pleural effusion (MPE). Rodriguez-Freixinos V, Sanchez-Olle G, Argiles G, Nuñez I, Mulet N, Martinez P, Cedres S, López I, Canela M, Felip E. Annals of Oncology 21: S398.

http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=Refine&qid=13&SID=2Eh41HAdiman9np6E5J&page=2&doc=14




41

106. Small Cell Lung Cancer in Women: The Spanish Female-Specific Database. Majem M, Vinolas N, Isla D, Felip E, Garrido P, Terrasa J, Domine M, Campelo RG, Amador ML, Rosell R. Annals of Oncology 21: S349-S349.

107. A Double, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotimib in Previous Chemotherapy-Treated Non-Small Cell Lung Cancer (NSCLC) Patients A Safety Review. Sbar E, Besse B, Felip E, Shaw A, Ahn MJ, Salvati M, Bhagavatheeswaran P, Soria JC. Journal of Thoracic Oncology, 5 (12) S385-S385.

108. The Lugano Consensus on pathology and molecular testing.K. O'Byrne, R. Rosell, P. Baas, E. Felip, et al. Lung Cancer Volume: 71 Supplement: 2 Pages: S4-S4 DOI: 10.1016/S0169-5002 (11)70142-8 Feb 2011.

109. ESMO Recommendation 2011: advanced NSCLC. C. Gridelli, B. Besse, F. de Marinis, E. Felip, et al. Lung Cancer Volume: 71 Supplement: 2 Pages: S3-S3 DOI: 10.1016/S0169-5002(11)70141-6 Feb 2011.

110. Erbb3 expression assessed by immunohistochemistry (IHC) in non-small cell lung cancer (NSCLC) tumors with egfr mutation, before egfr-tyrosine-kinase inhibitor (EGFR-TKI) exposure. E. Felip, J. Hernandez-Losa, N. Murtra-Garrell, et al. Journal of Thoracic Oncology volume: 6 issue: 6 supplement: s pages: s1104-s1105 Jun 2011.

111. Erbb2 and erbb3 expression in resected non-small cell lung cancer (NSCLC) patients (PTS). V. Freixinos, M. Salcedo, N. Tallada, E. Felip, et al. Journal of ThoracicOncology Volume: 6 Issue: 6 Supplement: S Pages: S1063-S1064 Jun 2011.

112. Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations - the EURTAC Phase II Randomized Trial Interim Results. F. De Marinis, R. Rosell, A. Vergnenegre, E. Felip, et al. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Stockholm, Sweden, Sep 2011 European Journal Of Cancer Volume: 47 Supplement: 1 Pages: S597-S597 Sep 2011.

113. Results of a Phase 2 Study of Gemcitabine/Cisplatin/Iniparib (GCI) Versus Gemcitabine/cisplatin (GC) in Patients With Advanced NSCLC S. Novello, E. Felip, F. Barlesi, et al. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Stockholm, Sweden, Sep 2011 European Journal Of Cancer Volume: 47 Supplement: 1 Pages: S593-S593 Sep 2011.

114. Erlotinib vs. Chemotherapy (CT) in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (p) with epidermial Growth Factor Receptor (EGFR) activating mutations –the EURTAC Phse II randomized Trial interim Results. De Marinis F., Rosell R, Vergnenegre A, massuti B, Felip E, Gervais R, Cardenal F, Garcia-Gómez R, Taron M, Paz-Ares L. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Stockholm, Sweden, Sep 2011 European Journal of Cancer, Volume 47: Supplement 1 pages S597-597, sep 2011.

115. Expression of ErbB2 and ErbB3 in Non Small Cell Lung Cancer. Salcedo Mt, Montero MA, Hernández Losa J, Teixido C, Alende H, Felip E, Murtra-Garell N, Pallisa E, Canela M, Cajal SR, Tallada N.101st Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, Canada, March 2012. Modern Pathology Volume 25 S489A-489A Supplement 2, Feb. 2012.

116. Cell Signaling pathways and Nuclear PTEN and FOXO3a Dysregulation in Pleural Mesotheliomas. Montero MA, gabaldón MA, Salcedo MT, Tallada N, Moline T, Hernández Losa, Felip E, Cedrés S, Cajal SR. 101st Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, Canadá, March 2012. Modern Pathology Volume 25 S484A-484A Supplement: 2. Feb. 2012.

42

117. ALK Rearrangement Detected by FISH and Inmunohistochemistry Methods. Prevalence and Clinical outcomes in a Selected Population of Advanced Non Small Cell Lung Cancer Patients. Hernandez Losa J, Martínez P, Castellvi J, Natalia T, Moline T, Montero MA, Cedres S, rodriguez-freixinós V, Felip E, Cajal SR. 101st Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, Canada, March 2012. Modern PathologyVolume 25 S478A-478A Supplement 2. Feb 2012.

118. Clinical, Molecular features and prognosis in a series of patients (PTS) never-smokers with resected Non Small Cell Lung Cancer (NSCLC). Martinez Marti A, Rodriguez P, Cedrés S, Sullivan I, Murtra N, Jiménez J, Aura C, Hernández J, canela M, Felip E. 3rd European Lung cancer Conference (ELCC), geneve, April 2012.Switzerland. Jorunal of Thoracic Oncology, Volume 7 (6) S54-S54, June 2012.

119. Retrospective analysis of clinicopathologic and survival data of malignant pleural mesothelioma (MPM) patients in a single center series. Cedrés S, Martínez A, Martínez P, Torrejón D, Sullivan I, Pallissa E, Murtra N, Montero MA, Hernández J, Felip E. 3rd European Lung cancer Conference (ELCC), geneve, April 2012.Switzerland. Jorunal of Thoracic Oncology, Volume 7 (6) S84-S85, June 2012.

120. GAIN-(L): efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular citotoxixity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC. Spicer JF, Felip E, Bosquee L, gregorc V, calderero IL, Martinez P, Montes A, Sorlini C, Ott MG, Golding S, Mariconti L, banholzer ML, passioukov A, Calile D, Manenti L, Paz Ares L. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

121. EGFR compound mutants and survival on erlotinib in Non-Small Cell Lung cancer (NSCLC) patients (P) in the EURTAC study. Rossel R, Molina-Vila MA, Taron M, Bertrand Alamillo, Mayo C, Vergnenegre A, De Marinis F, Massuti B, De Castro J, Gervais R, Carcereny E, Bugues C, Moran T, Santarpia M, Felip E, Majem M, Bosch J, Cardenal F, Drozdowskyj A, Bivona TG. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

122. First in human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. Mehra R, Camidge Dr, Sharma S, Felip E, Tan DWS, Vansteenkiste JF, de pas TM, Kim DW, Santoro A, Liu G, Goldwasser, Dai D, Radona M, Boral A, Shaw AT. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

123. Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (PTS) with squamous cell carcinoma (SCC) histology. Marti Am, martinez P, Aura C, cedres S, Sullivan I, Jimenez J, Prudkin, Montero MA, Murtra-garrell N, Zamora E, Navarro A, Hernández Losa J, Salcedo M, Canela M, Cajal SR, Tabernero J, Felip E. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

124. Population survey to assess the knowledge of smoking habit abd its consequences on women (w) in Spain. Majem M, Artal A, De Castro J, Felip E, López PG, Isla D, Bujosa JR, Cajal R, Viñolas N. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

125. Never-smoking women with lung cancer from the Spanish WORLD07 database. Dolores Isla, provencio M, Majem M, Felip E, Viñolas N, Campelo RG, de las Penas R, Carcereny E, ALberola V, Domine M, Blanco R, Dorta J, Bernabe R,

43

Guillen C, Vadell C, Maestu I, Rodriguez D, Rubio-Viqueira B, Figueroa S, Lopez PG. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

126. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). Garon EB, Moran T, Barlesi F, Gandhi L, Sequist LV, Kim SW, groen HJM, Besse B, Smit EF, Kim DW, Akimov M, Avsar E, Bailey S, Felip E. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

127. Menstrual Status and lung cancer in female patients from the Spanish WORLD07 database. Cantos B, Majem M, Lopez PG, Vinolas N, Isla D, Garcia Campelo MR, Catot S, Lianes P, Artal A, Bover I, Terrassa J, Blasco A, Rolfo CD, De Castro J, González-larribia JL, Quintela ML, izquierdo A, Estevez SV, Figueroa S, Felip E. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

128. Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (P) with EGFR mutations in the EURTAC study. Buges c, Marti Am, Rossell R, Vergnenegre A, de Marinis F, Massuti B, De Castro J, Gervais R, Costa EC, Moran T, santarpia M, Felip E, Majem M, Porta R, palmero R, Drozdowskyj A, Heidecke C, gasco A, taron M, paz Ares L. 48th Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, USA, June 2012. Journal of Clinical Oncology, Volume 30 (15) Supplement, May 2012.

129. Molecular characterization and pre-screening process in early drug clinical development of PI3K-Pathway Inhibitors. Rodon J, Dientsmann R, Cortés J, saura C, Aura C, Hernández Losa J, Vivancos A, Joan J, Del campo J, Felip E, Seoane J, Tabernero J. 4th WIN symposium on efficacy of Biomarkers and Persolaized Cancer Therapeutics. Paris, France, June 2012. Annals of oncology Volume 23, S9-S10 Supplement 5, June 2012.

130. Expression of WILM tumour gene (WT1) is assosciated with survival in malignant pleural mesothelioma: Retrospective analysis in a single center series. Cedrés S, Torrejón D, Stjepanovic N, Martínez P, Martínez A, Salcedo M, Montero MA, Felip E. 37th Congress of the Europe4na Society for medical Oncology (ESMO). Vienna, Austria Sept-Oct2012. Annals of Oncology Volume 23 S496-496 Supplement 9, September 2012.

131. Clinicopathological features of never-smoking women lung cancer (WLC): A review from the spanish world07 database: de Castro J, Isla D, Provencio M, Majem M, Viñolas N, Felip E, Artal A, Garcia-Campelo R, Domine M, Garrido P. 37th Congress of the Europe4na Society for medical Oncology (ESMO). Vienna, Austria Sept-Oct2012. Annals of oncology Volume 23 S414-414 Supplement 9, September 2012.

132. Lux-Lung 8: A randomized, open-label, phase III trial of afatinib vs. Erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy. Goss G, Lu S, Felip E, Ardizzoni A, Georgoulias V, gadgeel S, Chand V, Gu Y, Olivo YS, Soria J. 37th Congress of the Europe4na Society for medical Oncology (ESMO). Vienna, Austria Sept-Oct2012. Annals of Oncology Volume 23 S174-174 Supplement 9, September 2012.

133. Results of a first-in-human Phase I study of the ALK inhibitor LDK378 in advanced solid tumors. Shaw A, camidge DR, Felip E, Sharma S, Tan DSW, Kim D, de Pas T, Vansteenkiste JF, Santoro A, Liu G, Goldwasser, Dai D, Boral A, Mehra R. 37th Congress of the Europe4na Society for medical Oncology (ESMO). Vienna, Austria. Annals of Oncology Volume 23 S153-153 Supplement 9, September 2012.

44

134. Phase II ACtivity of the HSP90 inhibitor AUY922 in patients with ALK-Rearranged (ALK plus) or EGFR-mutated Advanced Non Small Cell Lung Cancer (NSCLC). Felip E, carcereny E, Barlesi F, Gandhi L, Sequist LV, Kim SW, Groen HJM, Besse, Kim DW, Smit E, Akimov M, Avsar E, bailey S, Ofosu-Appiah, garon EB. 37th Congress of the Europe4na Society for medical Oncology (ESMO). Vienna, Austria. Annals of Oncology Volume 23 S152-152 Suplement 9, September 2012.

135. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape project. Blackhall F, Soltermann A, Dooms C, Felip E, Marchetti A, Speel EJM, Price N, Savic S, De Jong J, Martorell M, Thunissen E, Bubendorf L, Dafni O, Rosell R, Stahel R. Annals of Oncology Volume 23 S73-73 Supplement 9, September 2012.

136. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer (NSCLC): Randomized, non comparative, phase IIIb NEXT trial. Heigener D, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress. Amsterdam (The Nederlands). European Journal of Cancer, 49 (2): S823-824. September 2013.

137. Phase IB study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) patients (pts). Campelo RG, Felip E, Massuti T, Majem M, Carcereny E, palmero R, Molina MA, González Arenas C, Sánchez Ronco M, Rosell R. 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress. Amsterdam (The Nederlands). European Journal of Cancer, 49 (2): S802-803. September 2013.

138. Non-small cell lung cancer in women: Description of early stages from the Spanish World07 database. Cortes A, Provencio M, Magem M, Garrido P, Felip E, Viñolas N, Isla D, Garcia-Campelo R, De las penas R, Carcereny E. 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress. Amsterdam (The Nederlands). European Journal of Cancer, 49 (2): S806-806. September 2013.

139. SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access. Besse B, Menis J, Adam J, Dziadziusko R, Hasan B, Lacroix L, Peters S, Lacombe DA, O’Biren M, Stahel RA. Ginebra (Suiza). Abril 2015.

140. Analysis of expression of PTEN/PI3K pathway and programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Perez SC, Aix SP, Sansano I; Navarro A, Marti AM, Zugazagoitia J, Farinas L, Sanz-Garcia E, Vilaro M, Felip E. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (USA). Journal of Clinical Oncol 33 (15). May 2015.

141. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK plus) non-small cell lung cancer (NSCLC). Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Nishio M, Dols MC, McKeage MJ, Su WC, Mok T. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (USA). Journal of Clinical Oncol 33 (15). May 2015.

142. Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). Felip E, Blackhall FH, Mok T, Cappuzzo F, Wilner KD, Reisman A, Iyer S, Solomon BJ. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (USA). Journal of Clinical Oncol 33 (15). May 2015.

143. Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. Gadgeel SM, Dols MC, Felip E, Soria JC, Lee KH, Lu S, Georgoulias V, Fulop A, Goker E, Syrigos KN. Annual Meeting of the American Society of

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Perez,%20SC&cacheurlFromRightClick=no

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Aix,%20SP

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Sansano,%20I

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Navarro,%20A

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Marti,%20AM

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Zugazagoitia,%20J

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Farinas,%20L

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Sanz-Garcia,%20E

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Felip,%20E


https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Orlov,%20S

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Park,%20K

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Yu,%20CJ

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Tsai,%20CM

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Nishio,%20M

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Dols,%20MC

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=McKeage,%20MJ

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Su,%20WC

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Mok,%20T


https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Blackhall,%20FH&cacheurlFromRightClick=no


https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Cappuzzo,%20F

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Wilner,%20KD

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Reisman,%20A

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Iyer,%20S

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Solomon,%20BJ

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Gadgeel,%20SM

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Dols,%20MC


https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Soria,%20JC

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Lee,%20KH

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Lu,%20S&cacheurlFromRightClick=no

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Georgoulias,%20V

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Georgoulias,%20V

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Fulop,%20A

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Goker,%20E

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Syrigos,%20KN

45

Clinical Oncology (ASCO), Chicago (USA). Journal of Clinical Oncol 33 (15). May 2015.

144. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Mok T, Spigel D, Felip E, de Marinis F, Ahn MJ, Groen HJM, Wakelee HA, Hida T, Crino L, Nishio M. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (USA). Journal of Clinical Oncol 33 (15). May 2015.

145. Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. Bauer TM, Shaw AT, Solomon B, Besse B, James, LP, Clancy JS, Mugundu G, Martini JF, Abbattista A, Felip E. ASCO Meeting. Journal of Clincal Oncol; 33 (15). Chicago (USA). Mayo 2015.

146. TIGER-3: A phase 3, open-label, randomized study of rociletinib versus cytotoxic chemotherapy in patients with mutant EGFR non-small cell lung cancer progressing on prior EGFR tyrosine kinase inhibitor therapy and doublet chemotherapy. Chih-Hsin Yang J, Popat S, Bazhenova L, Blakely C, Dichmann R, Felip E, Griesinger F, Groen H, Gurubhagavatula S, Leach J, Novello S, Perol M, Patel R, Reckamp K, Georgiou P, Miyamoto E, Isaacson J, Wakelee H. 16 XX 16th World Conference on Lung Cancer. Denver (USA). September, 2015.

147. TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results. Quoix E, Forget F, Chouaid C, Papai Z, Losonczy G, Felip E, Cobo M, Ottensmeier C, Beck JT, Bastien B, Tavernaro A, Lacoste G, Limacher J, Léna H. Denver (USA). September, 2015.

148. Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK plus) NSCLC and baseline (BL) brain metàstasis (BM): Results from ASCEND-1 and 3. Felip E, Tan DSW, Kim DW, Mehra R, Orlov S, Park K, Yu CJ, Mok T, Nishio M, Scagliotti G. ASCO Annual Meeting, Chicago (USA). May 2016.

149. Analysis of RSPO gene expression in sòlid tumors. Vivancos A, Palmer HG, Ogbah Z, Matito J, Mancuso F, Navarro A, Martí A, Argiles G, Élez E, Rodon J, Nuciforo P, Tabernero J, Felip E. ASCO Annual Meeting, Chicago (USA). May 2016.

150. Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types. Navarro A, Arance A, Reguart N, Pare L, Galvan P, Martí A, Nuciforo P, Pardo N, Cedrés S, Gaba L, Victoria I, Viñolas N, Vivancos A, Prat A, Felip E. ASCO Annual Meeting, Chicago (USA). May 2016.

151. Results of patients with thoracic cancers older than 70 years included in clínical trials: A center experience. Martí A, Cabrera G, Ortiz C, Vilaro M, Miquel JM, Cedrés S, Navarro A, Pardo N, Martínez P, Piera A, Carbonell Ll, De la Fuente I, Garcia S, Sansano I, Felip E. ASCO Annual Meeting, Chicago (USA). May 2016.

152. Outcome of RAS mutated Lung adenocarcinoma (ADC) patients (pts) on standard chemotherapy (chemo) and immune chekpoint inhibidors (immuneCl). Pardo N, Ruiz F, Martí A, Navarro A, Cedrés S, de la Fuente I, Baste N, Vivancos A, Miquel JM, Dientsmann R, Felip E. ASCO Annual Meeting, Chicago (USA). May 2016.

153. Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non-Small-Cell Lung Cancer (NSCLC). Martínez De Castro A, Navarro A, Cedrés S, Martínez A, Pardo N, Hernando A, Ortiz C, Amair F, Bisoca M, Aguilar J, Scheenard E, Recasens S, Carbonell Ll, Retter A, Martínez S, Piera A, Valverde S, Veñez L, Garcia S, Vilaro M, Felip E. January 2017.

154. Molecular Characterization of Malignant Pleural Mesothelioma (MPM9 by next Generation Sequencing. Cedrés S, Martínez De Castro A, Pardo N, Navarro A, Martínez A, Amair F, Racca F, Scheenard E, Recasens S, De la Fuente I, Retter A, Vilaro M, Vivancos A, Felip E. January 2017.


https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Spigel,%20D



https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=deMarinis,%20F

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Ahn,%20MJ

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Groen,%20HJM

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Wakelee,%20HA

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Hida,%20T

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Crino,%20L

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Nishio,%20M

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Bauer,%20TM&cacheurlFromRightClick=no

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Shaw,%20AT

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Solomon,%20B

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Besse,%20B

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=James,%20LP

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Clancy,%20JS

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Mugundu,%20G

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Martini,%20JF

https://apps.webofknowledge.com/OneClickSearch.do?product=UA&search_mode=OneClickSearch&excludeEventConfig=ExcludeIfFromFullRecPage&SID=P1H3mQd4vEf6HCXbIr1&field=AU&value=Abbattista,%20A


http://library.iaslc.org/search-speaker?search_speaker=31827














46

155. Atezolizumab as first-line (1L) therapy for Advanced non-small cell Lung cancer (NSCLC) in PD-L1-selected patients: Efficacy data from the BIRCH trial. Peters S, Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. ELCC (European Lung Cancer Conference), Geneve (Switzerland). April 2017.

156. Tepotinib in patients woth Advanced non-small cell Lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial. Felip E, Horn L, Patel J, Sakai H, Scheele J, Bruns R. ASCO Annual Meeting, Chicago (USA). May 2018.

157. Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14 – Skipping Mutations. Felip E, Sakai H, patel J, Horn L, Veillon R, Griesinger F, Bruns R, Scheele J, Paik P. ESMO Congress, Munich (Germany). October 2018.

158. Checkmate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs. Chemotherapy in Early-Stage NSCLC. Felip E, Brahmer J, Broderick S, Swanson S, Awad M, Mitsudomi T, Girard N, Kerr K, Spicer J, Cai J, Yang R, Forde P. ESMO Congress, Munich (Germany). October 2018.

159. ATALANTE 1 randomized phase 3 trial, OSE 2101 vs. standard treatment as 2ndor 3rdline in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. E. Felip, G. Giaccone, R. Dziadziusko, F. denis, T. Moran, D. Debieuvre, M. Cobo, D. Galetta, R. Vanel, G. Romano, A. Madroszyk, C. Chouaid, F. R. Ferrand, W. Hilgers, F. Capuzzo, P, Masson, N. peledi, V. Gabarre, B. Vasseur, J. Remon, B. Besse. ASCO Annual Meeting, Chicago (USA). June 2019.

160. A Phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in patients with advanced NSCLC: OS for stage I and preliminary stage II efficacy. E. Felip, P. Brunsvig, N. Vinolas, S. Ponce Aix, E. Carcereny Costa, M. Dómine Gomez, JMTrigo Perez, E. Arriola, R. Garcia Campelo, J. Spicer, J. Thompson, A. Ortega Granados, R. Holt, K. Lorens, James Lorens, M. Shoaib, A. Siddiqui, E. Schmidt, M. Chisamore, M. Krebs.

161. Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs). E. Felip, A. Navarro, A. Callejo, A. Martinez Marti, S. Cedrés, N. Pardo, J. Ros, J. Assaf, A. Pedrola, C. Viaplana, I. Sansano, J. Jimenez, P.

Nuciforo, M. Sansó, R. Dienstmann, R. Amat, F. Mancuso, A. Vivancos. ASCO Annual Meeting, Chicago (USA). June 2019.

Book Chapters: 1. E. Felip. Quimioterapia de inducción (neoadyuvante) en pacientes con cáncer de

pulmón no de célula pequeña. En “Cáncer de pulmón”. Biblioteca oncológica Roche, pagines: 137-154.

2. E. Felip. Cáncer de Pulmón. En “Documentos de consenso en oncologia”. Nova Sidonia Oncologia. 1999.

3. E. Felip. Impacto de la quimioterapia sobre la supervivencia en el cáncer de pulmón no microcítico: Análisis de estudios Fase III en el tratamiento neoadjuvante. En “Quimioterapia y cáncer: Impacto sobre la supervivencia”. Editor E. Díaz-Rubio, pàgines 125-136, 2000.

4. E. Felip. Carcinoma de pulmón no microcítico en el anciano. En “Oncología geriátrica”. Editor G. Perez Manga, 2000.

5. E. Felip, R. Rosell. Coordinadors del “Libro del año oncologia 2001”. Cáncer de pulmón. Saned 2001.

https://ascopubs.org/author/Felip%2C+Enriqueta

https://ascopubs.org/author/Brunsvig%2C+Paal

https://ascopubs.org/author/Vinolas%2C+Nuria

https://ascopubs.org/author/Ponce+Aix%2C+Santiago

https://ascopubs.org/author/Carcereny+Costa%2C+Enric

https://ascopubs.org/author/Carcereny+Costa%2C+Enric

https://ascopubs.org/author/D%C3%B3mine+Gomez%2C+Manuel

https://ascopubs.org/author/Trigo+Perez%2C+Jose+Manuel

https://ascopubs.org/author/Arriola%2C+Edurne

https://ascopubs.org/author/Campelo%2C+Rosario+Garcia

https://ascopubs.org/author/Campelo%2C+Rosario+Garcia

https://ascopubs.org/author/Spicer%2C+James+F

https://ascopubs.org/author/Thompson%2C+Jonathan+Robert

https://ascopubs.org/author/Ortega+Granados%2C+Ana+Laura

https://ascopubs.org/author/Holt%2C+Robert+J

https://ascopubs.org/author/Lorens%2C+Katherine

https://ascopubs.org/author/Lorens%2C+James+B

https://ascopubs.org/author/Lorens%2C+James+B

https://ascopubs.org/author/Shoaib%2C+Muhammad

https://ascopubs.org/author/Siddiqui%2C+Abdul

https://ascopubs.org/author/Schmidt%2C+Emmett+V

https://ascopubs.org/author/Chisamore%2C+Michael+Jon

https://ascopubs.org/author/Krebs%2C+Matthew

https://ascopubs.org/author/Felip%2C+Enriqueta

https://ascopubs.org/author/Navarro%2C+Alejandro

https://ascopubs.org/author/Callejo%2C+Ana

https://ascopubs.org/author/Martinez+Marti%2C+Alex

https://ascopubs.org/author/Cedres%2C+Susana

https://ascopubs.org/author/Pardo%2C+Nuria

https://ascopubs.org/author/Pardo%2C+Nuria

https://ascopubs.org/author/Ros%2C+Javier

https://ascopubs.org/author/Assaf%2C+Juan+David

https://ascopubs.org/author/Pedrola%2C+Anna

https://ascopubs.org/author/Viaplana%2C+Cristina

https://ascopubs.org/author/Sansano%2C+Irene

https://ascopubs.org/author/Jimenez%2C+Jose

https://ascopubs.org/author/Nuciforo%2C+Paolo

https://ascopubs.org/author/Nuciforo%2C+Paolo

https://ascopubs.org/author/Sans%C3%B3%2C+Miriam

https://ascopubs.org/author/Dienstmann%2C+Rodrigo

https://ascopubs.org/author/Amat%2C+Ramon

https://ascopubs.org/author/Mancuso%2C+Francesco+M

https://ascopubs.org/author/Vivancos%2C+Ana

47

6. E. Felip. Estado actual del tratamiento del cáncer de pulmón. En “Libro del año oncologia 2001”. Cáncer de pulmón. Saned 2001. Editor: E. Felip, R. Rosell, pàgines 7-13, 2001.

7. E. Felip. Carcinoma de pulmón no microcítico en el anciano. En “Oncología Geriàtrica”. Editor G. Pérez Manga, pàgines 169-174; 2002.

8. C. Agustí, R. Rosell, E. Felip. Tumores broncopulmonares. En Farreras Rozman; Medicina Interna; Decimoquinta edición, pàgines 780-792; 2004.

9. E. Felip, J. Baselga. Receptor Tyrosine Kinase Abnormalities in Lung Cancer. En “Lung Cancer: Principles and Practice”. Editores HI. Pass, DP. Carbone, DH. Johnson, JD. Minna, AT. Turrisi. Lippincott Williams & Wilkins, pàgines 147-159, 2005.

10. E. Felip. Quimioterapia neoadyuvante en el carcinoma pulmonar no microcítico (CPNM). Editor Vicente Alberola. You & Us, S.A., pàgines 27-37, 2005.

11. E. Felip, F.J. Ramos. El tabaco como responsable etiológico del cáncer de pulmón. En “Cáncer de Pulmón: Una nueva panoràmica de este problema sanitario”. Coordinador: José Andrés Moreno Nogueira, pàgines 17-24, 2006.

12. E. Felip, R. Rosell. Lung Cancer. En “Hematology-Oncology Therapy”. Editores M.M Boyiadzis, PF. Lebowitz, JN Frame and T. Fojo. Mc Graw Hill Medical, pàgines 262-281, 2006.

13. E. Felip. Nuevas dianas moleculares (I). Rituximab, trastuzumab, cetuximab. En “Oncomecum” Editors E. Díaz Rubio y P. Pérez-Segura. Permanyer 2ª Edición, pàgines 107-118, 2007.

14. E. Felip, S. Peralta, S. Cedrés. Cáncer de pulmón no microcítico. Minimanual práctico Nº 2. Ediciones Aran S.L. 2007.

15. E. Aranda, M. Benavides, A. Casas, E. Felip, P Garrido, J Rifá. Comité Coordinador del Primer Libro Blanco de la Oncología en España. Edita: Dispublic, S.L. 2007.

16. S. Cedrés, E. Felip. Cáncer de pulmón no microcítico. En “Oncoquest “ Editor A. Prat Aparicio. Elsevier España S.A., pàgines 126-145, 2007.

17. S. Cedrés, E. Felip. Mesotelioma. En “Oncoquest “ Editor A. Prat Aparicio. Elsevier España S.A., pàgines 146-147, 2007.

18. S. Cedrés, E. Felip. Tumores del mediastino. En “Oncoquest “ Editor A. Prat Aparicio. Elsevier España S.A., pàgines 148-149, 2007.

19. S. Cedrés, E. Felip. Cáncer de pulmón microcítico. En “Oncoquest “ Editor A. Prat Aparicio. Elsevier España S.A., pàgines 150-156, 2007.

20. C. Agustí, R. Rosell, E. Felip. Tumores broncopulmonares. En Farreras Rozman; Medicina Interna; Decimosexta edición, pàgines 785-796; 2008.

21. E. Felip. Cáncer de pulmón. Tratamiento de la enfermedad metastásica. En “Cáncer de Pulmón”. Coordinador Carlos Camps. Publicaciones Permanyer, pàgines 23-30, 2008.

22. E. Felip. Nuevas dianas moleculares. Sorafenib, tenserolimus, trastuzumab, sunitinib, imatinib y bevacizumab. En “Oncomecum” Editors E. Díaz Rubio y P. Pérez-Segura. Permanyer 3ª Edición, pàgines 133-148, 2009.

23. E. Felip y P. Martínez. Valor de la quimioterapia en cáncer de plumón no microcítico en estadios precoces: adyuvancia y neoadyuvancia. Editor Pilar Garrido. You & Us, S.A., pàgines 39-54, 2010.

24. E. Felip, T. Moran, B. Massuti, R. Rosell. Stage IIIB and IV NSCLC: recurrent disease. En: “Current Multidisciplinary Oncology”. Editors Kemp Kernstine and Karen Reckamp. Demos Medical Publishing New York 2010.

25. E. Felip, R. Vidal, M.A. Montero. Neoplasia Broncopulmonar en “Guía Pneumológica”. Editor Ferran Morell. Ergon. Pàgines 114-121.

26. Javier de Castro, Ángel Artal, E. Felip, Pilar Garrido, Dolores Isla, Margarita Majem, Núria Viñolas (Editores). “Cáncer de Pulmón en Mujeres”. ICAPEM. 2013.

48

27. E. Felip. Dianas moleculares. Sorafenib, temsirolimus, trastuzumab, sunitib, imatinib y bevacizumab. En “Oncomecum”. Coordinadores: Eduardo Díaz - Rubio, Pedro Pérez - Segura. Permanyer, pàgines 253 – 266.

28. E. Felip. “Futuro del tratamiento en pacientes biológicamente seleccionados” en Carcinoma de Pulmón en no fumadores. Coordinador E. Carcereny. 1a edición 2013. Págines: 181-192.

29. E. Felip. “Pacientes en tratamiento con quimioterapia sistémica y en tratamiento anticoagulante crónico por indicación no oncológica (fibrilación auricular, valvulopatía, otras indicaciones)”. “Pacientes en tratamiento con agentes estimulantes de la eritropoyesis”. “Complicaciones del tratamiento anticoagulante” en Capítulo 7 Situaciones Especiales en II Consenso SEOM sobre Enfermedad Tromboembólica en pacientes con Cáncer”. 2013. SEOM (Sociedad Española de Oncología Médica). Páginas: 131-138

30. “Interacciones Farmacológicas en el Tratamiento del cáncer de pulmón”. Prólogo E. Felip. Medinteract.net / Editorial Médica Jims, S.L. Diciembre 2017.

National Invited Lectures: 1. "Oncogens i Càncer, una visiò multidisciplinària". Facultat de Medicina, Hospital

Clínic, Universitat Central de Barcelona. Apr 1991. 2. Càncer d’ovari, noves perspectives. Departaments de Medicina i Anatomia

Patològica Hospital General Universitari Vall d' Hebron. Universitat Autònoma de Barcelona. Mar 1992.

3. Sessió interhospitalària: Càncer d’ovari. Hospital de Igualada. May 1993. 4. Oncogenes en el cáncer de ovario. Departaments de Medicina i Anatomia

Patològica Hospital General Universitari Vall d' Hebron. Universitat Autònoma de Barcelona. Jan 1994.

5. Oncoproteína p185 en cáncer de ovario.“II Curso sobre nuevas indicaciones y técnicas en Medicina Nuclear”. Universitat Autònoma de Barcelona. Barcelona. Apr 1994.

6. Spanish Lung Cancer Group neoadjuvant chemotherapy studies. "Non-small cell lung cancer Symposium". Barcelona. Nov 1997.

7. Quimioterapia y supervivencia del cáncer de pulmón de célula no pequeña. Estado actual. “XII Curso de avances en Neumologia Vall d'Hebron”. Barcelona. Feb1998.

8. Tratamiento con quimioterapia en estadios IIIa/IIIb. “I Jornadas de actualización en oncología: Cáncer de pulmón”. Hospital Universitari Arnau de Vilanova, Lleida. Jan 1999.

9. Is neodjuvant chemotherapy still necessary in stage IIIA non-small cell lung cancer?. "Third Congress on Lung Cancer". Barcelona. Feb 1999.

10. Terapias emergentes: Inmmunoterapia tratamiento con BEC2 y BCG en microcítico de pulmón. “VIII Jornadas Invernales de Actualización en Oncología”. Hospital Miguel Servet, Saragossa. Mar 1999.

11. Utilidad de la quimioterapia en CPNCP. “III Jornadas de actualización en Oncología: Nuevos retos”. La Toja. Sep 1999.

12. Tratamiento neoadjuvante en cáncer de pulmón. “I Simposium Cáncer en el Anciano”. Madrid. Nov 1999.

13. Ensayos fase II con quimioterapia neoadyuvante en estadio IIIA-N2 con la combinación carboplatino/docetaxel/gemcitabina. “II Jornadas de actualización en oncología”. Hospital Universitari Arnau de Vilanova, Vall d’Aran, Lleida. Jan 2000.

14. Coste-beneficio de la quimioterapia y radioterapia paliativa en cáncer de pulmón. “III Congreso de la Sociedad Española de Cuidados Paliativos”. València. May 2000.

49

15. Quimioterapia de segunda línea en cáncer de pulmon. “V Jornades Oncològiques Hospitalàries”. Andorra. Mar 2001.

16. Cáncer de pulmón. “Encuentros en Oncología”. Segovia. Apr 2001. 17. “1ª Jornada nacional sobre radioquimioterapia en el cáncer de pulmón”. Hospital

Clinic i Universitari. Barcelona. Apr 2001. 18. Optimización de la quimioterapia en tratamientos concomitantes en el cáncer de

pulmón. “1ª Jornada nacional sobre radioquimioterapia en el cáncer de pulmón”. Hospital Clinic i Universitari, Barcelona. Apr 2001.

19. El diseño, ¿alguien tiene alguna idea?. 3ª convocatoria: Investigaciò clínica”. Institut Català d’Oncologia, El Montanyà, Barcelona. Sep 2001.

20. Experiencia con Campto en otros tumores: cáncer de pulmón. “VIII Congreso de la Sociedad Española de Oncología Médica”. Valencia. Oct 2001.

21. Avenços en el tractament del càncer de pulmó. Departaments de Medicina i Anatomia Patològica. Hospital General Universitari Vall d' Hebron. Universitat Autònoma de Barcelona. Oct 2001.

22. NATCH Trial. Ponència al “Fourth Congress on Lung Cancer”. Spanish Lung Cancer Group. Barcelona. Nov 2001.

23. Cáncer de pulmón no microcítico: Tratamiento quimioterápico de primera línea. “IV Simposio de Revisiones en Cáncer”. Hospital Clínico San Carlos. Madrid. Feb 2002.

24. Carcinoma no microcítico de pulmón. “XIV Reunión anual de la Sociedad Oncológica de Galicia”. Hospital Clínico Universitario de Santiago de Compostela. Jun 2002.

25. Tratamiento neoadyuvante del carcinoma no microcítico de pulmón. “V Curso Intensivo de Oncología”. European School of Oncology. Sevilla. Jun 2002.

26. Nuevas estrategias para el tratamiento del cáncer de pulmón. “XIV Curso Avanzado de Oncología Médica. Hospital Universitario 12 de Octubre. Madrid. Jun 2002.

27. Estado actual en el tratamiento neoadyuvante del cáner de pulmón no microcítico. Segunda línea en cáncer de pulmón no microcítico. “Simposio Educacional del Grupo Español de Cáncer de Pulmón (GECP).Valencia. Oct 2002.

28. El estado actual en el tratamiento neoadyuvante del cancer de pulmón no microcítico. Segunda línea en cáncer de pulmón no microcítico: Epotilona. “Simposio Educacional del Grupo Español de Cáncer de Pulmón (GECP) Valencia. Oct 2002.

29. Carcinoma broncogénico. “XVII Curso de Avances en Neumología Vall d’Hebron”. Barcelona. Feb 2003.

30. Cáncer de Pulmón no microcítico. “V Simposio de Revisiones en Cáncer”. Hospital Clínico San Carlos, Madrid. Feb 2003.

31. Nuevos fármacos en el tratamiento de cáncer de pulmón. “II Simposium internacilonal de la Asociación Canaria de Oncología Médica”. Las Palmas de Gran Canaria. Mar 2003.

32. Qumioterapia Neoadyuvante. “XII Jornadas invernales de actualización en oncologia”. Huesca. Mar 2003.

33. Qumioterapia neoadyuvante en el tratamiento de cáncer de pulmón localmente avanzado. “II Jornada sobre radioquimioterapia en el cáncer de pulmón”. Hospital Clínico de Barcelona. Apr 2003.

34. Càncer de Pulmó no microcític estadi III. Quimioterápia. Societat Catalano-Balear d’Oncología (ACMCB). Barcelona. Apr 2003.

35. Estado actual del tratamiento del cáncer de pulmón no microcítico.Estadios Precoces (I y II): Papel de la Quimioterapia. “IX Congreso SEOM”. Tenerife. Jun 2003.

36. Nuevas estrategias para el tratamiento del cáncer de pulmón. “XV Curso Avanzado de Oncología Médica”. San Lorenzo de El Escorial, Madrid. Jun 2003.

50

37. Tumores de células redondas en cáncer de pulmón. VII Curso Oncología Médica R4: En el Umbral de la Pràctica Oncológica. Sant Feliu de Guixols, Girona. Oct 2003.

38. NATCH trial update. “V Congress on Lung Cancer”. Barcelona. Novembre 2003. 39. Tratamiento adyuvante del cáncer de pulmón no célula pequeña. “VI Simposio de

Revisones en Cáncer”. Madrid. Feb 2004. 40. Es vàlida esta estrategia en cáncer de pulmón?. “XIII Jornadas Invernales de

Actualización en Oncología”. Formigal, Huesca. Mar 2004. 41. Quimioterapia neoadyuvante en enfermedad precoz-estudio NATCH. “Simposium

del Grupo Español de Cáncer de Pulmón y del Grupo Gallego de Cáncer de Pulmón. Santiago de Compostela. May 2004.

42. Adequate delivery of lung cancer therapy. “Appropriate Dose Optimal Results”. Barcelona. Sep 2004.

43. Discusión por los expertos. “V Taller de Expertos sobre Gestión en Oncología Médica”. Madrid. Sep 2004.

44. Nuevos esquemas y estrategias en el tratamiento sistémico. “V Congreso Nacional FESEO. Valencia. Oct 2004.

45. Nuevas estrategias para el tratamiento del cáncer de pulmón. “XVI Curso Avanzado de Oncología Médica”. San Lorenzo de El Escorial, Madrid. Oct 2004.

46. Nuevas moléculas. Papel en el cáncer del anciano. Iressa. “V Simposio Iberoamericano”. Madrid. Nov 2004.

47. Update on neoadjuvant and adjuvant chemotherapy: assessment of HIF& mRNA. “Plenary Session & II Educational Sysmposium of the Spanish Lung Cancer”. Bilbao. Nov 2004.

48. Cancer de pulmón microcítico. “I Simposio Internacional de Quimio-Radioterapia en el tratamiento del cáncer”. Elche, Alicante. Jan 2005.

49. Tratamiento neoadyuvante y adyvante del cáncer de pulmón no microcítico. “VII Simposio de Revisiones en Cáncer”. Madrid. Feb 2005.

50. Tratamiento adyuvante en los estadíos iniciales de cáncer de pulmón no microcítico. ¿Hay alguna diferencia entre estadios I ó II-IIIA?. “X Congreso Nacional Sociedad Espanyola de Oncología Médica (SEOM)”. Zaragoza. Jun 2005.

51. Cáncer de pulmón con metàstasis suprarrenal. “XXXVIII Congreso Nacional Sociedad Espanyola de Neumología y Cirugía Torácica (SEPAR). Valencia. Jun 2005.

52. Nuevas estrategias para el tratamiento de cáncer de pulmón. “XVII Curso Avanzado de Oncología Médica”. San Lorenzo de El Escorial. Sep 2005.

53. Desarrollo en cáncer de pulmón. “El tratamiento antiangiogénico en el càncer: cambiando los estándares”. Sevilla. Sep 2005.

54. Cáncer de pulmón: Tratamiento adyuvante. “VI Simposio Internacional Cáncer en el Anciano”. Madrid. Nov 2005.

55. Tratamiento combinado de inhibidores VEGFR y EGFR en cáncer de pulmón. “I Aula Abierta Multidisciplinaria del Cáncer de Pulmón”. Santander. Nov 2005.

56. Cáncer de pulmón de células no pequeñas. “II Simposio Internacional de Quimio-Radioterapia en el Tratamiento del Cáncer”. Elche, Alicante. Feb 2006.

57. Nuevos retos en el cáncer de pulmón: hacia un tratamiento individualizado con los inhibidores de la tirosín-kinasa. “VIII Simposio de Revisiones en Cáncer”. Madrid. Feb 2006.

58. Tratamiento complementario cáncer de pulmón no célula pequeña. “Foro de debate sobre tratamiento adyuvante”. Sallent de Gállego, Huesca. Feb 2006.

59. Factores pronósticos en el cáncer de pulmón no microcítico: integración en el tratamiento actual. “IX Reunión de Consenso en Tratamiento Oncológico: Cáncer de Pulmón”. Córdoba. Mar 2006.

60. Tratamiento del mesotelioma pleural. Aspectos oncológicos”. “IX Reunión del Club de Cirujanos Torácicos”. Santander. Apr 2006.

51

61. Terapia dirigida contra dianas moleculares. “Primer foro de cáncer de pulmón de célula pequeña”. Madrid. May 2006.

62. Terapia génica: Nuevos tratamientos en el mesotelioma. “V Jornada del derrame pleural, Vall d’Hebron”. Barcelona. Jun 2006.

63. Cáncer de pulmón. “VI Jornadas de Revisión de ASCO”. Madrid. Jul 2006. 64. Nuevas estrategias para el tratamiento del cáncer de pulmón. XVIII Curso

Avanzado de Oncología Médica. San Lorenzo de El Escorial. Oct 2006. 65. Polémica en mesas de expertos: cáncer de pulmón. X Curso R4: En el umbral de

la pràctica oncológica. Barcelona. Octubre 2006. 66. Cáncer de Pulmón. “VII Simposio Internacional Cáncer en el Anciano”. Madrid. Oct

2006. 67. II Congreso SEOM de cuidados continuos en oncología médica. Moderator.

Sevilla. Oct 2006. 68. Mesa càncer de pulmón: Papel de las nuevas dianas en el tratamiento de la

enfermedad metastásica avanzada. “Hitos Oncológicos: Lo mejor de 2006”. Madrid. Nov 2006.

69. CPNCP estadio III. Controversias en el manejo terapéutico. “Sesiones Interactivas en Cáncer de Pulmón”. Barcelona. Jan 2007.

70. Tratamiento del càncer de pulmón avanzado: segunda línea. Conclusiones. “Aula Abierta Multidisciplinar en Cáncer de Pulmón”. Santander. Feb 2007.

71. Tumores torácicos. Conclusiones. “IX Simposio de Revisiones en Cáncer”. Madrid. Feb 2007.

72. El càncer de pulmón en la mujer. “III Jornada Intensiva de Estudio sobre Cáncer de Pulmón”. Barcelona. Mar 2007.

73. Los desafíos de la invesigación en càncer de pulmón. “El desafío oncológico: nuevos retos en oncología”. Valencia. Apr 2007.

74. ¿Es imprescindible en la actualidad la realización de estudios farmacogenómicos (ERCC1, RMM1, BRCA1, EGFR, etc) para definir el tratamiento específico de un carcinoma pulmonar escamoso, en la práctica cotidiana?. “Encuentros en Oncología”. Madrid. Apr 2007.

75. Quimioterapia de consolidación: Sí. “1ª Mesa Multidisciplinaria: Quimiorradioterapia concomitante en càncer de pulmón no célula pequeña estadios III”. Lugo. Jun 2007.

76. Tratamientos con antiangiogénicos en el càncer de pulmón. Ponència a “Revolucionando el tratamiento oncológico: profundizando en las bases moleculares del mecanismo de angiogénesis”. Madrid. Octubre 2007.

77. Sesión de controversias: cáncer de pulmón, tratamiento de la enfermedad avanzada basado en el perfil clínico. “XI Congreso Nacional de la Sociedad Española de Oncología Médica”. Madrid. Oct 2007.

78. Mesa cáncer de pulmón: nuevas estrategias para el tratamiento del cáncer de pulmón. “XIX Curso avanzado de Oncología Médica”. El Escorial, Madrid. Oct 2007.

79. ¿Las nuevas dianas han modificado el tratamiento estándar? cáncer de pulmón. “Hitos Oncológicos: lo mejor del 2007”. Valencia. Nov 2007.

80. Visión actual del tratamiento del mesotelioma. “XI Curso de Patología Ocupacional Respiratoria”. Barcelona. Nov 2007.

81. Quimio-radioterapia en cáncer de pulmón localmente avanzado. “Abordaje multidisciplinar del cáncer”. Elche, Alicante. Feb 2008.

82. Inhibidores del receptor VEGFR (Vandetanib). “X Simposio de Revisiones en Cáncer”. Madrid. Feb 2008.

83. Aportaciones del estudio NATCH. Propuestas de futuro en estudios iniciales en el càncer de pulmón. “XI Reunión del Club de Cirujanos Torácicos”. Palma de Mallorca. May 2008.

52

84. Control de la toxicidad de los nuevos fármacos. Inhibidores de la tirosin-quinasa. “II Simposio Internacional Nuevos Paradigmas de la Calidad Asistencial Oncológica”. Valencia. Jun 2008.

85. Tratamiento de la enfermedad avanzada basado en perfil clínico. “XI Congreso Nacional de la Sociedad Española de Oncología Médica”. Madrid Oct 2008.

86. Nuevas estrategias para el tratamiento del cáncer de pulmón. “XX Curso avanzado de Oncología Médica”. El Escorial. Oct 2008.

87. Cáncer de pulmón. “Estado del arte en la asociación de la radioterapia con las terapias biológicas y antiangiogénicas”. Barcelona. Oct 2008.

88. Visión actual del tratamiento del mesotelioma. “XII Curso de Patología Ocupacional Respiratoria”. Barcelona. Nov 2008.

89. Hacia un abordaje integral en el càncer de pulmón no microcítico: nuevo estándar de tratamiento de primera línea. “Oncoforum 2008”. Valencia. Nov 2008.

90. Novedades en el tratamiento del cáncer de pulmón dirigido a dianas terapéuticas. “3ª Jornadas Hitos Oncológicos”. Madrid. Nov 2008.

91. CPNM: Tratamiento de segunda y tercera línea con inhibidores de tirosina quinasa Gefitinib y Vandetanib. “XI Simposio de Revisiones en Cáncer”. Madrid. Feb 2009.

92. Histología como factor condicionante de la decisión terapéutica. “XII Reunión de Consenso en tratamiento Oncológico: Cáncer de Pulmón”. Córdoba. Mar 2009.

93. Aspectos básicos del cáncer de pulmón: Factores predictivos de sensibilidad / resistencia a la quimioterapia en cáncer de pulmón. “IV Jornada intensiva sobre radioquimioterapia en el càncer de pulmón”. Barcelona. Mar 2009.

94. Mecanismos moleculares de resistencia a inhibidores de EGFR en cáncer de pulmón. “XII Congreso Nacional de la Asociación Española de Investigación sobre el Cáncer ASEICA”. Madrid. May 2009.

95. Cáncer de pulmón metastásico: ¿Podemos individualizar los tratamientos?. Taula a “360º en Oncología”. Madrid. Jun 2009.

96. Mecanismos de resistencia a inhibidores de EGFR. “Modulo III del Máster en Oncología Molecular: Biología Molecular y celular del càncer. Quinta edición”. Centro de Estudios Biosanitarios. Madrid. Sep 2009.

97. ¿Se deben administrar las terapias siempre personalizadas en cáncer de pulmón? A favor. “ XII Congreso Nacional de Oncología Médica”. Barcelona. Oct 2009.

98. Estado del arte en el tratamiento neoadyuvante en cáncer de pulmón. “ La Oncología Española, 30 años de andadura. El desafío oncológico”. Valencia. Dec 2009.

99. Perspectivas futuras en terapia dirigida: nuevas terapias. “ Curso Avances en el abordaje multidisciplinario del cáncer de pulmón”. Majadahonda, Madrid. Mar 2010.

100. Cáncer de pulmón no microcítico: Perspectivas de futuro. “ Foro de debate en Oncología”. Formigal, Huesca. Apr 2010.

101. Cáncer de pulmón. Fisiopatología i epidemiología. Farmacoterapia y seguimiento de los pacientes. Professora en Máster de Farmacia Assistencial i Atenció Farmacèutica. Universitat de Barcelona. Apr 2010.

102. Inhibidores de las tirosin-quinasas. “III Simposio Internacional Nuevos Paradigmas en Soporte y Asistencia Oncológica”. Barcelona. May 2010.

103. Curs patòleg i dianes terapèutiques. “9è Congrés Català d’Anatimia Patològica”. Lleida. Jun 2010.

104. ALK, nueva diana terapéutica en adenocarcinoma de pulmón. “Nuevos horizontes en el manejo del càncer de pulmón”. Barcelona. Jun 2010.

105. Neoadjuvant therapy in early stage NSCLC: the value of chemotherapy.“V Simposio Educacional Grupo Español de Cáncer de Pulmón (GECP)”. Palma de Mallorca. Nov 2010.

106. Organización asistencial: optimización de recursos y tiempo. “I Symposium SEAP-SEOM” Sociedad Española de Oncología Médica. Madrid. Feb 2011.

53

107. Biomarcadores en Cáncer de Pulmón. “E-debates Sociedad Española de Oncología Médica (SEOM)”. Barcelona. Abr 2011.

108. De la investigación clínica a la investigación bàsica: modelos de intercambio de conocimiento. “Encuentro Nacional de Oncología SEOM 2011” Sociedad Española de Oncología Médica. Madrid. Oct 2011.

109. State of the art of clinical trials with novel agents. “9º Congreso en Cáncer de Pulmón” Grupo Español de Cáncer de Pulmón (GECP). Barcelona. Nov 2011.

110. Actualización de la Base de Datos WORLD2007. “II Simposio de Cáncer de Pulmón en Mujeres” (ICAPEM). Madrid. Febrero 2012.

111. Utilidad de los marcadores moleculares en tejido en neoplasia de pulmón: tratamiento dirigido. “XXVI Curso de Avances en Neumología Vall d’Hebron” (Servicio de Pneumología Hospital vall d’Hebron). Barcelona. Febrero 2012.

112. Histología como factor condicionante de la decisión terapeútica. “XV Reunión de Consenso en tratamiento Oncológico: Cáncer de Pulmón”.Córdoba. Marzo 2012.

113. Actualització en Oncología. Teràpia fins a on? “Update 2012”. Fundació Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i Balears. Març 2012.

114. Terapia anti-EGFR: Estado actual y desarrollo de futuro. Cáncer de Pulmón. Foro de debate en Oncología, Formigal, Abril 2012.

115. Estadificación del Cáncer de Pulmón. “XXIV Curso Avanzado de Oncología Médica”, San Lorenzo de El Escorial, Junio 2012.

116. Nuevos fármacos. Ensayos en Curso. “I SIMPOSIO: Abordaje Multidisciplinar del mesotelioma Pleural Maligno”, ICO (Institut Català d’Oncologia, Hospital Duran i Reynals), Barcelona, Octubre 2012.

117. State of the art of chemotherapy in early-stage NSCLC. VI simposio Educacional GECP, Alicante, November 2012.

118. HER2 driven NSCL: Potential therapeutic approaches. VI Simposio Educacional GECP, Alicante, November 2012.

119. Antiangiogénicos. Foro de Debate en Oncología, Panticosa (Huesca), Mayo 2013.

120. Valor del PET en la reestadificación del carcinoma bronquial después del tratamiento. Reunión SEOM – SEPAR. 46º Congreso Nacional de la "Sociedad Española de Neumología y Cirugía Torácica" (SEPAR). Barcelona, Junio 2013.

121. Estadificación del Cáncer de Pulmón. XXV Curso Avanzado de Oncología Médica. San Lorenzo de El Escorial, Junio 2013.

122. Tratamiento médico del càncer en el año 2014. XVI Simposio de Revisiones en Cáncer. Madrid, Febrero 2014.

123. Resultados recientes del tratamiento del cáncer de pulmón de célula no pequeña. Importancia delos marcadores moleculares. XXVIII Curso de Avances en Neumología Vall d’Hebron y Simposium Internacional sobre Enfermedad Pulmonar Intersticial (EPI). Barcelona, Febrero 2014.

124. III Simposio de Cáncer de Pulmón en Mujeres. Madrid, Febrero 2014. 125. Casos clínicos en NSCLC Estadio III/ A. VI Jornada Intensiva de Radio-

Quimioterapia en Cáncer de Pulmón. Barcelona, Febrero 2014. 126. Manejo de pacientes con EGFR mutado a la progresión tres una 1a línea con

EGFR-TKI. X Simposio Abordaje Multidisciplinar del Cáncer. Madrid, Abril 2014. 127. Estado del arte del tratamiento adyuvante y neoadyuvante en enfermedad

localizada. Factores pronósticos y biomarcadores. 3er Curso de Capacitación en Cáncer de Pulmón. Madrid, Abril 2014.

128. Tratamiento de pacientes con otras alteraciones moleculares: ROS1, BRAF, HER2. 3er Curso de Capacitación en Cáncer de Pulmón. Madrid, Abril 2014.

129. Agentes dirigides. Presente y Futuro. Cáncer de Pulmón. Curso Cáncer de Pulmón. Estrategia multidisciplinar y vías futures en su manejo diagnostico-terapeútico. Madrid, Octubre 2014.

130. Cáncer de Pulmón. XVII Simposio Revisiones en Cáncer. “Tratamiento Médico del Cáncer en el año 2015”. Madrid, Febrero 2015.

54

131. “Tratamiento del Cáncer de pulmón EGFR+ / ALK+”. XVIII Reunión de Consenso: Tratamiento del Cánder de Pulmón. Córdoba, Marzo 2015.

132. La secuencia óptima de tratamiento en cáncer avanzado: Cáncer de Pulmón. VII Simposium Bases Biológicas. Salamanca, Mayo 2015.

133. “Innovación en el desarrollo clínico”. Curso UIMP Scientiffic and Access breakthrough in Oncology. (Universidad Interncional Menéndez Pelayo), Valencia, Mayo 2015.

134. “State of the art in Lung cancer”. Curso UIMP The Future Cancer Treatment. Innovative Therapies and Medical Implications. Santander, Julio 2015.

135. “Enfermedad localitzada (estadios I, II): Adyuvancia y neoadyuvancia en estadios iniciales”. 4º Curso de Capacitación en Cáncer de Pulmón. (Grupo Español de Cáncer de Pulmón, GECP) Alcalá de Henares (Madrid) Marzo 2016.

136. “Tratamiento Médico del cáncer en el año 2016”. XVIII Simposio Revisiones en Cáncer, Madrid Febrero 2016.

137. “Enfermedad localizada (estadios I, II) adyuvancia y neoadyuvancia en estadios iniciale”s. 4º Curso de Capacitación en Cáncer de Pulmón. Alcalá de Henares, Madrid, Marzo 2016.

139. Ponente en el II Foro de Immunología Traslacional e Immunoterapia del Cáncet (FIT-CÁNCER 2). Organizado por GÉTICA (Grupo Español de Terapias Inmuno-Biológicas en càncer-GÉTICA). Sevilla, Marzo 2016.

140. "Manejo del tratamiento de primera línea del cáncer de pulmón matastásico no microcítico y no escamoso". I Foro La Oncología médica en 3 días. Madrid (Universidad Francisco de Vitoria), Mayo 2016.

141. “La immunoteràpia como nuevo paradigma en el Tratamiento del CPNM Avanzado”. VII Simposium Bases Biológicas del Cáncer y Terapias Personalizadas. Salamanca, Mayo 2016.

142. “Estado actual del tratamiento Neoadyuvante y Adyuvante a la Cirugía en Estadios Iniciales de Cáncer de Pulmón No Microcítico”. Curso Avanzado de Oncología Médica, San Lorenzo de El Escorial, Madrid. Junio 2016.

143. “Tratamiento de Carcinoma Microcítico de Pulmón”. Curso Avanzado de Oncología Médica, San Lorenzo de El Escorial, Madrid. Junio 2016.

144. “Atención farmacéutica al paciente oncohematológico”, 1a Reunión Anual del grupo GEDEFO (Grupo de Farmácia Oncológica de la SEFH), Madrid, Septiembre 2016.

145. “Inmunoterapia en NSCLC, recomendaciones actuales”. Curso de Cáncer de Pulmón, Vall d’Hebrón Instituto de Oncología, Barcelona, Octubre 2016.

146. “Nuevas estratègies en el tratamiento del cáncer de pulmón”, Vall d’Hebrón Instituto de Oncología, Barcelona, Octubre 2016.

147. “T790M: Nueva diana y Nuevos mecanismes de resistència. Sesión Multidisciplinar SEOM – SEAP de Cáncer de Pulmón”. SEOM (Sociedad Española de Oncología Médica), Madrid, Octubre 2016.

148. “Qué esperamos de la inmunoterapia”, 1er Simposio Nacional “Avances en el tratamiento del cáncer de pulmón de célula pequeña (CPCP), Santiago de Compostela, Noviembre 2016.

149. “Indicación de inmunoterapia solo en casos de expresión positiva de PD-L1”. Cáncer de Pulmón Estado del Arte, Hospital M Sanchinarro, Madrid, Noviembre 2016.

150. “Immuno Oncology; Immunotherpay and benefits in Lung Cancer”. Symposium Manipulating the Immune System in Cancer, Madrid, Noviembre 2016.

151. “Translocaciones y su tratamiento: ALK, ROS 1”. Desafío Oncológico. Más allà del Genoma. Valencia, Noviembre 2016.

152. “Cambio de paradigma en el EGFR mutado: Desde las primeres mutacions a las de resistència”. XIX Simposio Revisiones en Cáncer. Tratamiento medico del cáncer en el año 2017. Madrid, Febrero 2017.

55

153. “La Inmunoterapia como cambio de paradigma”. XIX Simposio Revisiones en Cáncer. Tratamiento Médico del Càncer en el año 2017. Madrid, Febrero 2017.

154. “Modelos en Inmuno-Oncología”. II Edición Título en Experto en Inmunología Tumoral e Inmunoterapia del Cáncer”. Alcalá de Henares, Madrid, Marzo, 2017.

155. “Debates en Cáncer de Pulmón”. Participante y Dinamizadora, Madrid, Abril 2017. 156. “Seleccionando la major alternativa para cada tipo de paciente de càncer de

pulmón en la consulta”. II Foro la Oncología Médica en 3 Días, Madrid, Mayo 2017. 157. “La Inmunoterapia en el tratamiento del CPNM avanzado. Impacto en la práctica

clínica actual”. IX Simposium Bases Biológicas del Cáncer y Terapias Personalizadas, Salamanca, Mayo 2017.

158. “Armonización de la expresión de PDL1 desde un punto de vista clínico”. VIII Curso Avances en el ABordaje Multidisciplinar del Cáncer de Pulmón, Hospital Universitario Puerta de Hierro (Madrid), Mayo 2017.

159. “Tratamiento de Carcinoma Microcítico de Pulmón”. XXIXX Curso Avanzado de Oncología Médica, San Lorenzo de El Escorial (Madrid), Junio 2017.

160. “Debate de los puntós más destacados presentados en el Congreso Europeo por parte de expertos en el àrea terapèutica de pulmón”. Tertulias Oncológicas del Congreso Europeo. IDIBELL – ICO, Octubre 2017, Barcelona.

161. “Integrando nuevas estratègies terapeúticas en CNMP estadios precoces”. SEOM, Octubre 2017, Madrid.

162. “Avances en el tratamiento del Cáncer de Pulmón”. Cáncer de pulmón: Estado del Arte. Nuevos Avances, nuevas preguntes”. Centro integral Oncológico, Madrid Noviembre 2017.

163. Moderadora: “De la epidemiologia a los estadios precoces”. Post Mundial Cáncer de Pulmón, Madrid Noviembre 2017.

164. “Neoantigenicidad e inmunoterapia. Paradojas y contradicciones”. Desafío Oncológico. Valencia, Noviembre 2017.

165. “Organització unitat de cap i coll a Oncología: Discussió de potencials projectes d’investigació i estudis Clínics”. Sessió d’Otorrinolarongología, Hospital Universitari Vall d’Hebron. Gener 2018, Barcelona.

166. “Nuevo algoritmo terapeútico en el CPNM EGFRM con T790 + a la progresión". Simposio Revisiones en Cáncer 2018, Febrero 2018, Madrid.

167. “Cáncer de Pulmón Avanzado. Otras Dianas”. XXI reunión de Actualización en Tratamiento Oncológico: Cáncer de Pulmón. Córdoba, Marzo 2018.

168. “Integración de la inmunoterapia en directrices existentes de tratamiento badasads en la evidencia”, Módulo V Título Experto en Inmuno-Oncología, Pamplona, Marzo 2018.

169. “¿Marcadores predictives de inmunoterapia en cáncer de pulmón? Módulo V Título Experto en Inmuno-Oncología, Pamplona, Marzo 2018.

170. “Mi algoritmo de decisión en el manejo del carcinoma no microcítico de pulmón estadio I". Ponente en el III Foro La Oncología Médica en 3 días, Madrid, Mayo 2018.

171. “Tratamiento de Carcinoma Microcítico de Pulmón”. XXX Curso Avazado de Oncología Médica, San Lorenzo de El Escorial (Madrid). Junio 2018.

172. “Priorització dels medicaments en base al valor terapèutic: Una aproximació de l’ESMO al benefici clínic dels fàrmacs oncològics”. I Jornada d’Actualització i debat de l’Àrea del Medicament. Servei Català de Salut, Junio 2018.

173. "Inmunoterapia en pacientes pretratados". Jornada Canaria de Cáncer de Pulmón Metastásico, Las Palmas de Gran Canaria, Septiembre 2018.

174. "Nuevas perspectives en teràpia precisión en CPNM avanzado: EGFR, ALK). Congreso SEOM (Sociedad Española de Oncología Médica), Septiembre 2018.

175. Post Mundial Cáncer de Pulmón. Organitzadora y Moderadora, Madrid, October 2018.

56

176. “Algoritmo de decisión clínica en tunores de pulmón basado en biomarcadores. Evidencia clínica de la inmuno-oncología”. Programa Interdisciplinar de Patología Molecular. Barcelona, November 2018.

177. “El fenómeno de las resistencias. Papel de la biòpsia líquida. Desafío Oncológico, Valencia, November 2018.

178. “TMB en biòpsia líquida como marcador de respuesta a inmunoterapia”, IV Simposio Biopsia Líquida, Santiago de Compostela, January 2019.

179. "EGFR: A favor de si hacer secuenciación", XXI Simposio Revisiones en Cáncer 2019, Madrid, February 2019.

180. “Nuevos fármacos en desarrollo en cáncer de pulmón". IV Foro “La Oncología Médica en 3 días”, Madrid, May 2019.

181. “Tratamiento de Carcinoma Microcítico de Pulmón”. XXXI Curso Avanzado de Oncología Médica. Junio 2019, San Lorenzo de El Escorial (Madrid), España.

182. “Nuevas terapias dirigidas frente a alteraciones accionables”. Congreso SEOM (Sociedad Española de Oncología Médica), October 2019,Pamplona, Spain.

183. “¿Qué le cuestan al sistema sanitario los tumores debidos a virus que podrían haberse evitado?, “Visión General de la Relaciones Virus y Cáncet. Un documento de Opinión. Fundación de Ciencias de la Salud, October 2019, Madrid, Spain.

184. “Future Approaches in SCLC Treatment: Nuevos Fármacos / Novel Agents in development”. “Hay Novedades en SCLC/ What’s new in SCLC”. Fundación Oncosur, December 2019. Madrid, Spain.

International Invited Lectures: 1. Spanish Lung Cancer Group randomized trial of preoperative MIC

(Mitomycin+Ifosfamide+Cisplatin) chemotherapy in stage IIIA(N2) NSCLC. “II Andorran Congress on Lung Cancer”. Andorra. Feb 1997.

2. Moderadora d’una taula rodona al “II Andorran Congress on Lung Cancer”. Andorra. Feb 1997.

3. Carcinoma broncogénico N2: Avances en técnicas de imagen y papel de la quimioterapia y cirugía. "3nd International Meeting on General thoracic surgery". Barcelona. Apr 1997.

4. Tratamiento del carcinoma broncogénico avanzado: T3-T4-M1. "3nd International meeting on general thoracic surgery". Barcelona. Apr 1997.

5. Tratamiento quirúrgico de las metástasis pulmonares. "3nd International meeting on general thoracic surgery". Barcelona. Apr 1997.

6. Other therapeutical options of NSCLC: neoadjuvant setting (docetaxel-carboplatin, etc.) and docetaxel with radiotherapy. “1st International forum on lung cancer treatment”. Toronto. Canada. Oct 1999.

7. Moderator: “Simposium conjunto franco-español en cáncer de pulmón no microcítico”. Cadis. Oct 1999.

8. Estado del arte en cáncer de pulmón. “XVII reunión Anual Médica del Instituto Nacional de Cancerología de Mexico”. San José de Costa Rica. Costa Rica. Feb 2000.

9. Gemcitabine doublets and triplets in NSCLC. “2000 Lilly Oncology Global Medical Conference”. Indianapolis. USA. May 2000.

10. Neoadjuvant chemotherapy in NSCLC: a standard approah?. “New strategies in the cancer treatment”. Nàpols. Itàlia. Oct 2000.

11. Current status and trends in bio-molecular and genetics in lung cancer. New strategies in the treatment of resectable non-small cell lung cancer. “11th World Congress The World Society of Cardio-Thoracic Surgeons”. Sao Paulo. Brasil. Ago 2001.

57

12. New Strategies in the treatment of resectablen non-small cell lung cancer. “The 42nd Japan Lung Cancer Society Meeting”. Osaka, Japan. Nov 2001.

13. Panorama y nuevas tendencias en tratamiento de cáncer de pulmón. Primer Congreso Regional Andino de Oncología Clínica. Lima. Perú. Jan 2002.

14. Stage IIIa & IIIb lung cancer and other issues: Chemotherapy in the subclinic disease. “V International Meeting on General Thoracic Surgery”. Barcelona. Apr 2002.

15. “Women and lung cancer: Raising awareness”. Orlando. USA. May 2002. 16. New cytotoxic drugs: New antitubulin agents. “International Conference on New

Drugs in Lung Cancer”. Bologna, Italy. Jun 2002. 17. Clinical trials in Europe: Spain. “8th Central European Lung Cancer Conference”.

Viena, Austria. Sep 2002. 18. Moving towards customized chemotherapy in non-small cell lung cancer. “8th

Central European Lung Cancer Conference”. Viena, Àustria. Sep 2002. 19. Current status in the treatment of Neoadjuvant NSCLC. “Educational Symposium of

the Spanish Lung Cancer Group. Valencia. Oct 2002. 20. NATCH trial update. “Fifth Congress on Lung Cancer”. Barcelona. Nov 2003. 21. Tratamentos adjuvantes em carcinoma de pulmao de células nao-pequenas. “I

Encontro Nacional sobre Càncer de Pulmao”. Sao Paulo, Brasil. Dec 2003. 22. Manejo sistémico. ”XI Congreso Venezolano de Oncología”, “VIII Congreso

Venezolano de Mastología”, “V Congreso Venezolano de Radioterapia” Pulmonar, Venezuela. Oct 2004.

23. Update on neoadjuvant and adjuvant chemotherapy: assessment of HIFα mRNA. Plenary Session & Educational Symposium of the Spanish Lung Cancer Group. Bilbao. Nov 2004.

24. Cancer de pulmao pequenas células: “XIV Congreso Brasileiro de Oncologia Clínica; XV CILAC Congreso Integrado Latino Americano de Cancerologia” Rio de Janeiro, Brasil. Oct 2005.

25. EGFRTKIs: can we preclude activity in lung cancer patients?. “2nd International Symposium on Cancer; New Trends in Cancer for the 21 Century. Valencia. Nov 2005.

26. Novel strategies for neoadjuvant therapy in lung cancer. “Six Congress on Lung Cancer”. Barcelona. Dec 2005.

27. Stage III non-small-cell lung cancer. Chairman en “III Workshop on radiochemotherapy in lung cancer”. Barcelona. Apr 2006.

28. The molecular epidemiology of non-small-cell lung cancer. “Horizons; 1st Annual Lung Cancer Expert Forum”. Hamburg, Gemany. Apr 2006.

29. Patient profiling in advanced disease. Panelist en “Interactive Lung Cancer Conference”. Lisbon, Portugal. May 2006.

30. Bevacizumab: turning the tide history in non-small cell lung cancer. “Forum of Excellence: Anti-angiogenesis in breast and lung cancer”. Barcelona. Jun 2006.

31. Sex-related differences in lung cancer. “Perspectives in Lung Cancer; 7th European Conference”. Athens, Greece. Sep 2006.

32. Preliminary data on a prospective data collection of women with lung cancer in Europe. “European Lung Cancer Partnership in Europe”. Turin, Italy. Sep 2006.

33. Gender differences in lung cancer. “II IASLC International Workshop early invasive lung cancer: new diagnostic tools & treatment startegies”. Turin, Italy. Sep 2006.

34. Current status of adjuvant chemotherapy. “Nordic Lung Cancer Meeting”. Oulu, Finland. Sep 2006.

35. The management of lung cancer: an oncologist’s perspective. “16th Annual Congress of the European Respiratory Society (ERS)”. Munich, Germany. Sep 2006.

36. The expanding role of systemic treatment in NSCLC: neoadjuvant treatment. Educational session; “31 st European Society Medical Oncology (ESMO) Congress”. Istanbul, Turkey. Oct 2006.

58

37. Integration of new drugs in NSCLC therapy. Plenary Session & III Educational Symposium of the Spanish Lung Cancer Group”. Madrid, Spain. Nov 2006.

38. Visión integral en la clínica oncológica. “1er Simposio Iberoamerica de Tratamiento de Soporte en Oncología”. Madrid, Spain. Feb 2007.

39. Options for first-line treatment of advanced NSCLC: what should the standard of care be?. “Horinzons II Lung Cancer Expert Forum”. Geneve, Switzerland. Mar 2007.

40. Gender-related differences in lung cancer. “Perspectives in Lung Cancer”. Sevilla, Spain. Mar 2007.

41. Chair summary and take-home messages. “Perspectives in Lung Cancer”. Sevilla, Spain. Mar 2007.

42. Chair poster discusion: Lung Cancer II. ASCO 43rd Annual Meeting. Chicago, USA. May 2007.

43. The role of anti-angiogenesis agents in the treatment of NSCLC. “Angiogenesis: A key target in oncology”. Barcelona, Spain. May 2007.

44. Hot topics in lung cancer: Adjuvant chemotherapy. “ESMO Conference Lugano (ECLU)”. Lugano, Switzerland. Jul 2007.

45. Risk factors for non-smoking women. “12th World Conference on Lung Cancer”. Seul, Corea. Sep 2007.

46. Clinical usage in lung cancer. Introduction. “1st Joint Meeting ASCO-SEOM in Oncology. Focus on angiogenesis”. Madrid, Spain. Oct 2007

47. Customized treatment. “Seveth Congress on Lung Cancer”. Barcelona, Spain. Nov 2007.

48. Genetic differences in lung cancer: clinical implications. “EACTS/AIDAcp joint meeting”. San Giuliano Terme, Pisa, Italy. Des 2007.

49. Consolidation chemotherapy in locally advanced NSCLC. “IX European Congress Perpectives in Lung Cancer”. Torino, Italy. Mar 2008.

50. Neoadjuvant vs adjuvant vs surgery alone in early NSCLC. “1st European Lung Cancer Conference”. Geneve, Switzerland. Apr 2008.

51. Delivering the promise of anti-EGFR therapy in advanced NSCLC. Simposium satelite “1st European Lung Cancer Conference”. Geneve, Switzerland. Apr 2008.

52. Multimodality management of locally advanced NSCLC: comparing experiences. “5th Conference on integrated therapies in oncology, state of the art and futures challenges”. Messina. Italy. Jul 2008.

53. Advanced NSCLC treatments before ASCO 2008. “3º Congresso Portugues do Cancro do Pulmao”. Albufeira, Portugal. Oct 2008.

54. Modern chemotherapy: what matters for the clinicians. “European Society for Therapeutic Radiation Oncology Teaching Course”. Vilamoura, Potugal. Nov 2008.

55. The NATCH trial. “IV Educational Symposium of the Spanish Lung Cancer Group”. Zaragoza, Spain. Nov 2008.

56. Genetic differences in lung cancer: clinical implications. “European association for cardio-thoracic surgery joint meeting”. San Giuliano Terme, Pisa, Italy. Dec 2008.

57. Early NSCLC. Neoadjuvant vs adjuvant vs surgery alone. “1st European Lung Cancer Conference”. Geneva, Switzerland. Apr 2008.

58. Highlights of the day chest tumors. Discussant. 33rd ESMO Congress of the European Society of Medical Oncology. Stockholm, Sweden. Sep 2008.

59. The role of bevacizumab and its clinical implications. “International Lung Cancer Seminar”. Tinos, Greece. Sep 2008.

60. New prospects in the first-line treatment of NSCLC. “Latest therapeutic advances in the treatment of NSCLC”. Barcelona, Spain. Jan 2009.

61. Nuevos tratamientos en el càncer no microcítico de pulmón. “4ª reunion internacional sobre investigación translacional y medicina individualizada”. Madrid, Spain. Feb 2009.

62. Lung cancer expert forum. “Anti-angiogenesis clinical experience exchange meeting”. Madrid, Spain. Apr 2009.

59

63. First-line treatment of advanced NSCLC with EGFR-inhibitors. Chair a “4th IASLC/ASCO/ESMO International Conference on Molecular Targeted Therapy in Lung Cancer”. Saint Paul de Vence, France. Apr 2009.

64. Lung cancer biology: Clinical implications predictive factors in NSCLC. “European Multidisciplinary Conference in Thoracic Oncology (EMCTO)”. Lugano, Switzerland. May 2009.

65. Surgery (S) alone, or preopeartive (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cáncer (NSCLC): Results of the NATCH multicenter, randomized, phase III trial. “Best of ASCO, Annual Meeting 09”. Paris. France. Jun 2009.

66. Surgery allowing neoadjuvant treatment of N2 NSCLC. Discussant: 13th World Cancer Conference on Lung Cancer. San Francisco. USA. Jul 2009.

67. Molecular biology: reality or vision in lung cancer. “ESSO Advanced Course: Interdisciplinary Treatment of Lung Cancer”. Berlin, Germany. Sep 2009

68. Rare tumours of the chest. Ponència a “ECCO 15 – 34th ESMO Multidisciplinary Congress”. Berlin, Germany. Sep 2009.

69. Adjuvant and neoadjuvant treatment. “ESTRO Multidisciplinary Course on Lung Cancer”. Praga, Chec Republic. Nov 2009.

70. Moving forward from the NATCH. “Eighth Congress on Lung Cancer”. Barcelona, Spain. Nov 2009.

71. Perioperative treatment in NSCLC: Results of NATCH. “International Joint Meeting on Thoracic Surgery”. Barcelona, Spain. Nov 2009.

72. Treatment options in the second-/third-line settings. “Non-small cell lung cancer – the changing treatment paradigm. Lung Cancer Summit 2010”. Athens, Greece. Apr 2010.

73. Case histories and panel discussion. “Non-small cell lung cancer – the changing treatment paradigm. Lung Cancer Summit 2010”. Athens, Greece. Apr 2010.

74. Neoadjuvant versus adjuvant chemotherapy in early stage I/II.“Second European Lung Cancer Conference”. Geneve, Switzerland. Apr 2010.

75. Early NSCLC invited papers. Chaiman a “Second European Lung Cancer Conference”. Geneve, Switzerland. Apr 2010.

76. Advanced NSCLC proffered papers. Chairman and discussant a “Second European Lung Cancer Conference”. Geneve, Switzerland. Apr 2010

77. Adjuvant vs neoadjuvant chemotherapy. “Second Italian Conference on Thoracic Oncology”. Rome, Italy. Jun 2010.

78. Early stages and LA-Disease, adjuvant therapy and Neo-adjuvant therapy. “2nd AIOT-ESMO Residential Advanced Course”. Italy. Jul 2010.

79. Towards an individualized approach in advanced non-small cell lung cancer. 35th ESMO Congress. Milan, Italy. Oct 2010.

80. What a physician should know chemotherapy for lung cancer. “Multidisciplinary Teaching Course on Lung Cancer” ESTRO, European Society for Radiotherapy and Oncology. Nice, France. Oct 2010.

81. Adjuvant and neoadjuvant chemotherapy for early lung cancer (Stage I-IIIa). “Multidisciplinary Teaching Course on Lung Cancer” ESTRO, European Society for Radiotherapy and Oncology. Nice, France. Oct 2010.

82. Targeted therapies beyond the EGFR gene mutation. “SAMO Interdisciplinary Workshop on Head Neck and Chest Tumors” Swiss Academy of multidisciplinary Oncology (SAMO). Lucerne, Switzerland. Nov 2010.

83. What, if resistant to TKI in patients with EGFR mutated tumours. “SAMO Interdisciplinary Workshop on Head Neck and Chest Tumors” Swiss Academy of multidisciplinary Oncology (SAMO). Lucerne, Switzerland. Nov 2010.

84. Chair: Personalised treatment in NSCLC. “European Multidisciplinary Conference in Thoracic Oncology (EMCTO). European Society for Medical Oncology (ESMO). Lugano, Switzerland. Feb 2011.

60

85. TK-Is as first line vs chemotherapy. “1st AIOT/ETOP Residential Course 2011”. Frascati, Rome, Italy. May 2011.

86. The future role of different specialists in multimodality medicine (lung cancer): Medical Oncologist. “14th World Conference on Lung Cancer (WCLC)”. Amsterdam, Netherlands. Jul 2011.

87. Stage III-N2 Non-Small Cell Lung Cancer – Choice of chemotherapy schemes. “ECCO16-ESMO36 2011 European Multidisciplinary Cancer Congress”. Stockholm, Sweden. Sep 2011.

88. Report by group chairs, discussion and conclusions. “WCLC 2011 ETOP, European Thoracic Oncology Platform”. Amsterdam, Netherlands. Nov 2011.

89. Variety of lung tumours. Implications for the management. “Symposium on Thoracic Oncology”. Munich. March 2012.

90. State of perioperative chemotherapy in lung cancer. “Symposium on Thoracic Oncology”. Munich. March 2012.

91. Recommendations on SCLC. “ESMO Multidisciplinary Interactive Sessions” during 3rd European Lung Cancer Conference, Geneva, Abril 2012.

92. Research direction with conventional cytotoxic agents. Systemic chemotherapy of advanced disease (first line and maintenance). “ETOP Residential Workhop”, Lugano (Switzerland), May 2012.

93. State of the art and developments in adjuvant chemotherapy. Systemic therapy as part of multimodality therapy. “ETOP Residential Workshop” Lugano (Switzerland), May 2012.

94. Appropriate Adjuvant Therapy for NSCLC. “ASCO Annual Meeting” Chicago (USA) June 2012.

95. Tratamiento del cancer de pulmón estadio IIIB. “XV Congreso Venezolano de Oncología” -Sociedad Venezolana de Oncología- Buenos Aires (Argentina). July 2012.

96. Selección del Esquema de quimioterapia en primera línea de enfermedad avanzada. “XV Congreso Venezolano de Oncología” -Sociedad Venezolana de Oncología- Caracas (Venezuela). July 2012.

97. Medicina personalizada en el tratamiento de cáncer de pulmón: Mito o realidad? . “XV Congreso Venezolano de Oncología” -Sociedad Venezolana de Oncología- Caracas (Venezuela). July 2012.

98. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) of EGFR-mutated advanced non small cell lung cancer (NSCLC). “37th ESMO Congress”, Vienna (Austria). September 2012.

99. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers? “37th ESMO Congress”, Vienna (Austria). September 2012.

100. Biomarkers of Resistance to EGFR-Targeted Therapies in Lung Cancer. Markers in Cancer (A Joint meeting by ASCO, EORTC and NCI), Hollywood, Florida (USA). October 2012.

101. Lessons learnt from clinical trials. “2nd International Joint Meeting on Thoracic Surgery”, Barcelona, November 2012.

102. How does a target therapeutic agent work? “2nd International Joint Meeting on Thoracic Surgery”, Barcelona, November 2012.

103. Current characterization of lung cancer (Focus on pathological and molecular subtypes. “ESMO Symposium 2013: Signalling Pathways in Cancer. Targeting the HER/EGFR family: Focus on breast, lung and colorectal cancers”. Sitges-Barcelona, March 2013.

104. HSP90 CAUY 922. “6th International Conference on Molecular Targeted Therapies in Lung Cancer (IASLC)”. Sorrento-Italy, April 2013.

105. How should we utilize biomarkers in Phase I trials? (Predictive and Prognostic markers, PD markers, optimal biological dose, companion diagnostics. “European Multidisciplinary Conference in Thoracic Oncology (EMTCO)”. Lugano (Switzerland), May 2013.

61

106. Integrating targeted treatment in a neoadyuvant approach: Opportunities and Risks. “European Multidisciplinary Conference in Thoracic Oncology (EMTCO)”. Lugano (Switzerland), May 2013.

107. Combining knowledge towards personalized treatment by a multidisciplinary team. “European Multidisciplinary Conference in Thoracic Oncology (EMTCO)”. Lugano (Switzerland), May 2013.

108. Whole-exome sequencing in tumor samples from sequenom-wild-type, ALK negative stage IV lung adenocarcinoma (ADC) patients (P). ASCO Annual Meeting Chicago (USA), June 2013.

109. Women in Academic Oncology: An International Perspective. ASCO Annual Meeting Chicago (USA), June 2013.

110. Utilidad clínica de la información molecular en cáncer de pulmón”. 1er Simposio de Hematología y Oncología Clínica. Universidad Libre Seccional Cali, (Colombia), July 2013.

111. State of the art and developments in adjuvant chemotherapy. 2nd ETOP residential workshop. Lugano (Switzerland), August 2013.

112. Adjuvant and Neoadjuvant therapy. X Mos Conference: “Lung Cancer and Mesothelioma”. Taranto (Italy), November 2013.

113. Management of Stage I NSCLC patients. 10th Congress on Lung Cancer (Spanish Lung Cancer Group), Barcelona (Spain), November 2013.

114. Future developments in medical lung cancer therapy. Molecular Diagnostics in Clinical Oncology (Vigareggio, Italy), November 2013.

115. The clinical significance of the MET pathway. 3rd Lung Cancer Network, “From bench to Bedside” (ESMO-IASLC-ETOP). Athens, Greece, January 2014.

116. Targeted agents in SCLC. ESMO-Christie Lung Cancer Course. Manchester, UK, February 2014.

117. “Treatment of NSCLC in the Elderly: 10 years later”, 8th International Experts Panel Meeting, (AIOT), Sperlonga, Italy, May 2014.

118. “New Challenges in Clinical Research”, SAKK Semi Annual Meeting (Swiss Group for Clinical Cancer Research SAKK), Bern, June 2014.

119. “New data in adjuvant setting including biomarkers”, 3rd ETOP Residential Workshop, Gdansk (Poland), August 2014.

120. “Introduction to ESMO Clinical Practice Guidelines”, ESMO Congress, Madrid (Spain), September 2014.

121. Immune based anti-tumor therapies. PD1 and PDL blockade. VII Educational Symposium of the Spanish Lung Cancer Group. Madrid, November 2014.

122. Future developments in Medical lung Cancer therapy. Molecular Diagnostics, Genomics and Epigenetics in Clinical Oncology (ESO -European School of Oncology-), Rome, November 2014.

123. “Current status and future directions in targeting ALK”. 3rd Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, February 2015.

124. “Harnessing immune System in NSCLC”. Refresher Course on Lung Cancer (ESO, European School of Oncology), Belgrade, March 2015.

125. “Optimal use of targeted agents in NSCLC”. Refresher Course on Lung Cancer (ESO, European School of Oncology), Belgrade, March 2015.

126. The role of EGFR TKI’s in non metastatic multifocal adenocarcinoma. ELCC 2015, Geneve, Switzerland, April 2015.

127. Are there new targets in Advanced NSCLC. ELCC 2015, Geneve, Switzerland, April 2015.

128. Is there a place for neoadjuvant treatment? ESMO Preceptorship Programme in Non-Small Cell Lung Cancer. Standards of care, evolving paradigma and future perspective. Copenhaguen, July 2015.

129. Tageted therapies for adenocarcinoma of the lung. ECCO, Vienna, September 2015.

130. Highlight Session: “Lung Cancer”. ECCO, Vienna, September 2015.

62

131. “Systemic Therapy for large cells neuroendocrine carcinomes”. 3rd International Joint Meeting on Thoracic Surgery. Barcelona, Spain, November 2015.

132. “Lung Cancer as a model for the development of personalized medicine: What should you ask from your pathologist in order to apply specific treatments”. ESO Conference, Molecular Diagnostics, Genomics and Epigenetics in CLinical Oncology. Rome, Italy, November 2015.

133. “Mechanisms of acquired resistance to third generation EGFR-TKI inhibidors”. 11th Congress on Lung Cancer, Barcelona, Spain, November 2015.

134. “The HER2”. 4th Lung Cancer Network, “From Bench to the Bedside”. Oncology Center of Biomedical Education and Research, Department of Medicine, Medicine School of Athens, Athens, Greece, January 2016.

135. “Targeted agents in SCLC”. ESMO-The Christie Preceptorship programme on Lung Cancer, Manchester, UK, February 2016.

136. “Novel targets in SCLC”. ELCC (European Lun Cancer Conference), Geneva, Switzerland 2016.

137. “Hope and reality for the treatment of NSCLC: looking at the future”. Instituto Nazionale Dei Tumori (Milano), April 2016.

138. “Ceritinib”. 5th International Conference on Thoracic Oncology (AIOT, Associazione Italiana Oncologia Toracica), Naples, Italy, May 2016.

139. “Avelumab”. 5th International Conference on Thoracic Oncology (AIOT, Associazione Italiana Oncologia Toracica), Naples, Italy, May 2016.

140. “Standard of care and future perspectives in Lung Cancer: Stage I-IIIa” ESMO Academy Program, Oxford, UK, August 2016.

141. “Signalling pathways in NSCLC: Opening new therapeutic opportunities”. VIII Educational Symposium of the Spanish Lung Cancer Group (GECP), Madrid, November 2016.

142. "Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC)”. 17th World Conference on Lung Cancer, Viena, December 2016.

143. “Mechanisms of acquired resistance to third generation TKI’s”. 32nd Ernst Klenk Symposium in Molecular Medicine Precision Oncology: Translating Basic Discoveries into Patient Survival, Cologne, December 2016.

144. "Immunotherapy, in combination first or second line? (incl. case presentation)”. SAMO interdisciplinary Workshop on Chest Tumors. Lucerne, Switzerland, January 2017.

145. “Immune checkpoint inhibitors in other thoracic malignancies”. ESMO Preceptorship Programme Immuno-Oncology. From the essentials of tumour immunology to Clinical application. Madrid, February 2017.

146. “Targeted agents in SCLC”. ESMO –The Christie Preceptorship Programme Lung Cancer. Multidisciplinary management, standards of care and future perspectives. Manchester, March 2017.

147. CERITINIB PLUS NIVOLUMAB (NIVO) IN PATIENTS (pts) WITH ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK+) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). ASCO Annual Meeting, Chicago, June 2017.

148. “Foreword: The State of Lung Cancer Therapy in 2017”. 1st Annual European Symposium on Lung Cancers. Barcelona, July 2017.

149. “How Do We Create a Continuum of Care for Patinets With ALK-rearranged NSCLC?”. 1st Annual European Symposium on Lung Cancers, Barcelona, July 2017.

150. “Emerging Target Therapy in NSCLC”. IASLC 18th World Conference on Lung Cancer, Yokohama (Tokyo), October 2017.

151. “ALERT-Lung Research project”. ETOP Annual Meeting. November 2017, Zurich, Switzerland.

152. “Neoadjuvant treatment in early stages”. 12th Congress on Lung Cancer. GECP (Grupo Español Cáncer de Pulmón), Barcelona, November 2017.

63

153. “Immunotherapy of immune checkpoint inhibidors toxicity”. 5th Lung Cancer Network: “From the Bench to the Bedside”. Athens, Greece, January 2018.

154. “Pre-Op Chemotherapy”. FDA-IASLC Workshop on Neoadjuvant Therapy in Lung Cancers. Bethesda, Washington, March 2018.

155. “Novel IO-Agents”. IASLC Lung Cancer Immunotherapy Meeting. Madrid, Spain, March 2018.

156. “HER2 and others” in ESMO Educational Session: “Less frequent driving alterations”. European Lung Cancer Conference 2018 (Geneva), Switzerland, April 2018.

157. “Adjuvant Chemotherapy for NSCL: Where are we now?” IASLC Africa Conference on Lung Cancer 2018 (Tangier, Morocco), April 2018.

158. “First Line Treatment Checkpoint Inhibitors and Other Immunoagents in Squamous Cell Carcinoma". IASLC Africa Conference on Lung Cancer 2018 (Tangier, Morocco), April 2018.

159. “NSCLC 2018: Status and Burning Questions”. 2nd Annual European Symposium on Lung Cancer (Barcelona), May 2018.

160. “New Standards for Genomic Testing in Lung Cancer Treatment”. II International Workshop Integrating Genomics in Cancer Management. Madrid, May 2018.

161. “On Either Side of the Knife: Novel Preoperative and Postoperative Systemic Therapies in Lung Cancer”. Meet the Professor Session. ASCO Annual Meeting, Chicago (USA), June 2018.

162. “El papel de los Nuevos Biomarcadores: TMB en Tejido”. Biomarcadores en Inmuno-Oncología. Madrid, July 2018.

163. "Optimal use of cancer immunotherapy (treatment algorithm, duration, biomarkers). ESO (European School of Oncology) Lung Cancer Course, Pristina, Kosovo, September 2018.

164. "Standard treatment for metastatic EGFR/ALK/ROS+ patients". ESO (European School of Oncology) Lung Cancer Course, Pristina, Kosovo, September 2018

165. "What's next in lung cancer management (immunotherapy, targeted agents, NGS". ESO (European School of Oncology) Lung Cancer Course, Pristina, Kosovo, September 2018.

166. "Standard treatment for stage III NSCLC". ESO (European School of Oncology) Lung Cancer Course, Pristina, Kosovo, September 2018.

167. "Phase II data for the met inhibidor Tepotinib in patients with Advanced NSCLC and MET Exon 14-Skipping Mutation”. WCLC (World Congress on Lung Cancer), Toronto, (Canada) September 2018.

168. "Guiding Secong Line treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?) WCLC (World Congress on Lung Cancer), Toronto, (Canada) September 2018.

169. “First-line-Chemo IO-Anti-VEGF combination –how to treat primary progression and

relapse? TOM (Thoracic Oncology Munich-Munich University), March 2019.

170. “Predictive diagnostics and treatment algorithms”. ELCC (European Lung Cancer Conference), Geneve (Switzerland), April 2019.

171. “Epidemiology and Clinical Characteristics of Lung Cancer in Women”. 2019 World

Congress on Lung Cancer (WCLC), Barcelona (Spain), September 2019.

172. "Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC" (WCLC), Barcelona Spain, September 2019”.

173. “Are biomarkers needed to select lung cancer patients for immunotherapy?

CONTRA”. ESMO2019 Congress, Barcelona (Spain), September 2019.

64

174.

Documents

Clinical Chief, Medical Oncology Department Head, Thoracic ... Awards, Honors and Recognitions: Best Poster Award, Nº 695: “Epidermal growth factor receptor (EGFR) expression correlation